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Abstract
Like many viruses, papillomaviruses appear to have evolved mechanisms resulting in escape 
from host immune surveillance and delay of resolution of infection. The E5 protein is 
expressed early in papillomavirus infection in the deep layers of the infected epithelium. 
Human papillomavirus type 16 (HPV-16) E5 is a small protein, 83 amino acids long, and has 
tliree hydrophobic domains connected by less hydrophobic regions. It is located mainly at the 
endosomal membranes, Golgi apparatus (GA) and, to a lesser extent, the plasma membrane. 
The E5 protein of bovine papillomavirus (BPV) impairs the synthesis and stability of major 
histocompatibility (MHC) class I complex and prevents their transport to the cell surface due 
to retention in the GA.
The results in this thesis demonstrated that HPV-16 E5 wild type down-regulates surface 
expression of MHC class I, retains MHC class I complexes in the GA and impedes their 
transport to the cell surface, which is rescued by treatment with interferon. Unlike BPV E5, 
HPV-16 E5 does not affect the synthesis of MHC class I heavy chains, and the morphology of 
the GA. HPV-16 E5 physically interacts with MHC heavy chain in the GA and this 
interaction is associated with the down-regulation of surface MHC class I. Moreover, we 
determined that HPV-16 E5 dovm-regulates selectively HLA-A and B but does not inhibit 
HLA-C and non-classical HLA-E thus potentially escaping both cytotoxic T lymphocyte 
(CTL) and natmal killer (NK) cells.
Deletion mutants of HPV-16 E5 lacking each one of the hydrophobic domains were generated 
to define its functional domains. HaCaT cells expressing either HPV-16 E5 wild type or its 
mutants were analysed for their ability to down-regulate surface MHC class I and determine 
the localization in the cells. All deletion mutants were expressed and localised in the GA. The 
deletion mutants containing the first hydrophobic domain were all able to down-regulate
XVIII
sui’face MHC class I, to retain the complex in the GA and interact with MHC heavy chain to 
extent as HPV-16 E5 wild type. Only the deletion mutant which lacks the first hydrophobic 
domain was unable to down-regulate surface MHC class I, to retain the complex in the GA 
and to interact with MHC heavy chain. This study demonstrated that the separate domains of 
HPV-16 E5 did not have the same function. We found that the first hydrophobic domain of 
HPV-16 E5 is important for down-regulation of surface MHC class I.
Lack of surface MHC class I in infected epithelial cells expressing E5 would allow evasion of 
CTL killing and thus establishment of viral infection. However, MHC class I down-regulation 
by E5 is selective, as E5 does not down-regulate HLA-C and non-classical HLA-E. It remains 
to be seen if E5 expressing cells evade CTL killing, through down-regulation of classical 
MHC I, and NK killing, through lack of down-regulation of non-classical MHC I.
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Chapter 1 Introduction
1 Introduction
1.1 Cancer
Uncontrolled cell proliferation is the hallmark of cancer. Cancer evolves from a single 
precursor cell acquiring a series of genetic and epigenetic changes conferring a growth 
advantage for the cell and leading to progressive conversion of normal cells into cancer cells. 
In cancer cells, various mutagens, oncogenic viruses and errors in replication trigger the genes 
regulation of their cell cycles. Genetic alterations and changes in DNA méthylation may 
affect a variety of genes such as proto-oncogene and tumour suppressor genes (Lengauer et 
al, 1998; Ponder, 2001). Normally, all cells reproduce by dividing in two, which each 
parental cell giving rise to two daughter cells on completion of each cycle of cell division. 
The division of all cells must be carefully regulated and coordinated with both cell growth and 
DNA replication in order to ensure the formation of progeny cells containing intact genomes. 
The cell cycle machinery is itself regulated by the growth factors allowing the division of 
individual cells to be coordinated. The growth factors control cell proliferation, 
differentiation, apoptosis and necrosis. When cell regulation is lost, cancer cells will grow and 
divide, and ultimately spread throughout the body by interfering with the function of tissues 
and organs. In a benign or malignant tumour, several genes regulate processes that are 
abnormal. During carcinogenesis, regulatory genes can be damaged, leading to production of 
more cells or reduction in normal cell death rate (Krontiris and Cooper 1981; Lengauer et al, 
1998). Tumours are classified according to the type of cell from which they aiise, including 
carcinomas, tumours that begin in epithelial tissue (e.g. cervical carcinoma) sarcomas, 
tumours that originate in the connective tissues, predominantly the muscles, skeleton and 
cartilage, and leukaemia and lymphomas originating the tissue forming the blood cells and 
immune system. Cancer results from alterations in critical regulatory genes that control cell
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proliferation, differentiation, and survival. It is believed that the development of cancer 
involves a complex series of interactions between several environmental factors and genetic 
factors. The environmental factors, which are exogenous factors, include physical agents or 
radiation agents (e. g. UV and X-ray), chemical agents (e.g. carcinogens and mutagens) and 
infectious agents (e.g. bacteria and viruses).
1.1.1 Oncogenes and tumour suppressor genes
Genetic changes in the progression of cancer typically affect two different types of genes, 
oncogenes (e.g., src and ras) and tumour suppressor genes (e.g., p53 and Rb). Both of the 
oncogenes and tumour suppressor genes encode many kinds of proteins that play a key role in 
cancer induction. These genes control cell growth and proliferation and mutations in these 
genes can contribute to the development of cancer (Yokota, 2000; Balmain et al, 2003; 
Yokota and Kolmo, 2004).
1.1.1.1 Oncogenes
Oncogenes are activated cellular proto-oncogenes, since these genes code for proteins that are 
directly involved in regulation of cell growth and proliferation. The oncogenes are abnormally 
expressed or mutated forms of the corresponding proto-oncogenes. As a consequence of such 
alterations, the oncogenes induce abnormal cell proliferation and tumour development. The 
viral and cellular oncogenes have defined a large group of genes that can contribute to the 
abnormal behaviour of malignant cells. The majority of oncoproteins function as elements of 
the signalling pathways that regulate cell proliferation and survival in response to growth 
factor stimulation. They include polypeptide growth factors, growth factor receptors, elements 
of intracellular signalling pathways, and transcription factors (Lengauer et al, 1998; Todd and
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Wong, 1999). The first was isolated in Rous sarcoma virus (RSV), which transforms chicken 
embryo fibroblasts in culture and induces large sarcomas rapidly after inoculation into 
chickens. The malignant changes are the consequence of the expression of a single viral gene 
termed src for sarcoma. The src gene is not required for virus replication; spontaneous 
deletions of the src gene can occur in the viral genome resulting in the generation of 
nonconditional transformation-defective viruses that replicate normally (Erikson et al, 1980). 
Like src, many of these genes encode proteins that are now recognized as key components of 
signalling pathways that stimulate cell proliferation. Some of the oncogenes identified in 
human tumours are cellular homologs of oncogenes that were characterized in retroviruses. 
Subsequently, the activation of oncogene was definitely proven in human cancer. Activation 
is mostly induced by point mutation of oncogenes such as ras family. These genes are 
involved in approximately 20% of all human malignancies, including about 50% of colon and 
25% of lung carcinomas (Salgia and Skarin, 1998; Downward, 2003; Soreide et al., 2006). 
The ras genes, encode guanine-nucleotide binding proteins that function in transduction of 
mitogenic signals from a variety of growth factor receptors (Campbell et al., 1998). The 
action of growth factors as oncoproteins results fi’om their abnormal expression, leading to a 
situation in which a tumour cell produces a growth factor to which it also responds. The result 
is autocrine stimulation of the gro’wth factor-producing cell, which drives abnormal cell 
proliferation and contributes to the development of a wide variety of human tumouis. A large 
group of oncogenes encode growth factor receptors, most of which are protein-tyrosine 
kinases. These receptors are frequently converted to oncoproteins by alterations of their 
amino-terminal domains, which would normally bind extracellular gro’wth factors (Nahta et 
al, 2003).
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1.1.1.2 Tumour suppressor genes
Tumour suppressor genes are a group of genes, which play an important role in regulating 
when cells ai’e allowed to divide and increase in number. When DNA damage is detected in a 
cell, some tumour suppressor genes can stop the cell from multiplying until the damage is 
repaired. When tumour suppressor genes do not function correctly, the cells with DNA 
damage continue to divide and can accumulate further DNA damage that can eventually lead 
to the formation of a cancer cell. In that way, a tumour suppressor gene is similai* to an 
oncogene. Most cancers have inactivating mutations in one or more proteins that normally 
function to restrict progression through the gap 1 (Gi) stage of the cell cycle such as 
retinoblastoma protein. Virtually all of human tumours have inactivating mutations in proteins 
such as p53 that normally function at crucial cell cycle checkpoints, stopping the cycle if a 
previous step has occurred incorrectly or if DNA has been damaged (Yokota, 2000; Sherr,
2004).
1.1.1.2.1 Retinoblastoma
The first tumour suppressor gene was identified as a genetic locus associated with the 
development of a retinoblastoma (Rb), a rare childhood eye tumour (Kuiudson, 1971; Friend 
et al, 1986). Children with hereditary retinoblastoma inherit a defective copy of the Rb gene, 
sometimes seen as a small deletion on chromosome 13. They develop retinal tumours early in 
life and generally in both eyes. The realization that it was a loss of function of Rb that was 
associated with disease established the tumoui' suppressor paradigm (Cavenee et al, 1983). 
The characterization of Rb as a tumour suppressor gene served as the prototype for the 
identification of additional tumour suppressor genes that contribute to the development of 
many different human cancers. Rb genes encode pocket proteins including pRb, p i07 and
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pl30. Rb family negatively regulates progression from Go through to Gi and into S-phase. 
These proteins bind to viral oncoproteins and cellular factors such as the E2F family of 
transcription factors. E2F family are functional transcriptional regulator of genes involved in 
cell cycle progression, DNA synthesis, apoptosis and other cellular processes (Dyson, 1998; 
Classon and Dyson, 2001). Rb binds E2F and inliibits transcription by blocking the E2F 
transcriptional activation domain. In cycling cells, Rb is inactivated in mid to late Gi tlnough 
phosphorylation by several cyclin-cyclin-dependent kinase (CDK) complexes. 
Hyperphosphorylated Rb no longer binds E2F; consequently, repression of E2F-dependent 
promoters is relieved. pRb, p i07 and p i30 also differ with regard to binding to E2F family 
members, with pRb binding to E2F1, E2F2 and E2F3 and pl07/p 130-binding E2F4 and E2F5. 
This binding represses E2F-dependent transcription. These E2F family members are generally 
thought of as transcriptional activators because they activate transcription when not bound by 
repressor molecules such as pRb (Dyson, 1998). Both p i07 and p i30 interact with E2F4 and 
E2F5, which are weak transcriptional activators when not bound by Rb family members. The 
expression patterns of Rb family members differ during the Go/Gi/S-phase transition, with 
p i30 highly expressed during Go, p i07 highly expressed in S-phase and pRb expressed at a 
fairly steady level throughout the cell cycle. This observation, together with the fact that 
different pocket proteins bind to distinct E2F family members, suggests the pocket proteins 
may regulate various E2F target genes at different times during the Go/Gi/S-phase transition 
(Classon and Dyson, 2001). The pocket proteins are regulated in part via phosphorylation by 
CDKs. Hyperphosphorylation of pRb results in a loss of binding to both E2F and chromatin 
remodeling factors, and reverses pRb-mediated cell cycle arrest by pRb (Dyson, 1998). 
Similar to pRb, p i07 and p i30 regulate cell cycle progression via interactions with E2F and 
are CDK substrates (Classon and Dyson, 2001). Both Rb and the CDK inhibitor p21 prevent
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S phase in differentiated cells (Woo et al, 1997; Mal et al, 2000). Rb binds to the E2F family 
of transcription factors in Gi and represses transcription of E2F-controlled S-phase genes 
(Dyson, 1998), while p21 inhibits the activity of Gi and S-phase cyciin/CDK complexes that 
is important for cell cycle progression (SheiT and Roberts, 1995). The Rb protein is a key 
target for the oncoproteins of several DNA tumour viruses, including polyomaviruses such as 
SV40 large T antigens, adenoviruses El-A, human papillomaviruses E7 (Helt and Galloway, 
2003), human T-cell leukemia virus type 1 Tax (Kehn et aL, 2005), Epstein-Barr nuclear 
antigen 3C (EBNA3C) (Knight et ah, 2006) and Hepatitis C virus NS5B polymerase 
(Munakata et aL, 2005). Inactivation of Rb family members by large T antigen, El-A  and E7 
oncoproteins may serve mainly to induce transcription of E2F-controlled cell cycle and DNA 
synthesis genes, thereby establishing an environment permissive for viral replication (Nevins, 
1995).
1.1.1.2.2 P53
The second tumour suppressor gene is p53 which is frequently inactivated in wide variety of 
human cancer. Mutations in the p53 gene or inactivation of its encoded protein by viral 
oncoproteins generally lead to a loss of these cellular defense functions. p53 mutations are 
common in human cancer and estimated to occur in up to 50% of all human cancers, making it 
the most common target of genetic alteration in human malignancies (Nigro et al, 1989; 
Hollstein et al, 1991; Olivier et al, 2002). The p53 tumour suppressor gene encodes a 
nuclear phosphoprotein that functions as a key regulator of DNA repair, cell cycle progression 
and apoptosis. The p53 protein is upregulated in response to a diverse array of cellular 
stresses, including DNA damage, hypoxia, oxidative stress, ribonucleotide depletion and 
oncogene activation (Ko and Prives, 1996; Giaccia and Kastan, 1998). When activated, p53
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can directly interact with DNA to yield transcription of a number of genes, including p21, and 
a temporary arrest of the cell cycle in the Gi or G2/M phase, prior to mitosis to allow for DNA 
repair. It is also capable of interacting with other cellular pathways to trigger apoptosis or 
differentiation (Lane et al, 1994). After DNA damage, p53 holds the cell at a checkpoint until 
the damage is repaired. If the damage is irreversible, apoptosis is triggered. The mechanism by 
which p53 promotes apoptosis is still not fully understood (Benchimol, 2001). The normal 
p53 function can be inactivated by somatic and germ line mutations and by binding to 
different viral oncoproteins (human papillomavirus protein E6, SV40 large T antigen, 
hepatitis B viral X protein and adenovirus protein El-B) (Harris, 1996).
1.1.2 Viruses and cancer
Many different agents have been implicated in various cancer including viruses, bacteria and 
parasites. Viruses have been the most studied in their relation to tumour formation. They are 
thought to be associated with 15-20 percent of all human cancers worldwide of which about 
80 percent are cancers of the cervix and liver (zur Hausen, 1991; Parkin, 2006). Viruses have 
evolved multiple strategies to transform host cells. One common route is to alter the 
expression of cellular genes by integration of the viral genome into the cellular DNA. Viruses 
also help cause malignancy by introducing an oncogene into a cell to disrupt the regulation of 
cell division (DiMaio et al, 1998; Murakami et ah, 2005; Kamihira et ah, 2005; Laurent-Puig 
et al, 2006; Aiias-Pulido et ah, 2006). Tumour viruses, which can cause human cancer, 
contain two groups: DNA tumour viruses and RNA tumour viruses. They include Hepatitis B 
virus, which is associated with hepatocellular carcinoma (Kao et al, 2000; Cougot et ah,
2005); the human T cell leukaemia virus type 1, which is a retrovirus, is associated with adult 
T cell leukaemia and lymphomas; Epstein-Barr virus which is linked to several human
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cancers including Bui'kitt's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma 
(zui' Hausen, 2001; Kurokawa et a l,  2005); Kaposi's Sarcoma-Associated Herpesvirus 
etiologically linked to Kaposi's sarcoma (Moore et al, 1996; Leao et a l,  2002) and human 
papillomavirus which is associated in carcinomas of the uterine cervix (Munoz et al, 2003), 
cancer of the oropharynx (Herrero et aL, 2003), and head and neck cancers (zur Hausen, 
2002; Ferris et al., 2005).
1.1.2.1 Hepatitis B Virus
The hepatitis B virus (HBV) is one of the most common chronic pathogens in the world, 
which is the major cause of liver disease and hepatocellular carcinoma (HCC). Chronic 
infection with this virus often leads to chronic liver disease, including cirrhosis or primary 
HCC. Over 2 billion of the world’s population have been exposed to this virus. About 350 
million of these, making 5% of the world’s population, are chronic carriers (Maynard, 1990). 
Annually up to 1 million of this population die due to the consequences of this infection such 
as cirrhosis and HCC (Mast et al, 1999). The prevalence of hepatitis B carriers varies in 
different parts of the world, ranging from less than 1% to 15% (Maynard, 1990). Many cases 
of infection recover completely but in 5-10% of patients, failure of the irmnune system to 
deal' the virus results in chronic carriers with HBV circulating in their blood for many years 
(Bollinger, 1996). These individuals usually develop persistent infections and an increased 
risk of liver cirrhosis and HCC. Integrated HBV genome is frequently detected in chronic 
virus infection and HCC patients. Epidemiology data have shown that HBV is one of the 
etiologic agents in HCC development. However, the molecular mechanism(s) of HBV leading 
to HCC remains unclear. A large number of cases are seen in eastern Asia and sub-Saharan 
Africa, where two of the most important health problems are chronic liver disease and liver
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cancer. Up to 80% of liver cancers are believed to result from this viral infection, which is the 
most important cause of cancer mortality worldwide (Mast et al, 1999).
1.1.2.2 Epstein-Barr virus
Epstein-Barr virus (EBV) has a large double stranded circular DNA genome. It belongs to the 
gamma-herpesvirus family that latently infects the majority of adults. EBV is the causative 
agent of infectious mononucleosis and is associated with malignancies that originate from 
lymphoid cells (e.g., Burkitf s lymphoma and Hodgkin's lymphoma) and epithelial cells (e.g., 
nasopharyngeal carcinoma) (Baumforth et al, 1999; Hsu and Glaser, 2000). Over 95% of the 
adult population worldwide are infected with EBV. Primary infection usually occurs during 
childhood and results in a mild, self-limiting illness. When infection is delayed until 
adolescence, infectious mononucleosis, characterized by fever, lymphadenopathy and 
pharyngitis, occurs in around 50% of individuals (Cohen, 2000). EBV enters via the 
oropharyngeal route and infects resting B cells (Niedobitek et al, 1997) and/or epithelial cells 
(Sixbey et al, 1984). Virus released during this productive primary phase subsequently infects 
B cells circulating through the oropharynx, resulting in a latent infection. The infected B cells 
are highly immunogenic and therefore induce a massive expansion of virus-specific and 
nonspecific T cells that cause the clinical symptoms of infectious mononucleosis. A small 
number of B cells express only latent membrane protein-2 and small nonpolyadenylated viral 
RNAs (EBV-encoded RNA 1 and 2) out of the almost 100 viral proteins encoded by the viral 
genome. This limited viral antigen expression allows these EBV-infected B cells to evade the 
immune response (Baumforth et al, 1999; Hsu and Glaser, 2000). The virus can then persist 
in its latent state for the life of the individual.
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1.1.2.3 Human T-cell leukemia virus type I
Human T-cell leukemia virus type-I (HTLV-1) is the first discovered human retroviral 
pathogen (Poiesz et al, 1980). HTLV-1 causes adult T-cell leukemia (ATL), which is an 
aggressive lymphoproliferative disease, and tropical spastic paraparesis or HTLV-1 associated 
myelopathy, which is a neurological progressive inflammatory syndrome (Barmak et al, 
2003; Jeang et al., 2004). In culture HTLV-1, which is an onco-retrovirus, can infect a wide 
variety of cell types from different species. However, in natural human infections this virus 
targets mainly mature CD4^ helper T-cells (Richardson et al, 1997), resulting in benign 
expansion the infected cells. HTLV-1-infected T-cells and deterioration of host immune 
activities are prerequisites for ATL development and 90-96% of the HTLV-I genome is found 
to segregate with CD4 cells in the peripheral blood of ATL patients (Richardson et al, 1990). 
HTLV-2 is molecularly and biologically similar to HTLV-1 (Seiki et al, 1983) but is not 
associated with ATL or any other leukaemia (Sugamura and Hinuma, 1993). HTLV-1 
encodes several proteins (e.g. Tax) that are responsible for distinct pathogenic activities of 
virus. It originally interacts with transcription factors and activates or represses transcription 
(Chen et al, 1985). Also the activation of Tax protein is essential for transforming primary 
human T-cells and T-cell immortalization. In addition, in transgenic animals Tax induces 
various malignancies such as fibrosarcoma and natural killer cell leukemia (Robek and 
Ratner, 1999).
1.1.2.4 Kaposi’s sarcoma-associated herpesvirus
Kaposi's sarcoma-associated herpesvirus or human herpesvirus 8 (HHV8) is a member of the 
gamma-herpesviruses like EBV, etiologically linked to Kaposi's sarcoma (KS) (Moore et al, 
1996). In 1994, HHV-8 was first detected in KS tissues from a patient with acquired
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immunodeficiency syndrome (AIDS) by representational difference analysis (Chang et al, 
1994), Since its initial discovery, HHV-8 has been found in all forms of KS: classical, 
endemic, and AIDS-associated acquired KS (Schulz, 2001). HHV-8 is detected in 95% of all 
KS. HHV-8 has been shown to infect a variety of cell types both in vivo and in vitro, 
including B cells, endothelial cells, kératinocytes, and macrophages (Moore and Chang, 
2003). This broad cellular host range suggests that HHV-8 may interact with ubiquitous host 
cell molecules to gain access to target cells.
1.2 Papillomavirus
Papillomaviruses are classified in family of their own, papillomaviridae, unrelated to the 
polyomaviruses, which belongs to polyomaviridae (de Villiers et al, 2004). PVs are non­
enveloped, circular double stranded and relatively small DNA viruses with a genome of 
approximately 8 kilo-bas pairs (kbp). The genome of papillomavirus is divided into three 
regions: a long control region and regions containing open reading frames conesponding to 
early and late genes. They have been found in many different types that infect a wild range of 
animals (from birds to rabits, dogs, sheep and cattle) and several primates including humans 
(Campo, 1997). These viruses are a very heterogeneous group of viruses, and individual types 
are associated with specific lesions. They are spread by contact and enter the body through 
minute abrasion in the skin and induce hyperproliferation of epithelial cells of the skin or 
mucosa (papillomas). The papillomas are mostly benign but some tumours may eventually 
undergo malignant conversion in both humans and animals when genetic or environmental 
factors are involved. Papillomaviruses-associated neoplasias comprise anogenital carcinoma 
and skin squamous cell carcinoma in humans, skin cancer in rabbits and upper gastrointestinal 
cancer and urinary bladder cancer in cattle (Campo, 1997 and 2002). Most cases of infections
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in both humans and animals are cleared following activation of the host immune system 
against viral antigen after several months (Frazer and Tindle, 1996). However, occasionally 
the lesions do not regress and can progress to cancer. The most commonly studied of these 
viruses are the cottontail rabbit papillomavirus (CRPV), bovine papillomavirus (BFV) and 
human papillomavirus (HPV). Animal papillomaviruses, particularly CRPV and BPV have 
been used as model systems in which to study virus biology, the interaction of the virus with 
its natural host and with environmental cofactors, and the host immune response to the virus.
1.2.1 Cottontail rabbit papillomavirus
CRPV was the first model of papillomavirus carcinogenesis, demonstrated in 1933 by Shope 
(Shope, 1933). CRPV induces papillomas in both cottontail and domestic rabbits infected 
under experimental conditions. These papillomas progress to carcinomas with high frequency 
(Breitburd et ah, 1997). A first link between papillomaviruses and skin cancer was obtained in 
1935 from an animal model system, when Rous and Beard described the development of 
squamous cell carcinomas in rabbits after experimental infection with CRPV (Rous and 
Beard, 1935). Thus far, the only model system for studying the progression of papillomavirus- 
induced skin tumours is the domestic rabbit infected with CRPV. Infection of domestic rabbits 
with CRPV particles or viral DNA leads to the development of local tumours within 2 to 8 
weeks post infection. These papillomas progress within 8 to 14 months in all of the cases into 
invasively growing and finally metastasizing carcinomas (Han et ah, 2000). These events 
parallel the outcome of HPV type 16 infections in human populations (explained later) 
(Hildesheim, 1997).
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1.2.2 Bovine papillomaviruses
BPVs induce papillomas of cutaneous or mucosal epithelia in cattle. Six different types of 
bovine papillomaviruses have so far been characterized, each one associated with a specific 
disease. These viruses were divided three subgroups Delta (Ô)-papillomavirus, Xi (Q- 
papillomavirus and Epsilon (s)-papillomavirus, on molecular, immunological, histological, 
pathological and clinical manifestation, ô-papillomavirus includes BPV type 1 and BPV type
2, which cause lesions of both dermal fibroblasts and kératinocytes, 8-papillomavirus includes 
BPV type 5 that like ô-papillomavirus cause lesions of both dermal fibroblasts and 
kératinocytes and ^-papillomavirus comprises the epitheliotropic papillomaviruses BPV type
3, BPV type 4 and BPV type 6, which involve only kératinocytes (de Villiers et al, 2004). 
The BPV genome, even though retaining the general organization common to all 
papillomaviruses, differs between ô-papillomavirus, ^-papillomavirus and s-papillomavirus. 
The Ô- papillomavirus and s-papillomavirus have a genome of approximately 7.9 kbp but the 
^-papillomavirus have a smaller genome of approximately 7.3 kbp (Campo, 1995). The BPV 
genomes are divided into a long control region, which includes responsive sites for viral 
transcription and replication, the early region, which encodes the early proteins (E1-E8) that 
are responsible for the establishment and maintenance of the viral infection and the late region 
that encodes structural proteins, LI and L2. It has been demonstrated that the ^- 
papillomaviruses lack the E6 oncogene, which is replaced by the E5 gene (Patel et al, 1987; 
Jackson et al, 1991). The E5 gene is functionally homologous to the E5 gene of BPV-1 and 2 
(Faccini et al, 1996; Ashrafi et al, 2000). Both BPV-1 and BPV-2 are capable of 
transforming primary bovine fibroblast or epithelial cells to complete oncogenicity (Campo,
1992), but BPV-4 DNA alone is not sufficient to induce transformation of primary bovine 
cells and needs the cooperation of an activated ras oncogene (Jaggar et al., 1990). In BPV-1,
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the E5 and E6 ORF encode functionally major transforming protein whereas E7 is a lesser 
extent to the transformation of bovine cells (Campo, 1992); while in BPV-4 the E5 and E7 
ORF encode the major transforming protein. Both E5 and E7 cooperate. The three groups of 
BPVs are evolutionarily more closely related to each other within three subgroups then they 
are among subgroups and there is a little or no immune cross-reaction between the members 
of the subgroups (Campo, 1995).
Table 1. Bovine papillomaviruses and the tumours they cause
Genus
Delta (Ô)-PV
Epsilon (s)-PV 
Xi (0-PV
type Tumom- caused
BPV-1 Fibropapillomas of paragenital areas
BPV-2 Fibropapillomas of skin and alimentary canal
BPV-5 Fibropapillomas of teats and udders
BPV-3 Papillomas of skin
BPV-4 Papillomas of alimentary canal
BPV-6 Papillomas of teats and udders
from de Villiers et al, 2004
Some of the BPV types have been identified to be associated with cancer in cattle, BPV-1 and 
BPV-2 which cause skin warts, also cause cancer of the urinary bladder, BPV-4 has been 
found as the etiologically agent of upper alimentary canal cancer; BPV-1 is also involved in 
cancer of the penis (Campo, 1997 and 2002). Both urinary bladder cancer and upper 
alimentary canal cancer develop as a result of the interaction between the virus, 
enviromnental factors (bracken fern) and host cell factors activation. BPV-1, BPV-5 and 
BPV-6 can cause economic consequence, as cows with papillomatosis of teats and udders 
cannot be milked, young calves cannot suckle (Campo, 1997).
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1.2.3 Human papillomaviruses
HP Vs are small double-stranded DNA tumour viruses of approximately 8 kbp. HP Vs are 
ubiquitous in the human population, and occasionally infection leads to cervical cancer. They 
infect cutaneous and mucosal epithelial tissues of the anogenital tract, the hands, or the feet, 
which cause a wide variety of disease from skin and anogenital warts to laryngeal papillomas 
and anogenital interaepithelial neoplasias that often progress to malignancy (Walboomers et 
al, 1999). To date, over 100 different types of HPV have been identified, and about one-third 
of these infect epithelial cells in the genital tract. The HPV types that infect the genital tract 
are divided into two categories: high-risk and low-risk (Table 2) (Munoz et al, 2003). The 
low-risk HPV types such as HPV-6 and HPV-11, commonly cause benign warts and low- 
grade premalignant lesion that regress and do not progress to cancer while the high-risk types 
of HPV which include HPV-16, HPV-18, HPV-31, HPV-33, and HPV-45 are associated with 
the development of anogenital cancers and found in more than 99% of all cervical carcinomas 
(Walboomers et al, 1999; Munoz et al, 2003), with HPV-16 occurring most frequently 
(Munoz and Bosch, 1997; Munoz et al, 2003). Infection by high-risk HPVs is not limited to 
the genital tract, since approximately 20% of cancers of the oropharynx contain DNA from 
these HPV types (Herrero et al, 2003).
Table 2. Genital HPV and their associated risk of cancer
Low risk 6, 11,40,42-45, 53-55, 57, 59, 61, 67, 69, 71, 74, 82
High risk 16, 18, 31-35, 51-52, 56, 58, 61, 66, 68, 70, 73
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1.2.3.1 HPV and Cervical cancer
Cervical cancer is the most common cause of cancer death in women worldwide. Both 
incidence and mortality from cervical cancer are second only to breast cancer and in parts of 
the developing countries, cervical cancer is the major cause of death in women of 
reproductive age (Boffetta and Parkin, 1994). Cervical intraepithélial neoplasia (CIN), which 
is a precursor of cervical cancer, is classified histologically into three classes (CIN I, CIN II 
and CIN III), based on its severity. The level of cellular changes is determined by 
histopathology and microscopy of Pap smears. Infection of the genital tract by HPVs can 
initially result in low-grade lesions termed dysplasias or CIN I (Bosch et al, 2002). These 
lesions exhibit only mildly altered patterns of differentiation, and many of them are cleared by 
the immune system in less than a year (Jenson et al, 1991; Hopfl et al, 2000). The 
mechanisms by which the cellular immune response clears HPV infections are still not clearly 
understood. Some of these lesions, however, are not cleared by the immune system and can 
persist for periods as long as several decades. Persistence of infection by high-risk HPV types 
is the greatest risk factor for development of genital malignancies (zur Hausen, 1996 and 
2000). Certain strains of HPV are associated with different risk levels of the transformation 
into cervical tumours. High-risk HPV-16 and 18 are found with the highest frequencies in 
cervical cancer and account for approximately two thirds of all cervical carcinomas 
worldwide (Munoz, 2000; Munoz et al, 2003). HPV-16, 18, and 31 are constantly associated 
with moderate to severe cases of cervical dysplasia and less associated with invasive cancers 
of the vulva, penis, and anus. It has been demonstrated that the presence of even minimal 
amounts of HPV DNA is associated with an increased risk in the development of cervical 
cancer (Munoz et al, 1992). HPV DNA is found in up to 100% of cervical tumoui’s, while in 
cervical tissue of healthy women the figure is typically below 10% (Wallin et al, 1999). It has
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been reported that the DNA of HPV-16, 18 can be found in about 70% of cervical cancer 
biopsies and HPV-16 is present in about 50% of these case (Figure 1) (Bosch et ai, 1995). 
The majority o f the remaining positive biopsies contain several additional types o f HPV.
Figure 1. Worldwide prevalence o f HPV DNA in cervical tumors
Other HPV
HPV45
HPV 31
HPV 16
HPV 18
Figure 1: The prevalence o f HPV DNA in cervical tumours in worldwide have been shown 
that HPV 16 50%, HPV 18 14%, HPV 31 5%, HPV 45 8% and other HPV types 23%, (Bosch 
et al, 1995).
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1.2.3.2 HPV type 16
HPV-16 is the most prevalent HPV subtype detected in CIN (Clifford et al, 2003). It is also 
found in cancer of the tonsils, anus, penis and cancer of neck (Klussmann et al, 2001 and 
2003). The HPV-16 genome consists of a single molecule of double-stranded, circular DNA 
containing approximately 7,900 bp associated with histones (Favre, 1975). The HPV-16 
genome is functionally divided into three regions of wliich at the end of each coding region 
there are polyadenylation sites (Figure 2). The first is a non-coding region, which has been 
referred to as the long control region (LCR), or the upstream regulatory region (URR). This 
region contains the p97 main early promoter, and sequences that regulate DNA replication. 
This region also contains the highest degree of variation in the viral genome. The second is an 
early region, consisting of ORFs E l, E2, E4, E5, E6, and E7, which are involved in viral 
replication and oncogenesis. The third is a late region, which encodes the LI and L2 structural 
proteins for the viral capsid. HPVs express many different polycystronic transcripts 
throughout the viral life cycle thus co-ordinating the expression of the viral gene products 
with the differentiation of the host cell. Additionally transcription initiates from several 
different promoters during keratinocyte differentiation (Doorbar et al, 1990). Viral 
transcription is controlled by cellular transcription factors binding the LCR and by the virally 
encoded E2 protein (Bouvard et al, 1994b; Steger and Corbach, 1997). The epithelial 
specificity of HPV infection is thought to be due in part to specific control elements in the 
enhancer and promoter sequences in the viral LCR (Vance et al, 1999). Viral replication is 
initiated within the viral origin of replication (Ori) and is dependent on the virally encoded 
replication factors El and E2 (Desaintes and Demeret, 1996). HPV-16 encodes two major 
oncoproteins: E6 and E7, which together modify the expression patterns and activities of 
many cellular gene and proteins. They can be retained and expressed in cei-vical cancer and
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cancer-derived cell lines and are enough for host-cell immortalization. The virus also encodes 
E5 protein, the minor transforming protein in HPV-16 but the major transforming protein in 
BPV.
Figure 2. Diagrammatic structure of HPV-16 gene
E7
E6
El E5
E2
E4
LI
El
LCR 
-------- ►
2 3 4 5
Non-Structural genes
6 7 kbp
Structural genes
Figure 2: Schematic of genome organization of HPV-16. ORFs are labeled E or L depending on 
their position in the early or late region of the genome. The early region contains the early genes 
E l, E2, E4, E5, E6 and E7 and the late region contains the late genes LI and L2. The LCR, which 
is a non-coding sequence, has the position of the El and E2 binding sites. Also LCR has an origin 
of replication site that is required for efficient viral DNA replication.
1.2.3.3 The HPV life cycle
In the case of infection by low-risk HPV types (HPV-6 and 11), which cause papillomas or 
warts, the viral genome appears to remain episomal, and this extrachi'omosomal DNA 
maintains gene expression. This is in contrast to high-risk HPV types (HPV-16 and 18), 
which are associated with anogenital dysplasia and cancer. HPV infects the squamous 
epithelium thi'ough micro-traumas and its life cycle is closely linked to the differentiation
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status of host epithelial tissue (Laimins, 1993). Infection is thought to occur in cells where 
viral genomes are established as episomes in the nucleus at approximately 50-100 copies per 
cell in the basal layers of the epithelium and are replicated synchronously with chromosomal 
DNA and following cell division (LaPorta and Taichman 1982; Stubenrauch and Laimins,
1999). The establishment and maintenance of HPV genomes are associated with the 
expression of the HPV early proteins, E l, E2, E4, E5, E6 and E7, involved in DNA 
replication and transcription in host cell. Coincident with the distal movement of infected 
cells, late gene expression occurs, giving rise to LI and L2 capsid proteins and virion 
formation in the upper-layers (LaPorta and Taichman 1982). The HPV genome replication is 
dependent on El and E2 and the cellular replication apparatus and E2 also controls viral 
transcription (Fehrmann and Laimins, 2003). Additionally, it has been demonstrated that E6 
and E7 play important roles in the HPV life cycle (Thomas et al, 1999; Flores et al, 2000). 
This results in the proliferation of infected cells and a drive into S-phase that allows the 
replication of the viral genome and its segregation into the daughter cells (Lambert, 1991). 
The presence of E7 protein leads to the characteristic retention of nuclei throughout all layers 
of infected epithelial cells (Cheng et al, 1995). Both E6 and E7 have also been shown to be 
necessary for the maintance of extrachromosomal forms. Following infected cell division, 
viral DNA is distributed between both daughter cells. One of the infected daughter cells 
migrates away from the basal layer and begins to differentiate and the other daughter cell 
continues to divide in the basal layer and provides a reservoir of viral DNA for further cell 
division. In contrast to uninfected kératinocytes, which exit the cell cycle as soon as they 
detach from the basement membrane, HPV-infected cells do not exit the cell cycle. 
Amplification of the genome to high levels prior to encapsidation is thought to occur with 
HPV-16 in cells of the suprabasal layer. This is followed by the synthesis of the EHE4
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proteins and both o f the LI and L2 capsid proteins, resulting in the assembly of infectious 
virions. Infectious virions are released into the environment as the upper layer of the 
epithelium is shed to infect new individuals or new sites in the same host (Frattini et al,
1996). The EU E4 protein is suggested to help counteract the effects o f the E7 protein, 
facilitating a productive life cycle (Flores et al, 2000).
Figure 3. Schematic o f HPV-16 life cycle
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Basal
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Viral infection
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Figure 3: Schematic normal and HPV-infected epithelia are compared, and differentiation- 
dependent viral functions are shown. When a basal cell divides, a daughter cell will migrate 
upwards in the cell layers and start to differentiation. The migration of cells will continue to 
the upper layer o f the epithelium until it is terminally differentiated whereby it is sloughed 
off. Papillomavirus enters the epithelium through micro-traumas and infects the basal layer 
cells. In the early stage, virus infection will be established but no viruses will be produced.
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Late in cell differentiation, the viral structmnl genes will be expressed and infectious virus 
assembled. Viruses are released as eells are sloughed off (Fehrmann and Laimins, 2003).
1.2.3.4 Integration of the HPV-16 genome in the host cell
HPV types are associated with the development of malignant lesion such as squamous cell 
carcinoma (zur Hausen, 1996). Initial infection with the HPV-16 causes low-grade disease 
and the viral DNA exists in episomal form in the cell nucleus. In the majority of the HPV- 
associated cancers, the viral DNA has been integrated into the genome of the host eell by 
accidental disruption of the viral genome from eircular to linear (Schwarz et al, 1985). The 
integration of HPV-16 genome is apparently non-specific with respect to the site in the host 
cell genome, although in some cases integration has occurred in the vicinity of cellular 
oncogenes (Lazo et al, 1992). HPV DNA integration has been suggested to be an important 
event in the development of cervical cancer, since this often results in a disruption of the E2 
region (Figure 4) (Schwarz et al, 1985; Baker et al, 1987; Fehrmann and Laimins, 2003), 
which controls viral replication and transcription. This not only allows the viral oncoproteins 
E6 and E7 to remain expressed but also up-regulates their expression due to loss of the viral 
transcriptional regulatory gene E2 (Fehrmann and Laimins, 2003).
Figure 4. Schematic of HPV-16 genome integration in the host eell
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Figure 4: Papillomavirus DNA integration into host cells may accelerate progression to 
malignancy, since this often results in a disruption of the E2 region. The loss of the viral E2 
genome allows the E6 and E7 to express. The early and late ORFs of an integrated form of 
HPV are indicated (Fehrmann and Laimins, 2003).
1.2.3.5 HPV-16 proteins
1.2.3.5.1 Viral DNA replication proteins
Viral DNA replication occurs in the infected cell by using the cellular DNA replication 
machinery. HPV encode two non-structural viral proteins El and E2, which are efficient HPV 
DNA replication factors. Both of the E l and E2 proteins together recruit the cellular proteins 
required for the viral genome replication. E l and E2 proteins bind the viral DNA, which is 
necessary to initiate replication from ori, the viral origin of replication. Also it has been found 
out that the EME4 protein has a significant role in the vegetative replication of the viral 
genome (Longworth et al, 2004).
1.2.3.5.1.1 HPV-16 E l protein
The HPV-16 El protein is a nuclear phosphoprotein of 649 amino acids that contains blocks 
of homology in the C-terminal amino acids with the SV40 replication protein large T antigen 
and other pollyomaviruses (Clertant and Seif, 1984; Fonts et al, 1999). The El protein of 
papillomavirus has ATPase functions and ATP dependent helicase activity, which are 
essential for both initiation of viral replication and elongation of viral DNA (Hughes and 
Romanos, 1993). It is capable both of binding to the origin of replication and interacting with 
the E2 protein (Liu et al, 1995; Benson and Howley, 1995) as a hexanier, where it hydrolyses 
ATP to unwind the DNA (Sedman and Stenlund, 1998). The El amino terminus binds to the
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p68 of the polymerase a-primers, which is the only polymerase able to initiate DNA 
synthesis, and it is essential for the replication of DNA fork (Masterson et al, 1998; Conger 
et al, 1999). The p68-binding domain is in a region of the El C-terminus where E2 binds; 
therefore it is possible that the initiation of DNA synthesis by El is after the function of E2 in 
HPV replication has been fulfilled. Both El and E2 have been shown to be essential for the 
replication of the DNA of various HPV types (Ustav and Stenlund, 1991). As well as binding 
to specific sequences at the origin of replication, both El and E2 proteins bind each other. El 
binds the origin with weak affinity but the additional binding of E2 increases this affinity. The 
El binding site is AT rich region with more variability than the E2 binding site and lies 
between E2 sites (Frattini and Laimins, 1994; Sun et al, 1996). As mentioned above, both 
proteins are required for episomal replication of the genome in human kératinocytes and when 
either ORF is disrupted the genome integrates into the host chromosome.
1.2.3.5.1.2 HPV-16 E2 protein
The E2 ORF encodes a 42-48 kilo dalton (KDa) protein that contributes to multiple biological 
processes including viral transcription, viral DNA replication, and is essential for completion 
of the viral life cycle. HPV E2 protein can be divided into thi'ee functional domains; an N- 
terminal acidic transactivation domain, a C-terminal DNA binding domain and a central 
flexible hinge domain. E2 binds to 12 base pairs (bp) palindromic sequences (5'- 
ACCGN4CGGT-3 ') in the viral LCR as a homodimer to the C-terminus domain (Hegde, 
2002), The central flexible hinge domain is rich in potential phosphorylation sites and is 
involved in tethering the HPV episomal circular DNA to the chromosomal DNA (Gauthier et 
al, 1991). The amino terminal transactivation domain is involved in transcriptional 
regulation, replication and direct association with the El protein (Ferguson and Botchan,
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1996; Sakai et al, 1996). Interaction between El and E2 is essential for replication of the 
viral genome, E2 binds to DNA binding sites that flank the El binding site and the amino- 
terminal of E2 interacts with El and recruits El to the origin of replication (Chao et al., 1999; 
Titolo et al., 1999). The activation of E2 protein usually occurs when the full-length 
molecules are presented but acts as a repressor of the early promoter in high-risk HPV (e.g. 
HPV-16). The HPV genome is frequently integrated in the host cell genome by accidental 
disruption of the viral genome from circular to linear. In cell lines derived from HPV 
associated cervical cancers with an integrated high-risk. In HPV associated cancer cell lines a 
common event is the deletion of E2 coding sequences during viral integration. This results in 
very high levels of expression of the viral oncogenes E6 and E7. Expression of either HPV-16 
or 18 E2 in these cells represses the expression of E6 and E7 resulting in the induction of 
apoptosis (Dowhanick et al, 1995; Desaintes et al, 1999).
1.2.3.5.1.3 HPV-16 E4 protein
The HPV E4 protein is translated from spliced transcripts as a fusion with the first 5 amino 
acids of El to the protein encoded by the E4 ORF hence is often referred to as El'^Ed. The 
E1^E4 protein can be easily detected in papilloma HPV-16 positive lesions. In genital lesion, 
EME4 expression occurs in the supra-basal layers (Doorbar et al, 1997), whilst in HPV-1 
positive cutaneous warts, it occurs much deeper in the epithelial layers and observed as early 
as the supra-basal layers (Chow et al, 1987). In some HPV infection the E1'^E4 proteins are 
expressed in the late phase of the viral life cycle and expression correlates with the onset of 
vegetative viral DNA amplification, prior to the expression of the viral structural proteins 
(Doorbar et al, 1997; Middleton et al, 2003). The EME4 protein is also present in superficial 
cells that express the structural proteins LI and L2 (Crum et al, 1990; Brown et al, 1994).
26
Chapter 1 Introduction
The expression of the HPV-16 E1‘^ E4 protein in cultured epithelial cells can cause 
reorganization of the keratin intermediate-filament network by interaction with the keratins 
which are major structural protein in epithelial cells. It has been determined that transient 
expression of the HPV-16 E1'^E4 protein in human kératinocytes (the natural host cell for 
HPV infection) associates with intermediate filaments resulting in the total collapse of the 
cytokeratin matrix within the epithelial cell. It was proposed a role for E1^E4 in facilitating 
viral egression by destroying the keratin matrix and compromising the strength of the 
keratinized squama in infected tissue. However, in natural infections of high-risk types only a 
limited amount of collapse has been observed. It has also been demonstrated that the HPV-16 
EME4 also binds to a DEAD-box RNA helicase protein (a tetra-peptides Asp-Gla-Ala-Asp) 
(Doorbar et al, 1991), which regulates gene expression at various levels. Hence, E1^E4 may 
regulate the expression of either cellular or viral gene or both of them by binding to DEAD- 
box proteins (Doorbar et al, 2000). However a direct role for E1^^E4 protein in the viral life 
cycle has not yet been demonstrated but several studies suggest how it may be able to 
significantly enhance viral replication. It has been shown that many HPV EME4 proteins, 
including HPV-16 EME4, induce a cell cycle arrest at the G2 (Davy et al, 2002; Nakahara et 
al., 2002). It is suggested that the role of E1'^E4 protein in the productive life cycle may be to 
counteract the effects of E7, which acts to push cells into the S phase (Chang and Laimins,
2000). It has been suggested that HPV-1 E4^E1 protein may be involved in the replication of 
the virus in the differentiated cells (Davy et al, 2002; Roberts et al, 2003).
1,2.3.5.2 Viral transforming proteins
HPVs of the high-risk type such as HPV-16 encode three transforming proteins E5, E6 and 
E7. While E6 and E7 are mainly responsible for their transforming properties (Munger and
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Howley, 2002) E5 has weak transforming activity but increases greatly the oncogenic 
properties of E7 (the E5 protein will be discussed later) (Valle and Banks, 1995; DiMaio and 
Mattoon, 2001).
1.2.3.5.2.1 HPV-16 E6 protein
HPV-16 E6 ORF encodes a small nuclear protein, 151 amino acids, containing two zinc 
finger domains. E6 protein induces several important changes in the host cell that impact both 
are the normal viral life cycle and the process of immortalization. E6 protein interacts with 
several cell proteins and this function can alter the cell, making it more amenable to 
production of new viral particles (Li et al, 2005). The main activity of the high-risk HPV E6 
proteins is the stimulation of the ubiquitin mediated degradation of p53 tumour suppressor 
protein. Both the binding of E6 to p53 and the ubiquitination are dependent on the cellular 
E6-associated protein (E6-AP) (Li and Coffmo, 1996; Scheffner and Whitaker, 2003). The 
low-risk E6 proteins are able to interact with p53 “m vitro” but do not target p53 for 
proteolysis vivo” (Elbel et al, 1997). p53 is a transcription factor that stimulates the 
expression of genes involved in cell cycle arrest and apoptosis, such as the cyclin dependent 
kinase inhibitor, p21. The prevention of translocation and degradation of p53 by E6 inhibit the 
ability of p53 to activate or repress transcription of target genes (Mietz et al, 1992). Pan and 
Griep showed (Pan and Griep, 1994 and 1995) that using transgenic mice with targeted 
expression of E6 in the lens of the eye, E6 could block apoptosis. Another study (Jackson and 
Storey, 2000) showed that using E6 genes from mucosal and cutaneous subtypes of HPV all 
E6 proteins was capable of blocking apoptosis induced by ultraviolet (UV) radiation. This 
interaction probably contributes to the p53 independent inhibition of apoptosis. If left 
unchecked, the increase in p53 and induction of p53 dependent apoptosis would most likely
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kill an infected cell before viral replication could take place. Thus, the ability of E6 to 
modulate p53 levels may be integral during productive infection. It has been shown that E6 
can up-regulate the activity of the cellular’ telomerase complex, which is an enzyme that 
maintains the telomeric DNA at the ends of chromosomes (Gerider and Blackburn, 1985). 
Without telomerase, telomeres gradually shorten with each cell division, imtil they reach a 
critically short length. It has been suggested that telomere shortening functions as a sort of 
molecular clock, controlling the number of cell divisions. Additionally, cells that normally 
proliferate in vivo have detectable telomerase activity, as do most tumour cells, while cells 
that normally have a limited lifespan in vivo generally do not show telomerase activity 
(Harle-Bachor and Boukamp, 1996). It has been shown, in vitro, that the telomerase activity is 
increased in HFK (human foreskin keratinocyte), HFF (human foreskin fibroblast) and 
HMEC (human mammai’y epithelial cell) expressing HPV-16 E6 (Klingelhutz et al, 1996; 
Stoppler et al, 1997). E6 expression was shown to transactivate the HPV early promoter in 
the URR (Gius et al, 1988). The mechanism for this transcriptional alteration was not 
dependent on p53. HPV-16 E6 proteins are capable of interacting with p300 and GBP to 
inhibit p300/CBP mediated transcriptional activation. Both p300 and GBP are transcriptional 
co-activators and bring together transcription factors and the basal transcription machinery at 
gene promoters. They also have intrinsic histone acetyltransferase activity, allowing them to 
acetylate histone core proteins and alter chiomatin structure (Patel et al, 1999; Zimmermann 
et al, 1999). Therefore, an explanation of the earlier work on the transcriptional repression by 
E6 may be the interaction of E6 with the coactivators GBP and p300. E6-GBP/p300 binding 
probably impacts transcription of other genes.
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1.2.3.5.2.2 HPV-16 E7 protein
The HPV-16 E7 ORE is predicted to encode a 98-amino-acids protein, which is divided into 
three conserved regions (CRl, CR2, and CR3), which share significant homology with 
conserved domains 1 and 2 of adenovirus oncoprotein ElA. The homology with conserved 
domain 2 is also found in the SV40 large T proteins. E7 induces significant biological 
changes, particularly in regard to cellular growth (Barbosa et al, 1990; Dyson et al, 1992). 
E7 binds and inactivates pRb and two pRb related proteins p i07 and p i30 (Munger et al,
2001). The retinoblastoma protein family members play a central role in the regulation of the 
eukaryotic cell cycle. More specifically, in its hypophosphorylated state, Rb can bind to 
transcription factors such as the E2F family members and repress the transcription of 
particular genes. As cells progress from Go thi'ough Gi and into S phase, Rb family members 
become progressively hyperphosphorylated by Gi cyclins- CDKs, consequently releasing the 
transcription factor E2F, which in turn activates genes involved in DNA synthesis and cell 
cycle progression (Dyson, 1998). Since E7 is able to bind to unphosphorylated Rb, it is 
believed that E7 can prematurely induce cells into S phase by disrupting Rb-E2F complexes 
(Huang et al, 1993; Patrick et al, 1994). Additionally, E7 is able to bind transcription factor 
AP-1 and activate its activity and therefore hypothetically after the differentiation of the cells 
(Antinore a/., 1996).
1.2.3.6 Papillomavirus E5
The analysis of the DNA sequence of the papillomavirus genome revealed that E5 ORFs 
commonly is located at the 3 ’ end of the early region before the L2 ORF and overlaps the E2 
ORF in the early region. However, in the ^-papillomavirus epitheliotropic BP Vs the E5 ORF 
(previous named E8) is located 5’ to the E7 ORF and replaced the E6 ORF (Jackson et al,
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1991). The CRPV genome has two E5-like (E8 and E5) ORFs in the early region (Han et al, 
1998), suggesting either gene duplication or translocation without loss of the E6 ORF. The E5 
genes of PVs encode small hydrophobic proteins, many of which have been shown to have 
transforming activity, from 42 amino acids residues in BPV-4 to 83 amino acids residues in 
HPV-16. The most studied PV E5 proteins in animal and human are BPV-1 and HPV-16 
respectively. BPV-1 E5 protein can be divided into two domains, N-terminus and C-terminus, 
The N-terminus, which is a hydrophobic domain, includes 30 amino acids and is thought to 
exist in an a-helical conformation important for membrane anchoring and cell transformation. 
The C-terminal amino acids are generally hydrophilic, 14 amino acids in BPV-1 including 
two cysteine residues which are important for homodimerization and transforming activity 
(Burkhardt et al, 1987; Horwitz et al, 1988). It has been suggested that E5 protein is a type II 
transmembrane protein that is localized asymmetrically in Golgi membranes with its C- 
terminus being oriented toward the Golgi lumen (Bmkhardt et al, 1989). HPV-16 E5 is a 
hydrophobic membrane protein, 83 amino acids long, located mainly at the endosomal 
membranes, Golgi apparatus and, to a lesser extent, the plasma membranes (Conrad et al,
1993). It has been determined by hydropatic analysis that HPV-16 E5 protein has three 
hydrophobic domains connected by less hydrophobic regions (Bubb et al, 1988), and in vitro 
transcription-translation experiments show the protein is rapidly incorporated into microsomal 
membranes. In contrast to BPV-1 where E5 is the main oncoprotein, little is known about the 
biological activity of HPV-16 E5. However, the amino acid analysis of the HPV E5 proteins 
and BPV E5 has revealed that they are very different (Table 3).
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Table 3. Amino acid sequences of BPV-1 E5 and HPV-16 E5 proteins
BPV-1 E5 iMPNLWFLLFL GLVAAMQLLL LLFLLLFFLV YWDHFECSCT GLPF44 1 atgccaaatc tatggtttct attgttcttg ggactagttg ctgcaatgca51 actgctgcta ttactgttct tactcttgtt ttttcttgta tactgggatc101 attttgagtg ctcctgtaca ggtctgccct tttaa
HPV-16 E5 IMTNRDTASTT LLACFLLCFC VLLCVGLLIR PLLLSVSTYT 
SLIILVLLLW ITAASAFRCF IVYIIFVYIP LFLIHTHARF LIT 83 
1 atgacaaatc gtgatactgc atccacaaca ttactggcgt gctttttgct51 ttgcttttgt gtgcttttgt gtgtctgcct attaatacgt ccgctgcttt
101 tgtctgtgtc tacatacaca tcattaataa tattggtatt actattgtgg151 ataacagcag cctctgcgtt taggtgtttt attgtatata ttatatttgt201 ttatatacca ttatttttaa tacatacaca tgcacgcttt ttaattacat251 aa
But some limited sequence similarities have been suggested between the HPV-16 E5 and 
BPV-1 E5 proteins, such as a few hydrophobic residues (Bubb et al, 1988). The HPV-16 E5 
protein is nearly twice as long as BPV-1 E5, and is likely to form three transmembrane 
segments. The C-terminal portion of BPV-1 E5, which appears to be important for biological 
function, does not have an identifiably similar region in the HPV-16 E5. It has been reported 
that in BPV-1 and HPV -16-transfected cells, most of the synthesized E5 protein localizes to 
the Golgi apparatus but a small proportion can be found at the plasma membrane (Burkhardt 
et al, 1989; Conrad et al, 1993). The expression of the PV E5 occurs during the early stages 
of infection in the deep layers of the infected epithelial cells like as E6 and E7, and its 
expression is extinguished as the lesion progresses (Burnett et al, 1992; Anderson et al,
1997). Initial infection with the high-risk HPV-16 can cause low-grade disease and the viral 
DNA exists in episomal form in the cell nucleus. During the progression to malignant disease, 
HPV DNA frequently integrates into the host cell genome (Choo et al, 1987; Cullen et al, 
1991). The integration of viral DNA allows for persistent expression of the E6 and E7 
oncogenes. In the episomal form of the viral DNA present in the initial stages of HPV- 
infection, the E5 ORE is present and transcribed in the major abundant viral transcript, E1^E4 
niRNA (Zur Husen and de Villiers, 1994). However, the E5 gene is frequently deleted when
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the HPV genome is integrated (Zur Husen and de Villiers, 1994; DiMaio and Mattoon, 2001). 
Therefore, E5 gene expression is often extinguished after integration of the viral genome 
during the progression from low-grade to malignant disease. For E5 protein to exert effects on 
carcinogenesis, it should therefore act at any early stage. In addition, in well-developed 
carcinomas, E5 has been found to be frequently deleted upon incorporation of the viral DNA 
into the host genome, suggesting that E5 is not necessary to maintain the malignant state 
(Bauer-Hofmann et al, 1996). It was suggested that HPV E5 plays a role in the first steps of 
cellular transformation. This is supported by the fact that in cervical intraepithélial neoplasia 
(low-grade intraepithélial neoplasia) lesions large amounts of E5 mRNA as well as of E5 
protein can be detected (Stoler et al, 1992). The E5 protein is able to interact with several 
different cellular proteins, including the epidermal growth factor receptor and the 16 k subunit 
c of the vacuolar H'^-ATPase. In addition, BPV-1 E5 protein interacts with platelet-derived 
growth factor receptor (Petti and DiMaio, 1994).
1.2.3.6.1 BPV-1 E5 and platelet-derived growth factor receptor
The BPV E5 protein induces tumorigenic transformation of rodent fibroblasts and is the major 
transforming protein of this virus (Bergman et al, 1988). This small, 44-amino-acid 
transmembrane protein exists as a dimer with a subunit size of 7 kDa and localizes primarily 
to the endoplasmic reticulum and Golgi membranes of transformed cells (Burkhardt et al, 
1989). It has been suggested that the E5 protein transforms cells by modulating the activity of 
a cellular membrane-associated growth-regulatory protein. Several studies have demonstrated 
that the BPV E5 protein is critical for binding and activation of the platelet-derived growth 
factor receptor (PDGF) p receptor and for cell transformation (Sparkowski et al, 1996). It has 
also been shown that the interaction between BPV E5 oncoprotein and the activated PDGF p­
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receptor takes place in naturally occuning urinary bladder tumours in cattle (Borzacchiello et 
al, 2006). It has been demonstrated that the E5 protein forms a stable complex with and 
activates the PDGF p-receptor in E5-transformed fibroblasts (Petti et al, 1991; Petti and 
DiMaio, 1992). The PDGF p-receptor is a cell surface receptor tyrosine kinase, which 
stimulates cell proliferation and has been associated with some cancers. The binding of PDGF 
to its receptor causes activation of the tyrosine kinase receptors and receptor 
autophosphorylation, followed by activation, leading to cell transformation (Claesson-Welsh,
1994). The binding of the E5 protein to the PDGF receptor (PDGF-R) results in PDGF-R 
activation and this activated PDGF-R transmits a sustained growth-stimulatory signal, 
resulting in cell transformation in the absence of ligand (Petti and DiMaio, 1992 and 1994). 
Complex formation between the E5 protein and the PDGF p-receptor is mediated by 
interactions between the transmembrane and juxtamembrane regions of the two proteins, and 
removal of the ligand-binding domain of the receptor does not disrupt interaction with the E5 
protein. A positive charge at position lysine 499 in the extracellular juxtamembrane region of 
the receptor and threonine 513 in the transmembrane domain are required for interaction with 
the E5 protein and for E5-induced receptor activation but not for activation by PDGF. The E5 
protein does not interact with the related PDGF a-receptor, a difference that map to the 
transmembrane/juxtamembrane region of the receptor (Staebler et al, 1995): both a positively 
charged juxtamembrane residue and the transmembrane threonine are absent from the PDGF 
a-receptor. The E5 protein is thought to be a type II membrane protein and consequently 
would be inserted into membranes in an orientation opposite that of the PDGF p-receptor 
(Claesson-Welsh, 1994). This places aspartate 33 of the E5 protein and lysine 499 of the 
receptor on the extracytoplasmic side of the membrane at the membrane surface, with 
glutamine 17 and threonine 513 buried in the membrane at roughly the same distance relative
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to the membrane surface. These considerations have led to the proposal that t-wo pairs of 
interacting residues, aspartate 33-lysine 499 and glutamine 17-threonine 513, are essential for 
complex formation between the E5 protein and the PDGF p-receptor. It has been shown that 
the dimeric E5 protein in lipid bilayers is largely a-helical and has a transmembrane 
orientation. Computational searches generated two related structural models for the E5 dimer 
that account for the role of glutamine 17 and aspartate 33 in complex formation and are 
consistent with the position of conserved and transformation-sensitive residues (Surti et al,
1998).
1.2.3.6.2 HPV-16 E5 and epidermal growth factor receptor
The transforming activity of E5 may be due in part to its ability to inhibit down-regulation of 
the epidermal growth factor (EGF) receptor (EGF-R). It has been suggested that HPV E5 
associates with the EGF-R that the function of this protein is in a manner similar to BPV E5 
and the PDGF-R (Hwang et al, 1995). In human kératinocytes, the major growth factor 
receptor is the EGF-R, so multiple studies have suggested a link between the HPV-16 E5 gene 
and EGF-R signaling. In addition to the interaction between BPV E5 with PDGF-R, it has 
been reported that BPV-1 E5 cooperates with EGF-R in the transformation of NIFI 3T3 cells 
and induces receptor hyperphosphorylation as well as altered down-regulation (Martin et al, 
1989). The EGF-R that is a transmembrane receptor protein with ligand-activated tyrosine 
kinase activity is present on all epithelial cells, including cervical mucosal cells (Carpenter 
and Cohen, 1990). The expression of HPV-16 E5 in human kératinocytes results in an 
increase of the number of EGF-Rs at the cell surface and in inhibition of receptor degradation 
(Straight et al, 1993). In other studies, E5 has been shown to increase cellular proliferation in 
the presence of EGF in the mouse fibroblasts transfected with HPV-16 E5 (Leechanachai et
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al, 1992). The molecular basis for this effect is not cleai', although it has been suggested that 
E5 associates with the EGF-R (Hwang et al, 1995). Stimulation of the receptor with EGF 
activates a number of signal transduction pathways including the mitogen activated protein 
(MAP) kinase pathway that is associated with both cell proliferation and differentiation 
(Sumbayev and Yasinska, 2005). It has been reported that E5 gene was able to induce an 
increase in the MAP kinase activity (Gu and Matlashewski, 1995). In comparison, the E6 and 
E7 proteins did not stimulate or prolong MAP kinase activity. Additionally, it was revealed 
that the inhibition of the down-regulation of the EGF-R by E5 may be associated with the 
ability of E5 to bind to a 16 kDa proteolipid, which is a component of the vacuolar proton- 
ATPase pump (H^-ATPase) (Comad et al, 1993) and to inhibit the acidification of 
endosomes (Straight et al, 1995). This binding has been suggested to result in a delay in 
EGF-R degradation and an increased recycling of EGF-R to the cell surface (Straight et al, 
1993). Moreover, HPV-16 E5 has been also demonstrated to cooperate with E7 to potentiate a 
mitogenic response, which is enhanced in the presence of the EGF (Bouvard et al, 1994a). 
The close association of E5 biological activities with growth factor receptors would suggest 
that E5 might contribute to the normal viral life cycle and the early stage of viral infection, by 
increasing cell responsiveness to grovrth factors such as EGF.
1.2.3.6,3 E5 and 16 K subunit c/ductin
Several viral oncoproteins such as BPV-1 E5 protein (Goldstein and Schlegel, 1990), HPV-16 
E5 protein (Conrad et al, 1993) and T-cell leukaemia virus type 1 p i2 (Franchini et al., 1993) 
bind to 16 K subunit c/ductin, which is a hydrophobic polypeptide. It is found in two distinct 
membrane complexes, subunit c is a component of the vacuolar H+ ATPase (Mandel et al, 
1988) and as a ductin in a component of gap junctions (Finbow and Pitts, 1993). The binding
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of E5 to ductin has led to the suggestion that the function of the ductin’s transport might be 
impaired. The V-ATPase is a universal transmembrane proton pump of eukaryotic cells and is 
responsible for acidification of cytoplasmic organelles (e.g. Golgi, endosomes, lysosomes, 
and certain secretory vesicles) (Finbo’W and Harrison, 1997). Thus, it has been postulated that 
binding of E5 to the 16K proteolipid would inhibit endosomal acidification leading to an 
increase in receptor recyling to the plasma membrane (Straight et al, 1993 and 1995). The 
effect of this mechanism would be to increase the number of receptors at the cell surface 
signalling in E5-expressing cells (Leechanachai et al, 1992; Pim et al, 1992). It has been 
determined that E5 binds to 16K subunit c which is thought to increase the pH of Golgi 
(Schapiro et al, 2000). Since growth factor receptors are processed in the Golgi apparatus and 
are internalized via clathrin-coated vesicles, E5 binding to the 16 K subunit c within these 
components may be an intermediate step to receptor activation and signal transduction,
1.2.3.6.4 E5 and gap junction
Gap junction channels span the plasma membrane of two adjacent cells and allow cell-cell 
communication via diffusion of small molecules. This channel is called connexon (Simon and 
Goodenough, 1998). Each hemi-channel consists of the oligomers of six protein subunits. 
Most cells such as epithelial cells form gap junctions. They contribute to the maintenance of 
homeostasis between cells in a tissue or in a proliferative unit (Kam and Hodgins, 1992). 
Numerous reports have shown that gap junction communication can be regulated at various 
cellular levels, including mRNA transcription, mRNA stability and channel gating (Bruzzone 
et al, 1996). Often, gap junctions are not functional in transformed cells and the isolation of 
transformed cells from their normal neighbours is thought to contribute to the neoplastic 
process (Budunova et al, 1995). 16 K subunit c is also the ‘ductin’ component of a type of
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gap junction, an intercellular complex that provides sites of cell-to-cell movement (Finbow 
and Pitts, 1993; Finbow et al, 1995). Connexins also form gap junction channels, and mutant 
forms of ductin that have transforming ability disturb connexin localization and down-regulate 
gap junction communication (Saito et al., 1998). It has been reported that several E5 proteins 
(e.g. BPV-1, 4 and HPV-6, 16) bind to ductin and this interaction is deemed responsible for 
the observed down-regulation of gap junctions (Goldstein et al, 1991; Conrad et al, 1993; 
Faccini et al, 1996; Ashrafi et al, 2000), In addition, HPV-16 E5 reduces gap junction- 
mediated intercellular communication via dephosphorylation of connexin 43 (Oelze et al,
1995). This results in the inhibition of tissue homeostatic feedback, which has also been 
described as an early event in carcinogenesis progression (King et al, 2000).
1.2.3.6.5 E5 and Apoptosis
Cell growth normally reflects a dynamic balance of cell proliferation, differentiation, and 
apoptosis. Apoptosis is a morphologically and biochemically distinct form of eukaryotic cell 
death that occurs under a variety of physiological and pathological conditions (Arends et al, 
1991). Two main apoptotic routes have been identified that include the death receptor (DR) 
pathway and the mitochondrial pathway (Danial and Korsmeyer, 2004). The activation of the 
DR pathway takes place by ligation of members of the tumour necrosis factor (TNF) family, 
such as Fas ligand (FasL; also called Apol) and Apo2 ligand (Apo2L; also called TNF-related 
apoptosis-inducing factor [TRAIL]), to DR on the plasma membrane. This family consists of 
trimeric ligands that induce defined cellular responses upon binding to their respective 
receptors. They include the adaptor protein F ADD (Fas-associated death domain) and 
subsequent recruitment of procaspase-8 and this protein complex is called death-inducing 
signaling complex (DISC). DISC formation provides the necessary environment for activation
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of procaspase- 8  by autocatalytic cleavage (Scaffidi et al, 1999; Krueger et al, 2001). FasL, 
which is a 40-kDa, binds to the Fas (CD95) receptor leading to activation and clustering of the 
death receptors (Schneider et a l, 1997; Walczak et al, 2000). TRAIL interacts with several 
cellular soluble receptors (Emery et al, 1998), the TRAIL receptors 1 and 2 that contain 
intracellular death domains (DDs) to transmit the apoptotic signal (Pan et al, 1997; Kischkel 
et al, 2000; Sprick et al, 2000). Fas and TRAIL receptors are expressed by a broad panel of 
normal epithelial cells (Leithauser et al, 1993; Wiley et al, 1995). Down-regulation of Fas 
expression is a common abnormality in gynecological cancers (Das et al, 2000), whereas the 
expression of TRAIL receptors is not reduced in cervical cancer (Ryu et al, 2000) compared 
to normal tissue. Therefore, it is plausible that HPV-16, like many other viruses (Teodoro and 
Branton, 1997; O'Brien, 1998), has developed mechanisms to delay apoptosis of the infected 
cell and one of its early proteins, namely, E6 , has been identified to prevent intrinsic, p53- 
dependent apoptosis (Scheffner et al, 1990). It has been reported that the HPV-16 E5 protein 
protects the human keratinocyte cell line from TRAIL and FasL-mediated apoptosis and that 
this effect correlates with the level of E5 expression. It proposed that this is a primary 
function of the viral protein (Kabsch and Alonso, 2002).
1.2.3.7 HPV-16 capsid proteins
HPVs encode two capsid proteins LI and L2. The LI protein is the major capsid protein and 
the L2 protein is the minor capsid protein in the virion. Both of them are expressed in the 
terminally differentiated layers of the epithelium and form a protective shell around the viral 
genome (Okun et al, 2001). The L2 protein is found mainly on the inside of the virion and is 
required for infectious virions to form and has been shown to interact with a cell surface 
receptor (Kawana et al, 2001). The HPV L2 protein may play a major role in papillomavirus
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capsid assembly by introducing HPV DNA into the virus particles formed by the self- 
assembly of the LI major structural protein (Zhou et al, 1994). It has been shown that the 
antibody against L2 protein neutralises papillomavirus without preventing virion attaching to 
the cell surface (Roden et al., 1994). The LI protein is the major capsid protein and when 
expressed in various eukaryotic an expression system is able to self-assemble into virus-like 
particles (Kirnbauer et al, 1992). On encapsidation of the double stranded circular viral 
genome the virion conformationally changes into an icosahedral structure with 72 pentamers 
of LI.
1.3 The human immune system
Two main arms of the immune response play an important role in the natural clearance of 
viral infection, innate and adaptive immunity. Innate immunity consists of a quickly induced, 
non-specific response, which does not result in immunological memory. The innate immune 
system is localized at epithelial borders and is stimulated via several immunomodulatory 
cytokines and cellular effectors including monocytes, macrophages, natural killer and antigen 
presenting cells (APC). The innate immune system is likely to play an important first line of 
defence in the control of viral infections (Uthaisangsook et a l, 2002). The adaptive immune 
response arises from a breach of the innate immune response resulting in the generation of 
antigen specific effectors cells and their products that specifically target the pathogen or 
pathogen infected cell, as well as memory cells that will prevent or limit subsequent infection 
with the same organism (Sigal, 2005). It is now presumed that activation of the innate 
immune system stimulates the adaptive immune responses. Different pathogens are handled 
by specific immune responses. At the same time, unwanted immune responses against self­
proteins are avoided. However due to the polymorphism of the vertebrate major
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histocompatibility complex (MHC) genes, different individuals in a population respond 
differently to identical antigens (Ploegh, 1998; Sigal, 2005).
1.3.1 The human leukocyte antigen system
The human MHC is known as human leukocyte antigen (HLA) system, which is located on 
the short arm of chromosome 6 , encodes class I proteins (presenters to cytotoxic T cells) and 
class II proteins (presenters to helper T cells), as well as class III proteins (components of the 
complement subunits). The MHC locus consists of a linked set of genetic loci encoding many 
of the proteins involved in antigen presentation to T cells, most notably the MHC class I and 
class II glycoproteins that present peptides to the T-cell receptor (Sigal, 2005). The 
outstanding feature of the MHC molecules is their extensive polymorphism. This 
polymorphism is of critical importance in antigen recognition by T cells. A T cell recognizes 
antigen as a peptide bound by a particular allelic variant of an MHC molecule, and will not 
recognize the same peptide bound to other MHC molecules. This behavioui' of T cells is 
called MHC restriction (Dunbar and Ogg, 2002). The main function of the MHC class I 
molecules is to present antigenic peptides to cytotoxic T cells (CTLs), When a pathogen 
infects a host cell, the proteins of the pathogen are degraded intracellularly, and a subset of 
different peptides are loaded onto the groove of class I MHC molecules that are transported to 
the cell surface. Once the MHC-peptide complex is present on the cell surface, CTLs can 
mount an immune response against pathogens. The MHC class II genes are very polymorphic 
in human population. They encode proteins that are found on antigen processing/presenting 
cells such as B-lymphocytes and macrophages. The MHC Class II proteins present 13-18 
amino acid peptides derived from extracellular pathogens to T helper lymphocytes and are 
important in the priming and maintenance of the humoral immune response (Dunbar and Ogg,
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2002). MHC class III genes are located between the class I and class II genes and contained a 
variety of genes with known and unknown immune mechanisms. These genes encode for 
some components of the complement system, TNF-a and TNF-p (Ryder and Svejgaard, 1981; 
Beck and Trowsdale, 2000).
1.3.2 MHC class I
The MHC class I molecules are subdivided into two families, classical MHC I or MHC class 
la or and non-classical MHC I or MHC class Ib.
1.3.2.1 Classical MHC class I
The classical MHC I molecules are a family of exceedingly polymorphic cell surface 
glycoproteins found on almost all nucleated somatic cells. These proteins play an important 
role in alerting the immune system to virally infected cells. In human, the classical MHC class 
I glycoproteins, HLA-A, B and C, are expressed on the cell surface of all nucleated cells and 
present peptide fragments derived from intracellular proteins (Hewitt, 2003). These peptides 
are normally derived from the cell's own 'house-keeping' proteins but in a virally infected cell, 
peptides derived from viral proteins are also presented. MHC class I molecules are 
heterodimers of a heavy chain and p2-microglobulin (P2M). The extracellular region of the 
heavy chain includes a l ,  a2 and a3 domains with P2M contributing a fourth domain. The a l  
and a 2  domains form the peptide-binding site that is a groove on the upper surface of the 
MHC class I molecule and binds antigenic peptides of 8-10 amino acids in length (Hewitt, 
2003; Princiotta et al, 2003). These proteins are cotranslationally inserted into the lumen of 
the endoplasmic reticulum (ER). In the ER, the MHC/P2M heterodimer binds peptide that is 
generated by proteasomal protein degradation in the cytosol and translocated into the ER by
42
Chapter 1 Introduction
the transporter associated with antigen processing (TAP) (Pamer and Cresswell, 1998). The 
loading o f peptides into MHC class I molecules occurs in an assembly complex which 
includes TAP. Upon peptide binding, MHC class I molecules leave the ER and traverse to the 
cell surface via Golgi and vesicular transport (Reits et ai, 2000). At the surface, the peptides 
are exposed for recognition by T lymphocytes able to lyse infected cells, an outcome that 
pressures viruses to take defensive measures (Figure 5) (Hewitt, 2003). Given the role that the 
MHC class I antigen presentation pathway plays in the detection o f virally infected cells by 
CTLs, it is not surprising that many viruses have evolved proteins that interfere with this 
pathway (Tortorella et al, 2000).
Figure 5. The processing of viral proteins for presentation o f peptides to cytotoxic T cells
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Figure 5; An effector cytotoxic T cell kills a virus-infected cell when it recognizes fragments 
of viral protein bound to class I MHC proteins on the surface o f the infected cell. Not all
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viruses enter the cell in the way that this enveloped RNA virus does, but fragments of internal 
viral proteins always follow the pathway shown. Some of the viral proteins synthesized in the 
cytosol are degraded, and this is a sufficient amount to attract an attack by a cytotoxic T cell. 
The folding and assembly of a class I MHC protein is aided by several chaperone proteins in 
the ER lumen, only one of which is shown. The chaperones bind to the class I MHCa chain 
and act sequentially. The last one binds the MHC protein to the ABC transporter, as shown 
(Molecular Biology of the cell)
1.3.2.2 Non-classical MHC class I
The human non-classical MHC I includes HLA-E, HLA-F, and HLA-G molecules. Like the 
classical MHC I loci, the non-classical MHC I genes are highly transcribed in many tissues, 
but they display only limited genetic variation. These molecules show homology to classical 
MHC I molecules but generally have limited polymorphism, low cell surface expression, and 
more restricted tissue distribution (Shawar et al., 1994). The function of the non-classical 
MHC I molecules remains unclear, but some of them may have more specialized antigen 
presentation activities. In humans, the non-classical HLA-G molecule binds a wide range of 
peptides derived from cellular proteins and has been suggested to play an important role in the 
maintenance of maternal tolerance to the fetus by interacting with inhibitory receptors on 
natural killer (NK) cells (Lee et aL, 1995). HLA-E is another non-classical MHC I molecule 
and, like classical MHC I loci, the HLA-E gene is highly transcribed in many tissues (Roller 
et ah, 1988). HLA-E preferably binds to a peptide derived from amino-acid residues 3-11 of 
the signal sequences of most HLA-A, B, C, and G molecules, but cannot bind its own leader 
peptide. Cell-surface expression of HLA-E depends on a functional TAP, and is up-regulated 
by the binding of the peptides derived from MHC molecule signal sequences (Brand et ah.
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1998). The close correlation between the surface expression of HLA-E and other classical 
MHC I molecules (HLA/A and B) suggests a possible role for HLA-E in NK cell-mediated 
recognition of target cells.
1.3.3 Natural killer Cells
While classical MHC I molecules (HLA-A/B) are the main presenters of antigenic peptides to 
CTL, HLA-C and non-classical HLA-E inliibit NK cell-mediated lysis by interacting with 
inhibitoi-y receptors. NK cells play an important role in the non-adaptive immune response, 
which is related to their ability to kill target cells lacking MHC class I without prior 
instmction (Ploegh, 1998; Natarajan et a l, 2002). NK cells express receptors that interact 
with MHC class I serving to inhibit or activate their effector function. Two types of receptors 
are specific for self-HLA class I molecules to inhibit NK cells. They include the killer Ig-like 
receptors (KIR) and the lectin-like heterodimer CD94/NKG2 receptors. The KIRs recognize 
classical MHC I to inhibit the activation of NK cells (Colonna and Samaridis, 1995; 
Wagtmann et al, 1995), whereas the CD94/NKG2 receptors recognize HLA-E which is a 
non-classical MHC I molecule (Lopez-Botet et a l, 1997). The inhibitor receptors provide 
the mechanism by which NK cell effector function is prevented against cells expressing 
normal levels of class I HLA molecules but is permitted against cells expressing reduced 
levels of class I HLA molecules, such as on virally infected or tumour cells (Ploegh, 1998). 
The activating receptors provide a mechanism by which NK cell function is stimulated. Thus, 
NK cells would kill classical MHC I negative vims-infected cells, unless non-classical MHC- 
E molecules are present.
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1.3.4 MHC and virus infection:
The MHC class I molecules, which are essential for presentation of foreign peptides to the 
host CTL, are targets of many pathogens, including viruses (Ploegh, 1998; Tortorella et al, 
2000). CTLs recognize virus-infected cells through the specific interaction of their T-cell 
receptor with an MHC class I molecule presenting a viral peptide. The MHC class I complex 
consists of a heavy chain containing the peptide binding site and P2M, which assemble very 
rapidly in the lumen of the ER. Peptides, generated by the proteasome in the cytoplasm, are 
translocated by TAP into the ER where they assemble in ternary complexes and are 
transported to the cell surface for presentation to CTL (York and Rock, 1996). Interference 
with the assembly and/or trafficking of the MHC class I complex can contribute to the 
persistence of a virus, although NK cells can recognize and lyse cells that lack MHC class I 
antigens (Karre, 1991).
Several viruses that induce chronic infections encode proteins that target or modulate the 
host's immune system. Adenovirus was the first virus demonstrated to express E3/19K 
adenovirus protein that binds to MHC class I in the ER and prevents its transport to the cell 
surface. Human cytomegalovims (HCMV) encodes multiple proteins that target MHC class I 
synthesis, peptide loading, and transport. Murine CMV glycoprotein, gp34, also interacts with 
the heavy chain P2M complex in the ER and has been recently shown to target MHC class I 
for degradation in the lysosomes. Infected cell protein (ICP) 47, a protein encoded by herpes 
simplex virus, inliibits the TAP transporter (Tortorella et a l, 2000). More recently, it was 
demonstrated that the K3 and K5 proteins encoded by Kaposi's sarcoma-associated 
herpesvirus down-regulate MHC class I from the cell surface (Ishido et al., 2000). It has been 
demonstrated that the human immunodeficiency virus (HIV) Nef and HCMV US10/UL40 
proteins down-regulate HLA-A/B but does not down-regulate HLA-C/E, which are mostly
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involved in positive selection of inhibitory receptors on NK cells (Cohen et al, 1999: 
Tomasec et al, 2000; Furman et al, 2002).
In HPV infections, several lines of evidence suggest that the immune responses play an 
important role in the control of HPV infection. Generally, HPV infection is characterized by a 
veiy high rate of spontaneous clearance suggesting that immune responses play the essential 
role in the control of infection (O'Brien and Campo, 2003). The first line of defence would be 
at the mucosal surface via the innate immune system. It has been reported that the BPV E5 
protein down-regulates the expression of MHC class I molecules on the cell surface (Ashrafi 
et a l, 2002; Marchetti et a l, 2002). Cells that express E5 have reduced levels of MHC class I 
mRNA and protein and surface MHC class I (Aslirafi et al, 2002). E5 can retain MHC class I 
interacellularly in different cell types, and the site of blockade has been shown to be the Golgi 
(Marchetti et a l, 2002). It has also been shown, in vivo, that BPV-4 E5 protein down- 
regulates MHC class I in BPV-4 papilloma samples (Araibi et al, 2004).
1.3.5 HPV-16 and immune evasion
Interferons (IFNs), which consist of type I {a and jS) and type II (7 ) IFNs, play an important 
role in host defence, having both anti-viral and anti-tumour effects, and may influence 
expression of a number of genes associated with both apoptosis and cell cycle progression 
(Sangfelt et al, 1997). One of the functions of IFNs is to up-regulate the expression of MHC 
class I. The role of MHC class I is to present antigen peptides to CTL. Many viruses down- 
regulate MHC class I either directly or indirectly to establish infection. It has been 
demonstrated that both E6  and E7 proteins of the high-risk HPV (types 16 and 18) inhibit IFN 
CL and pathway. It has been reported that HPV 16 E6  protein binds to interferon regulatory 
factor-3 (IRF-3) and can inhibit its trans-activation function. IRF family members like as IRF-
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3 are believed to play a critical role in the regulated expression of the IFN a  and jS genes 
(Ronco et al, 1998). It has been demonstrated that HPV E7 protein is functionally and 
physically associated with IRF-1, in vivo, and in vitro. The interaction between the IRF-1 and 
the HPV E7 proteins hinder the interferon response (Park et a l, 2000). Additionally, HPV 16 
and HPV 18 E7 protein repress the MHC class I heavy chain gene promoter. Expression of 
the HPV 18 E7 oncoprotein represses MHC class I heavy chain promoter, as well as 
repression of a bidirectional promoter that regulates the expression of the genes encoding 
TAP-1 and a proteasome subunit, low molecular weight protein (LMP2) (which enhances 
degradation of cytoplasmic proteins) (Georgopoulos et al, 2000). E7 down-regulates MHC 
class I by interacting with and inhibiting TAP-1 (Vambutas et a l, 2001). HPV-16 E7 also 
interacts with the human subunit 4 (S4) ATPase of the 26 S proteasome and degrades Rb 
tlu'ough the 26 S proteasome pathway (Berezutskaya and Bagchi, 1997).
1.3.6 E5 and MHC class I
MHC class I molecule is essential for presentation of foreign peptides to the host CTL and 
plays a critical role in immune surveillance to target many pathogens (Ploegh, 1998; 
Tortorella et a l, 2000). The BPV-1 and 4 E5 proteins which are a major transforming protein 
causes a down-regulation of surface MHC class I molecules in transformed cells by reducing 
transcription of the MHC class I heavy chain gene. It also causes a lower level of the MHC 
class I molecules by prevention of transport of the MHC class I complex to the cell surface 
(Ashrafi et al, 2002; O'Brien and Campo 2003). This is achieved by the trapping of MHC 
class I in the Golgi apparatus and prevention of its transport to the cell surface (Marchetti et 
al, 2002). It has been also reported that BPV E5 proteins causes a down-regulation of surface 
MHC class I molecules in transformed cells (Ashrafi et al, 2002) and IFN treatment increases
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transcription of the MHC class I heavy ehain gene, but can not overcome the block in 
exocytic transport (Marchetti et al, 2002). It has been investigated that the expression of 
BPV-4 E5 protein down-regulates MHC classes I in clinical samples of BPV-4 papillomas 
(Araibi et al, 2004). Down-regulation of MHC class I in the cell expressing BPV-4 E5 is 
caused by physical interaction between the C-terminus of E5 and MHC class I heavy chain 
(Marchetti et al, 2006).
1.4 Aim of Ph.D. project
Previous studies have shown that cells transfoimed by BPV E5 do not express MHC class I 
molecules on their surface, and that E5 expression also impairs both transport of MHC class I 
to the cell surface and production/stability of the MHC class I complex (Ashrafi et a l, 2002, 
Marchetti et a l, 2002 and O’Brien and Campo, 2003). Also BPV E5 down-regulates MHC 
class I in clinical samples of BPV-4 papillomas (Araibi et a l, 2004). It has been shown that 
the C-terminus of BPV-4 E5 is important to down-regulate MHC class I by interaction to 
heavy chain (Marchetti et al, 2006). To this end, E5 protein escapes immune systems by 
reducing the level of MHC class I on the cell surface.
The overall aim of project was to investigate the relationship between HPV-16 E5 and MHC 
class I. The objeetives are:
-To determine whether HPV-16 E5 down-regulates classical MHC I on the cell surface and 
localization of MHC class I.
-To determine whether down-regulation of MHC class I by E5 is reversible.
-To determine whether the domain of HPV-16 E5 responsible for down-regulation of classical 
MHC I on the cell surface and the mechanism of HPV-16 E5 down-regulates classical MHC I 
on the cell surface.
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-To determine whether there is a physical interaction between HPV-16 E5 and MHC heavy 
chain.
-To determine whether HPV-16 E5 does not down-regulate non-classical MHC I on the cell 
surface.
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2 Materials and Methods 
2.1 Materials
2.1.1 Antibodies 
-Sigma
Monoclonal antibody (mAb) W6/32 and FITC conjugated against human HLA/A, B & C 
mAh 4A3 raised against the Golgi protein GM130 
DAPI (4 ’ - 6  ’ -Diamidino-2-phenylindole)
Anti mouse IgG FITC conjugated antibody 
Anti mouse IgG TRITC conjugated antibody 
Horse Radish Proxidase 
mAb HA against HA-Tag 
mAb AB-1 (anti-actin)
-Serotec
mAb W6/32 raised against HLA/A,B and C 
mAb MEM-E/02 raised against HLA-E 
-kind gifts from
mAb DT9 anti human HLA-C/E (for FACS & IF) (A kind gifts from Dr. Véronique Braud, 
Centre National de la Recherrche Scientifique, Sophia Antipolis, France)
Anti HPV-16 E2 (A kind gifts from Dr.Merlin Hibma, Tumour Virus Group (TVG), 
Department of Pathology, University of Cambridge, England)
E5 N-terminus and E5 C-terminus antisera against E5 (kind gifts from Dr. DiMaio, 
Department of Genetics, Yale University School of Medicine, New Haven, USA). 
mAb HCIO against HLA-A2 heavy chain (kind gifts from Dr. Stephen Man, University of 
Cardiff)
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2.1.2 Antibiotics 
-Sigma
Ampicillin
Kanamycine
-Invitrogen
Geneticine (G-418)
2.1.3 Bacteriology
-Institute of Comparative Medicine Central Services
L-broth
LB-agar
-Becton Dickinson Labware (Oxford, U.K.)
Falcon 1059 polypropylene tubes 
Falcon 2059 polypropylene tubes 
-Bibby Sterilin Ltd (Staffordshire, U.K.)
90mm bacteriological petri dish 
-Invitrogen
E.coli DFI5-a competent cells with SOC medium 
-Nunc (Hereford, U.K.)
Sterile disposable inoculating loops
2.1.4 Cell line
Immortalised Human Keratinocyte (HaCaT)
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2.1.5 Cell Culture materials 
-Institute of Comparative Medicine
Sterile phosphate buffered saline (PBS)
-Becton Dickinson Labware (Oxford, U.K.)
90 mm tissue culture dishes
Falcon 2097 polypropylene tubes
Falcon 2098 polypropylene tubes
Serological plastic pipettes
24 well cell culture
Cover glass 22x22mm
Cover glass 13mm
Sterile plastipak syringes
Sterile syringe needles
-Bibby Sterilin Ltd (Staffordshire, U.K.)
Sterile plastic bijoux
Sterile plastic universal containers
-Costar Corporation (Bucks, U K)
Disposable cell scrapers 
-Invitrogen
Dulbecco’s Modified Eagle Medium (DMEM), without CaCb supplemented 
2.5% Trypsin-EDTA (IX)
Foetal Calf Serum (FCS)
L-Glutamine (lOOX)
Sodium pyruvate MEM lOOMM
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-Nunc (Hereford, U.K.)
Cryotubes
T25, T75 and T175 cm^ tissue culture flasks 
-Gelman Science, Northampton, England
Sterile 0.2 pm acrodisc filters 
-Sigma
Interferon-p Human
2.1.6 Chemicals and Reagents
-Amersham International pic (Buckinghamshire, U.K.)
Enhanced Chemiluminescence (ECL-plus) Western detection agent 
-Molecular Probes Europe BP, The Netherland 
Bodipy® TR Ceramide 
-Invitrogen
Agarose (ultrapure electrophoresis grade)
Tablet of Phosphate Buffered Saline (PBS)
20 X MES SDS running buffer
20 X MOPS SDS running buffer
20 X MOPS SDS transfer buffer
NUPAGE® Antioxidant
NUPAGE® Sample Reducing Agent (lOX)
NUPAGE® EDS Sample Buffer (4X)
Tricine Glycin SDS Sample Buffer 
Tricine SDS Runing Buffer (lOX)
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Nu PAGE™ 4-12% Bis-Tris gel 
Nu PAGE™ 16% Tricine gel 
-Institute of Comparative Medicine
IX TBE buffer
10 X loading buffer (65% Sucrose, lOmM Tris-HCl, lOmM EDTA, 0.3% BPB, Bromophenol 
Blue up to 10ml dH2 0 )
-Gibco
HEPES
-Sigma
p-mercaptoethanol 
Bicinchonoinic Acid (BCA) solution 
Bovine Serum Albumen (BSA)
Copper (II) sulphate (pentahydrate 4% (w/v) solution)
Ethidium bromide 
Nonidet P-40 (NP-40)
Tween-20 (Polyoxyethylene sorbitan nonolaurate)
-Roche (Lewes, U.K.)
dATP
dCTP
dOTP
dTTP
dUTP
-University of Glasgow (Glasgow, U.K.)
Crude Ethanol
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“VWR International (Dorset, U.K.)
Acetic acid
Dimethyl sulfoxide (DMSO)
1 0 0 % pure ethanol
Ethylene diamine tetraacetate (EDTA) disodium salt
Hydrochloric acid
Magnesium chloride
Methanol
Propan-2-ol
Sodium acetate
Sodium chloride
Sodium dihydrogen orthophosphate 
Sodium dodecyl sulphate (SDS)
Tris base
2.1.7 Enzymes and Kits
-Applied Biosystems (Warrington, U.K.)
Amplitaq® DNA polymerase with Geneamp® buffer
Bigdye v3.1 DNA sequencing kit
Hi-Di formamide
Taq-Man® EZ RT-PCR® kit
Taq-Man® p-actin Detection Reagents
-Invitrogen
Superscript one-step RT-PCR with platinum Taq (100 reaction)
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The restriction enzymes EcoR-I, Nhe-I, Begl-Il and their respective reaction buffers. 
Calf Intestinal Alkaline Phosphatase (CIAP)
T4 DNA ligase 
5X ligase buffer 
-Promega
Transcription and Translation assay (T/T)
Canine Pancreatic Microsomal Membranes 
-Qiagen Ltd (Crawley, U.K.)
QIAquick PCR purification kit 
QIAprep plasmid maxiprep kit 
QIAprep Spin plasmid miniprep kit 
QIAquick Gel extraction kit 
RNease mini kit 
-Centra Systems, USA 
Generation Capture column kits
2.1.8 Molecular Weight Markers 
-Invitrogen
Ikb ladder 
lOObp ladder
See-Blue 2 protein markers
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2.1.9 Plasmids
pcDNA empty vector carrying the universal immediate early (IE) promoter of 
cytomegalovirus (CMV) (Invitrogen, Glasgow, UK).
pL2 empty vector carrying the ED-L2 promoter of Epstein-Barr Virus (EBV) active only in 
basal epithelial cells (A kind gifts from Dr. J. Wilson, Division of Genetics, University of 
Glasgow).
pL2-16E5 carrying the E5 ORE of HPV-16 E5 under the transcriptional control of the EBV 
ED-L2 promoter, active only in epithelial cells (A kind gifts from Dr. H. Ashrafi, Institute of 
Comparative Medicine, University of Glasgow, Glasgow).
pcl6E5 expresses the wild type HPV-16 E5 protein under the control of the CMV IE 
promoter.
pcl6E5-R79 expresses a mutant of HPV-16 E5 protein, which lacks the last 5 amino acids, 
under the control of the CMV IE promoter.
pcl6E5-A54 expresses a mutant of HPV-16 E5 protein, which lacks the third hydrophobic 
domain, under the control of the CMV IE promoter.
pcl6E5-V36 expresses a mutant of HPV-16 E5 protein, which contains the first hydrophobic 
domain plus the 6  amino acids of the hydrophylic region between the firs hydrophobic 
domain and second hydrophilic region, under the control of the CMV IE promoter. 
pcl6E5-R30 expresses the mutant of HPV-16 E5 protein, which contains the first 
hydrophobic domain, under the control of the CMV IE promoter. (pcl6E5 and the above 
mutants were kind gifts from Professor Alonso, German Cancer Research Centre, Heidelberg, 
Germany).
pcl6E5-Del-l expresses a mutant of HPV-16 E5 protein, which lacks the first hydrophobic 
domain, under the control of the CMV IE promoter.
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pHA“l (pcDNAHA-1) vector carrying three HA tag, a kind gifts from Dr.Winnie Boner, 
Institute of Comparative Medicine, University of Glasgow.
pEGFP-Cl is a eukaryotic expression plasmid for the Green Flourescent Protein (GFP). 
Expression is driven by the CMV promoter (BD Biosciences Clontech). 
pEGFP-Cl-16 E5 is a pEGFP plasmid expressing the GFP protein fused to the amino 
terminus of the full-length HPV-16 E5 protein.
pEGFP-Cl-16 E5Del-l expresses a mutant of HPV-16 E5 protein, which lacks the first 
hydrophobic domain.
pEGFP-Cl-16 E5R79 expresses a mutant of E5 protein, which lacks the last 5 amino acids. 
pEGFP-Cl-16 E5A54 expresses a mutant of HPV-16 E5 protein, which lacks the third 
hydrophobic domain.
pEGFP-Cl-16 E5V36 expresses a mutant of HPV-16 E5 protein, which contains the first 
hydrophobic domain plus the 6  amino acids of the hydrophylic region between the firs 
hydrophobic domain and second hydrophobic domain.
pEGFP-Cl-16 E5R30 expresses a mutant of HPV-16 E5 protein, which contains the first 
hydrophobic domain.
pAL3 56HLA-A2 was a kind gifts from Dr Stephen Man fi'om University of Cardiff, Cardiff, 
and HLA-A2 was cut from pAL356HLA-A2 and put in pBS/A2 between EcoRV/Spel sites, 
which is a plasmid [pBlueScriptll SK(+)] carrying HLA-A2, a kind gifts from Barbara 
Marchetti, Institute of Comparative Medicine, University of Glasgow.
2.1.10 Radiochemical 
-Promega
REDIVUE f'^S] Methionine
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2.1.11 Miscellaneous
-Amersham International pic (Buckinghamshire, U.K.)
Hyperfilm ECL
-Eastman Kodak Co., Rochester, New York, USA
X-ray film
-Whatman International Ltd (Maidstone, U.K.)
Whatman 3 MM filter paper 
Whatman 1 filter paper
-Applied Biosystems Ltd (Warrington, U.K.)
Real-time PCR 96-well plates and their caps 
-Costar Corporation (Bucks, UK)
96-well plates
-Elkay International (Basingstoke, U.K.)
Microcentrifuge tubes 
Pastettes
-Equibio (Kent, U.K.)
2 mm electroporation cuvettes 
-Sigma
Protein G immobilised on agarose beads
Formaldehyde
Saponin
-Institute of Comparative Medicine
Diethyl Pyrocarbonate (DEPC)
-Invitrogen
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Lipofectamin Reagent 
Plus Reagent
NuPAGE 4x LDS sample buffer
NuPAGE lOx sample reducing agent
NuPAGE Antioxidant
-Roche Diagnostics, Mannheim, Germani
Protease inhibitor cocktail tablets
“Camlab, Cambridge, England
1.5 ml Screw Top Microtubes
-Amersham Biosciences
Amplify solution
-Merck, England
Steel and plastic cloning rings
Silicon Grease
-Safeway Supermarkets (Glasgow, UK)
Marvel (dried skimmed milk)
2.1.12 Water
Distilled water (dHzO) for the preparation of buffer stocks was obtained from a Millipore 
MilliRo 15 system, and when used for protein, enzyme, RNA or recombinant DNA procedure 
was further purified on a Millipore MilliQ system to 18MQ/cm. Sterile distilled water for 
making up tissue culture media was supplied by the Institute of Comparative Medicine 
Technical Service.
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2.2 Methods
2.2.1 Transformation of Competent Bacterial Cells
E. coli DH5-a competent cells were used for the propagation of plasmid DNA unless stated 
otherwise. Stocks of competent cells were stored at -70°C until use when they were thawed 
slowly on ice. 20 pi of competent cells were aliquoted to a 1.5 ml micro-centrifuge tube and 
then 4 ng of plasmid DNA was added into each tube and left on ice for 30 minutes. Cells were 
heat shocked at 42°C for from 45 second to 1 minute and then returned to ice for 2-5 minutes. 
180 pi sterile SOC medium (25 bactotryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCli, 10 mM MgS0 4 , 20 mM glucose) was added to each sample and the 
tubes were incubated at 37°C for 1 hour with shaking at 225 revolution per minute (rpm). 50 
pi of the transformation mixes were spread on LB-agar plates containing the appropriate 
antibiotic, and then plates were inverted and incubated overnight at 37°C to allow colony 
formation.
2.2.2 Small Scale Preparation of Plasmid DNA (Miniprep)
Small amounts of plasmid DNA were obtained from transformed bacterial colonies to allow 
the identification of positive transformants. A single bacterial colony was used to inoculate 4- 
5 ml of L-broth [1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl] medium 
in Bijoux tubes containing the appropriate antibiotic (100 pg/ml Ampicillin or 50 pg/ml 
Kanamicin unless stated otherwise) and was grown overnight at 37°C with shaking. The 
bacteria culture was transferred into 1.5 ml micro-centrifuge tube and pelleted by 
centrifugation at 14000 rpm for 1 minute. Plasmid DNA was prepared from the colony using 
the QIAprep Spin plasmid miniprep kit according to the manufacturer’s instructions.
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2.2.3 Large Scale Preparation of Plasmid DNA (Maxiprep)
One colony of the overnight bacterial culture was used to inoculate 200 ml of L-broth 
containing the appropriate antibiotic in a 0.5 litre glass conical flask. The culture was 
incubated overnight at 37°C with shaking at 225 rpm. Bacterial cells were transferred in a big 
centrifuge tube and pelleted by centrifugation 7000 rpm at 4°C for 15 minutes, using a 
Backman J2-21 centrifuge. The supernatant was removed and the bacterial pellet was 
resuspended in 10ml buffer PI (50 mM Tris-Cl (pH 8.0), 10 mM EDTA, 100 pg/ml RNase A) 
and transferred to a medium centrifuge tube (JA-20), then gently mixed with 10ml buffer P2 
(200 mM NaOH, 1% SDS (w/v)) and allowed to stand at room temperature for 5 minutes to 
ensure efficient lysis. Next, 10 ml of chilled buffer P3 (3M potassium acetate pH 5.5) was 
added and inverting the tube sharply several times mixed the contents. The solution was 
incubated on ice for 20 minutes and then centrifuged at 13000 rpm for 30 minutes at 4°C and 
the supernatant was removed in a fresh medium centrifuge tube then centrifuged at 13000 rpm 
for 15 minutes again. The bacterial debris forms a tight pellet on the bottom of the tube. The 
supernatant was filtered through nylon gauze and was loaded onto a QIAfilter Mega 
Cartridge. The column was washed twice with 30ml of QC (IM  NaCl, 50 mM MOPS pH 7, 
15% isopropanol (v/v), 0.15% Triton (v/v)). Plasmid DNA was eluted by 15 ml of QF (1.25 
M NaCL, 50mM Tris-Cl pH 8.5, 15% isopropanol (v/v)). DNA was precipitated by the 
addition of 10.5 ml isopropanol. Nucleic acid was pelleted by centrifugation at 12000 rpm for 
30 minutes, the supernatant was removed and the pellet was washed with 1 ml 70% ethanol 
(v/v). Next the nucleic acid was transfen-ed to a micro-centrifuge tube and pelleted by 
centrifugation at 14000 rpm for 10 minutes, the supernatant was removed and the pellet was 
allowed to air dry. The pellet was re-suspended in 200 pi dH2 0  and DNA quantification was 
determined as explained later (see section 2 .2 .2 1 ).
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2.2.4 Cell culture
All cell culture work was performed following strict aseptic techniques inside a laminar flow 
hoods (Class-2 Microbiological Safety Cabinets, Gelaire BSB-4). Cells were incubated in a 
dry atmosphere at 37°C containing 5% (v/v) CO2 (Nopco Scientific).
2.2.5 Maintenance of Human Kératinecyte cells
The human immortalised keratinocyte stable cell line (HaCaT) was grown in Dulbecco’s 
Modified Eagle Medium (DMEM) without CaCE supplemented with ImM Sodium Pyruvate, 
2mM L-Glutamine and 10% Fetal Calf Serum (FCS) at 37°C in a dry atmosphere containing 
5% (v/v) CO2 . The cells were fed twice weekly, old medium was aspirated from sub­
confluent tissue culture flask and fresh medium, which had been pre-warmed at 37°C was 
added. HaCaT cells were grown until 80% confluent and replating was performed as follows: 
the medium was aspirated off and the cells were washed twice with sterile phosphate-buffered 
saline (PBS). Then the PBS was removed and trypsin was added to cells (0.25% trypsin in Ix 
PE buffer; PBS with the addition of EDTA to 1 mM, pre-warmed to at 37°C). Flasks were 
incubated at 37°C until the cells had detached from the flasks (5-10 minutes). Complete 
medium was added to neutralised trypsin and the cells suspension transferred to a universal 
tube. The cells were pelleted by centrifugation at 1000 rpm for 5 minutes at room 
temperature. The pellet was resuspended in fresh growth medium and the cells reseeded at an 
appropriate density.
2.2.6 HPV-16 E5 expression veetors
The HPV-16 E5 ORF from 3850 to 4101 of the HPV-16 was cloned in two different 
expression plasmids, either under the transcriptional control of the universal IE promoter of
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CMV in pcDNA3 or pci-neo (Invitrogen, UK) and called p c i6 E5; or under the 
transcriptional control of the EBV ED-L2 promoter, active only in the basal epithelial cells, in 
pL2 and called pL2-16 E5 (A kind giftsss fro Dr. J. Wilson, Division of Genetics, University 
of Glasgow).
2.2.7 Generation of HPV-16 E5 Del-1
HPV-16 E5 Del-1 mutant protein was made by deletion of the first hydrophobic domain of 
the HPV-16 E5 ORF. The primers used to make deletion mutant in the HPV-16 E5 ORF were 
designed as follows: forward primer of the Del-1 was made from 91 to 105 of the HPV-16 E5 
including A/ze-/restriction enzyme site and HA-tag and four non specific nucleotides; 5’ CAT 
TGC TAG CAT GTA CCC ATA CGA TGT TCC AGA TTA CGC TCC GCT GCT TTT 
GTC T 3’ and reverse primer of the HPV-16 E5 Del-1 was made from 252 to 231 of the 
HPV-16 E5 including EcoR-I restriction enzyme site and four non specific nucleotides; 5’ 
TCG CGA ATT CTT ATG TAA TTA AAA AGC GTG 3’. All reagents were provided in the 
Genamp® PCR reagent Kit and core Reagents with AmpliTaq® DNA polymerase. For this 
mutation, 5 ng of p c i6 E5 was mixed with 100 ng of each forward and reverse primers, with 
Ix PCR kit buffer, MgCL2, 2 units Taq DNA polymerase and dNTPs (32 pM of each dATP, 
dGTP, dCTP and dTTP) in a total volume of up to 50 pi dHzO (control included distilled 
water) and then aliquoted into 0.5 ml GeneAmp PCR reaction microfuge tubes. The tubes 
were placed into the PCR machine (PTC-200 Peltier Thermal Cycle) to make PCR products. 
For PCR amplification, the sample was heated to 95°C for 3 minutes to inactivate DNase and 
ensure all DNA duplexes were melted, in addition to activating the Taq DNA polymerase. 
The DNA was then amplified for 28 times as follows: the sample was heated to denaturalise 
double stranded DNA at 94°C for 30 seconds, 57°C for 30 seconds for annealing and 72°C for
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30 seconds to elongate DNA. After completion o f the cycles, the reaction was incubated at 
72°C for a further 7 minutes to ensure full extension and then got cold to 4°C. After PCR 
amplification, 5 pi o f each sample was analysed by agarose gel electrophoresis using 
appropriate marker to check the correct product was amplified. The PCR products were 
digested by using appropriate restriction enzymes and reaction buffer and then purified by 
using PCR purification kit. The pcI-neo vector was digested (Figure 6) with EcoR-I and Nhe-I 
sites, which located multi-cloning site by using appropriate restriction enzymes and reaction 
buffer according to the manufacturer instructions.
Figure 6. pCI-neo vector multiple cloning region and circle map
CMVI.E. Enhancer/PronxMer \-Ppo\
Imron
p C I - m o
V i c t o r
(5472DP)
SV40Lstepoly(A) SanAcc\
Notl
Symhetic
P P »y(A ) SV40 EnMancef/ EarV Promofc^
BamH I
Figure 6: pCI-neo vector circle map and sequence reference points (Promega).
Neo = neomycin phosphotransferase; CMV I.E. = cytomegalovirus immediate-early.
The digestion of the pci-neo vector was monitored by using agarose gel electrophoresis and 
the cut DNA was purified by using gel extraction kit. The DNA fragment was ligated into the
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cut vector at different inserts:vectors ratio, 1:1, 3:1, 6:1 using 1 pi (4 Units) of T4 DNA ligase 
in Ix ligase buffer in a 20 pi reaction volume (see section 2.2.11). It was found that the best 
ratio of inserts:vectors was 6:1 for ligation. 5 pi of the ligated samples was transformed in 
E.coli DH5-a competent cells (see section 2.2.1). 50 pi of transformation mixes were spread 
on LB-agar plates containing the appropriate antibiotic (100 pg/ml Ampicilin) and incubated 
at 37°C overnight. A single bacterial colony was used to inoculate 5 ml L-broth medium 
containing the appropriate antibiotic in Bijoux tubes and grown overnight at 37°C (to select 
10 colonies in 10 Bijoux tubes). Plasmid DNA was prepared from the colony using the 
QIAprep Spin plasmid miniprep kit according to the manufacturer’s instructions (see section 
2.2.2). The plasmid DNA was sequenced, confirmed and transfected into HaCaT cells.
2.2.8 Cloning of E5 and E5 mutants into a Green Fluorescent Protein plasmid
The pEGFP-Cl vector, which is a eukaryotic expression plasmid for the Green Fluorescent 
Protein (GFP) was digested with EcoR-1 and Bgl-II sites, located in multi-cloning sites by 
using appropriate restriction enzymes and reaction buffer according to the manufacturer 
instructions. The primers were designed for making HPV-16 E5 and all mutants (R79, A54, 
V36, R30 and Del-1), with the oligonucleotides are listed as follows:
a) Forward primers of HPV-16 E5 and mutants (R79, A54, V36, R30) were from 1 to 22 of 
HPV-16 E5 sequences;
5’ CAT TAG ATC TAT GAG AAA TCG TGA TAG TGC AT 3’
b) Forward primer of HPV-16 E5Del-l was from 91 to 112 of HPV-16 E5 sequences;
5’ CAT TAG ATC TCC GCT GCT TTT GTC TGT GTC TA 3’
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c) Reverse primers HPV-16 E5 wild type and HPV-16 E5Del-l were from 252 to 231 of 
HPV-16 E5 sequences;
5’ TCG CGA ATT CTT ATG TAA TTA AAA AGC GTG CA 3’
d) Reverse primer HPV-16 E5R79 was from 237 to 216 of HPV-16 E5 sequences;
5’ TCG CGA ATT CTT AGC GTG CAT GTG TAT GTA TTA A A 3 ’
e) Reverse primer HPV-16 E5 A54 was from 162 to 141 of HPV-16 E5 sequences;
5’ TCG CGA ATT CTT AGG GTG CTG TTA TCC ACA ATA GT 3’
f) Reverse primer HPV-16 E5V36 was from 111 to 90 of HPV-16 E5 sequences;
5’ TCG CGA ATT CTT AAG ACA CAG ACA AAA GCA GCG GA 3’
g) Reverse primer HPV-16 E5R30 was ftom 93 to 72 of HPV-16 E5 sequences;
5’ TCG CGA ATT CTT AAC GTA TAA TAG GCA GAC A.
All forward and reverse primers were contained four non-specific nucleotides with restriction 
enzyme site (for forward primers Bgl-U and reverse primers EcoR-I) using for cloning. The 
DNA fragments were made by PCR and digested by using appropriate enzymes and reaction 
buffer. The DNA fragment was ligated into the cut vector with inserts: vectors ratio 6:1 and 
transformed in E. coli DH5-a competent cells. 50 pi of transformation mixes were spread on 
LB-agar plates containing 50 pg/ml kanamycin and incubated at 37°C for overnight. A single 
bacterial colony was used to inoculate 5 ml L-broth medium containing the appropriate 
antibiotic in Bijoux tubes and grown overnight at 37°C. Plasmid DNA was prepared from the 
colony using the QIAprep Spin plasmid miniprep kit according to the manufacturer’s 
instructions (see section 2.2.2). The plasmid DNA was sequenced, confirmed and transfected 
into HaCaT cells.
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2.2.9 DNA purification
DNA fragments for PCR used for cloning were routinely purified using the Qiagen 
QIAquick® PCR Purification Kit. DNA samples were added 5 volumes of buffer PB to 1 
volume the PCR samples and mixed together. It was placed a QIAquick spin column in a 
provided 2 ml collection tube and centrifuged at 13000 rpm for 30-60 seconds. The DNA 
samples were washed with 0.75 ml buffer PE and centrifuged as before. The QIAquick 
column was placed in a clean 1.5 micro-centrifuge tube and added 50 pi or 30 pi H2O to the 
center of the QIAquick membrane and then centrifuged the column at 13000 for 1 minute.
2.2.10 Digestion of DNA with restriction enzymes
Restriction digests were performed in small reaction volumes using the appropriate enzymes 
and reaction buffers according to the manufacturer instructions. Plasmid DNA was incubated 
with 5-10 units of restriction enzyme/pg DNA in a buffer solution. In general, small quantities 
of plasmid DNA (<5 pg) were digested in a 20 pi reaction volume for 2-3 hour s at 37°C and 
large quantities of plasmid DNA were typically digested in a 50pl reaction volume overnight 
at 31°C. The digestion of the vector plasmid was monitored by using agarose gel 
electrophoresis and the cut DNA was purified by using a gel extraction kit. Digestion of HPV- 
16 E5 wild type and mutant fragments were carried out using the appropriate restriction 
enzymes at 37°C for overnight and purified by using DNA purification kit.
2.2.11 Ligation of DNA fragment
Both plasmid DNA and the DNA fragment to be inserted into the vector were separately 
digested using the appropriate restriction enzymes and isolated by gel electrophoresis and
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then purified as described above (see section 2.2.10). The linearised vector DNA was 
dephosphorylated to prevent vector religation. 1 pi (1 unit) of calf intestinal alkaline 
phosphatase (CIAP) and dephosphorylation buffer were added at the end of a restriction 
digest reaction DNA vector and then the reaction mixture was incubated for 30 minutes at 
37°C. The reaction was followed by a second incubation at 70°C for 10 minutes to stop all 
enzyme activity. The plasmid and DNA fragment were purified by using the PCR purification 
kit. The DNA fragment was ligated into the cut vector using 1 pi (4 units) of T4 DNA ligase 
in Ix ligase buffer in a 20 pi reaction volume. This was carried out according to the 
manufacturer’s instruction. An excess of DNA fragment compared to vector was used for 
ligation reactions. Reactions were routinely incubated overnight at 16°C.
2.2.12 DNA sequencing
The fidelity of all plasmid constructions was verified using an Applied Biosystems 3100 
automated DNA sequencer. The region to be sequenced was sequenced using a primer 
complementary to the appropriate region of the vector DNA (see table 1). Reactions 
containing 500 ng DNA, 3.2 pmol forward or reveres primer, 2 pi 5x buffer and 4 pi Big Dye 
Terminator Reaction premix were made up to 20 pi with dHiO. 250 pi thin walled eppendorf 
tubes were used for all sequencing PCR reactions. Samples were heated to 95°C for 10 
seconds, 50°C for 15 seconds and 60°C for 4 minutes. This cycle was repeated 25 times. PCR 
products were precipitated using Spin Column Purification. The purification columns were 
centrifuged at 3K for 2 minutes then transferred to sample collection tubes. Next, the PCR 
products were transferred into centre of the gel to spin at 3K for 2 minutes and dried under 
vacuum. The samples were resuspended in 25 pi Hi-Di formamide and transfeiTed into 96-
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wells plate. Subsequently the samples were analysed using an ABI3100 genetic analyser 
(sequencer) and confirmed by DNASTAR program.
Table 4. Oligonucleotides used for sequencing
Primer Nucleotide Sequence Plasmid Sequenced
Forward primer 5 ’ CAT GOT GCT GCT GGA GTT CGT G 3 ’ pEGFP-C 1 
Reverse primer 5 ’ CGT CGC CGT CCA GCT CGA CCA G 3 pEGFP-C 1 
T3 primer 5’ T3 ATT AAC CCT CAC TAA ACG G 3’ pci-neo 
T7 primer 5 ’ ATT AAT ACG ACT CAC TAT AGG GA 3 ’ pci-neo
2.2.13 Seeding of cell lines
When seeding cells, the culture medium was removed and cells were washed with sterile 
PBS. 4 ml trypsin-EDTA was added into T175 cm^ flasks, 2ml to T75 cm^ and 1 ml to T25 
cm^ flasks. The cells were incubated at 37°C until the cells had detached from the flask 
bottom. Two volumes of appropriate medium were added to neutralise the trypsin and the 
cells were centrifuged at 1000 rpm for 5 minutes. The cells were resuspended in fresh 
medium at the required cell density and were maintained in new flasks as before.
2.2.14 Counting cells
Total live cell count was performed using trypan blue which stains dead cells dark blue. 50 pi 
of cell suspension was added to 50 pi of trypan blue (Gibco BRL, UK) and mixed. 10 pi of 
mixing sample was loaded onto a haemocytometer with a coverslip added. The number of
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non-coloured cells in each of the 4 open squares was counted under lOx objective and a mean 
of these counts was taken. This mean multiplied by Ix 10"^  represented the number of cells per 
ml.
2.2.15 Transfection of HaCaT cells
HaCaT kératinocytes were stably transfected with a range of plasmid DNA; pcDNA, pL2, 
pHA-1, pc-16E5, pL2-16E5, pEGFP-Cl, pEGFP-Cl-16E5 and all mutants (R79, A54, V36, 
R30 and Del-1, see section 2.1.9) by using Lipofectamine Plus (Invitrogen). One day before 
transfection, Ix 10  ^HaCaT cells had been seeded in 80 mm petri dishes with 15 ml complete 
medium and incubated at 37°C for over night. The following day, the medium was removed 
and the cells were washed twice with sterile PBS, then 5 ml medium without FCS was added. 
4 pg plasmid with 750 pi medium without FCS was mixed with 20 pi of Plus Reagent and 
incubated at room temperature for 15 minutes. 30 pi Lipofectamin Reagent was mixed with 
750 pi medium without FCS in a separate reaction vial. Both solution were mixed together 
and incubated for 15 minutes at room temperature. This mixture was then slowly added to the 
petri dishes of cells and incubated at 37°C for 3 hours. After this time, cells were washed 
twice with PBS, fed with fresh medium with FCS and incubated at 37°C for overnight. 
Sixteen to eighteen hours later, the old medium was removed and the cells were re-fed with 
fresh growth medium.
2.2.16 Selection and Isolation of Transfected HaCaT cells
Following transfection, HaCaT cells were selected in medium containing 500 pg/ml G418 for 
3-4 weeks. After this time, G418-resistant colonies were marked under the microscope using a 
microscope ring marker attachment. The cells were then washed with sterile PBS. A sterile 6
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mm steel or plastic cloning rings coated with sterile silicon Grease (Merck, England) at the 
base was then placed over the identified colony thus providing a waterproof seal round each 
isolated colony. 100 pi of trypsin, which had been pre-warmed to 37°C was added within 
each cloning ring to cover the whole colony and incubated for 5-10 minutes at 31°C. An equal 
volume of complete medium which had been pre-warmed to 31° C was added within each 
cloning ring and the cell suspension transferred to a small flask (T25 cm^) and incubated at 
31°C. Where appropriate, several colonies were picked from each transfection class and 
expanded into cell lines for analysis.
2.2.17 Long-term cells storage
For long-term storage of cells, confluent cultures were trypsinised, and pelleted as described 
above. The pellet was then resuspended at a concentration of approximately 1x10^ cells/ml in 
growth medium containing 10% (v/v) DMSO and 40% (v/v) FCS. The DMSO in the medium 
acts as a cryoprotectant but all solution must be chilled as DMSO is toxic to cell at room 
temperature. Suspensions were aliquoted into 2 ml Nunc cryotubes and placed in a 
polystyrene box and frozen, well insulated, at -70°C for at least 24 hours to ensure a slow rate 
of cooling. The following day the tubes were placed in liquid nitrogen until further use. When 
needed, the ampoules were removed from liquid nitrogen and placed into a small, covered 
bucket of water at 37°C. Once thawed, the cells were added to 10 ml of the appropriate pre- 
warmed growth medium, centrifuged, re-suspended in fresh growth medium and transferred 
to a T75 cm^ flask.
2.2.18 DNA preparation from HaCaT cells
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For DNA extraction, HaCaT cells were grown until 80% confluent and washed with PBS and 
then tripsinized. The cells were washed twice with PBS and resuspended in 500 pi PBS and 
then applied into the Capture column by using Generation Capture column kits (Centra 
Systems, USA). After quick centrifugation, the cells were washed twice with 500 pi 
purification solution and quickly centrifuged (2-3 seconds). Next, the cells were washed once 
with elution solution and pelleted by a quick centrifugation. 200 pi of elution solution was 
added again and wrapped with parafilm around the either top of the tube and then put them in 
the boiled water (99°C) for 10 minutes and then spin them down as above. The DNA was 
determined and the PCR product was performed using PCR purification kit.
2.2.19 RNA preparation from HaCaT cells
RNA extraction from cells was done using a Qiagen RNeasy kit with QIAshredder columns. 
Cells were grown until sub-confluent, washed twice with PBS and detached, then counted and 
lysed by addition of RTL buffer with R-mercaptoethanol (if the cells were less than 5x10^, it 
should be added 350 pi of RTL buffer with R-mercaptoethanol but if the cells were more than 
5x10^ should be added 600 pi). Cells were then scraped into a QIAshredder spin column then 
centrifuged to homogenise the sample at 8-1 Ox 10  ^rpm for 15 seconds. Next 350 pi or 600 pi 
of 70% ethanol was added to the lysate and the sample was added to an RNeasy mini column 
by centrifugation. Subsequently the column was washed once with 700 pi of RWl and with 
500 pi RPE by centrifugation as above. The sample was washed once again with 500 pi RPE 
by centrifugation at 8-1 Ox 10^  rpm for 2 minutes and then centrifugation at 14000 rpm for 1 
minute to remove all RPE buffer. The purified RNA was eluted from the column in 30 pi or 
50 pi of RNase-free water or dHzO by centrifugation at 8-1 Ox 10^  rpm for 1 minute and then 
the concentration of nucleic acid was determined. Following preparation RNA sample prior to
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RT-PCR, 1 pg of RNA sample, 1 pi of lOx DNase I reaction buffer, 1 pi of the DNase I Amp 
Grade lU/pl, and up to 10 pi DEPC were mixed together and incubated 15 minutes at room 
temperature. For inactivation of the DNase I, 1 pi of 25 mM EDTA was added and mixed and 
then heated at 65°C for 10 minutes.
2.2.20 Concentration and purity determination of nucleic acids
The concentration of nucleic acid was determined by absorbance measurement at 260 nm and 
280 nm using a Biotech spectrophotometer model UVllOl. Samples were diluted in dH20 
and transferred to a quartz cuvette with a pathway of 1 cm. The spectrophotometer was 
initially calibrated using dH20 only as a blank and the optical density (OD) reading were 
obtained at 260 mn and 280 nm. An OD260 reading of 1 corresponds approximately to 33 
pg/ml single stranded DNA or 50 pg/ml double stranded DNA and for RNA an OD260 of 1 
was taken to correspond to 40 pg/ml. The ratio, which is 1.8 for DNA and 2 for RNA between 
reading at OD260 and OD280 provided an estimate of the purity of the nucleic acid.
2.2.21 Protein extract preparation
The cells were washed twice with PBS, then trypsinised, and washed two times with 10 ml of 
ice cold PBS. The cell pellet was then resuspended in 1ml of ice cold PBS and transferred to a 
1.5 ml microcentrifuge tube and pelleted. They were then resuspended in 100 pi of lysis 
buffer (0.5% NP40, 50mM Tris pH 7.8, 150 mM NaCl with a protease inliibitor cocktail 
(Roche, Lewes, UK) dissolved in the lysis buffer. The extracts were then incubated on ice for 
30 minutes with occasional mixing. Following this they were centrifuged in a refrigerated 
microfuge for 10 minutes at maximum speed at 4°C. The supernatant was then removed to
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another tube and the cell debris discarded. The protein concentration was then deteitnined 
using the BCA/CUSO4 assay.
2.2.22 Amplification of HPV-16 E5 wild type and all mutants DNA sequences from 
HaCaT cells
For PCR amplification of DNA from HaCaT cells to see if viral E5 sequences were in the cell 
transfected. HaCaT cells expression with HPV-16 E5 wild type and HPV-16 E5Del-l mutant 
were grown until sub-confluent and tripsinized and then washed with 500 pi PBS (see section 
2-2-18). All reagents were provided in the Genamp® PCR reagent Kit and core Reagents with 
AmpliTaq® DNA polymerase. Primer sequences are followed; forward primer of E5 was 
designed from 91 (5’CCG CTG CTT TTG TCT GTG TCT A 3’) to 112 and reverse primer 
was designed from 249 (5’TGT AAT TAA AAA GCG TGC ATG TGT A 3’) to 225. The 
reaction mixture comprised, see section, 32 pM of each dATP, dGTP, dCTP and dTTP, 1 x 
PCR kit buffer, 100 ng of each primer, 2 units Taq polymerase and 5 ng of DNA sample 
(controls included distilled water and 5 ng of pcl6E5) up to 50 pi dH2 0  and then aliquoted 
into 0.5 ml GeneAmp PCR reaction microfuge tubes. The tubes were placed into the PCR 
machine (PTC-200 Peltier Thermal Cycle) and heated to 95°C for 3 minutes to inactivate 
DNase and ensure all DNA duplexes were melted, in addition to activating the Taq DNA 
polymerase. The DNA was then amplified for 28 cycles at 94°C for 30 seconds, 57°C for 30 
seconds, to allow the primers to anneal to the template DNA, followed by 72°C for 30 
seconds to allow extension of the amplimer sequences. After completion of the cycles, the 
reaction was incubated at 72°C for a further 7 minutes to ensui’e full extension and then 
cooled to 4°C. 5 pi of each sample was analysed by agai'ose gel electrophoresis (as described 
before) to check the correct product was amplified.
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2.2.23 Amplification of E5 RNA from HaCaT cells by RT-PCR
RNA was prepared (see 2.2.19) and used as the template for reverse transcription and PCR 
amplification by using Superscript one-step Reverse Transcriptase PCR (RT-PCR) with 
platinum Taq, 100 reaction (from Invitrogen Ltd.). Primer sequences are as follows: forward 
primer of HPV-16 E5 was designed from 91 (5’CCG CTG CTT TTG TCT GTG TCT A 3’) 
to 112 and reverse primer was designed from 249 (5’TGT AAT TAA AAA GCG TGC ATG 
TGT A 3’) to 225. For each sample were used 25 pi of 2x Reaction Mix, Ipl RT/Platinum® 
Taq Mix, 100 ng RNA sample and up to 50 pi dH^O. Amplification proceeded at 50°C for 30 
minutes and then 94°C for 2 minutes and then for 35 cycles of 94°C for 15 seconds, 55°C for 
30 seconds, 70°C for 45 seconds and extension at 72°C for 10 minutes. PCR was carried out 
in a PTC-200 Peltier Thermal Cycle. 5 pi of each sample containing Ix loading buffer was 
then analysed by agarose gel electrophoresis to ensure correct amplification. Primers 
sequences for (3-actin quantitation were purchased from Applied Biosystems.
2.2.24 Real time RT-PCR
Total RNA was isolated fi'om HaCaT cells using the RNeasy Mini kit (Qiagen, Sussex, UK), 
and residual DNA was removed by DNase I treatment according to the manufacturer’s 
guidelines (Invitrogen, UK). Real-time RT-PCR for HPV-16 E5 wild type, all mutants and [3- 
actin mRNA was carried out using the Taq-Man EZ RT-PCR kit (Applied Biosystems, Foster 
City, CA, USA). Each reaction was performed in triplicate using 100 ng of RNA samples, 5 
pi of 5x TaqMan E2 buffer, 6  pi of 25 mM MgCL, dNTPs (16 mM of each dATP, dGTP, 
dCTP and dUTP), 10 pM of each forward and reverse primer, 5pM of probe, 2.5 U/pl of the 
rTth DNA polymeras, lU/pl of Amperase and up to 50 pi sterile dHiO. Oligonucleotide 
primers for HPV-16 E5 wild type and all mutants (R79, A54, V36, R30 and Del-1) were
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designed using Primer Express (vl.7, Perkin-Elmer, Oak Brook, IL) as follows in the table 5 
(Forward=F, Reverse=R and probes).
For [3-actin quantitation, the primers and probe sequences were purchased from Applied 
Biosystems. The samples were placed into the 96-well real time RT-PCR plate and amplified 
in triplicate. Amplification was proceeded at 60°C for 30 minutes, 95°C for 5 minutes and 
then for 40 cycles of 94°C for 20 seconds and 62'’C for 1 minute. PGR reaction was 
performed using an ABI prism 7700 sequence detector. Standard carves were generated using 
10-fold serial dilutions of each template DNA, which were used to quantitate the relative 
levels of E5 and (3-actin mRNA. The Level of E5 mRNA was normalized according to the (3- 
actin controls.
Table 5. Oligonucleotides used for Real Time RT-PCR
Primer Nucleotide Sequence
F. primer E5,R79,A54,V36,R30 5’ GAC AAA TCG TGA TAG TGC ATC C A 3’
R. primer E5,R79,A54 5’CTG CTG TTA TCC ACA ATA GTA ATA CCA A T A G 3’
R. primer V36,R30 5’ TAA TAG GCA GAC ACA CAA A 3’
Probe E5,R79,A54, V36,R30 5 ’AAC ATT ACT GGC GTG CTT TTT GOT TTG CT3’ 
F. primer Del-1 5 ’ CTG CTT TTG TCT GTG TCT ACA TA 3 ’
R. primer Del-1 5’ TAT AAT ATA TAC AAT AAA ACA CCT A A 3 ’
Probe Del-1 5 ’ TTA ATA ATA TTG GTA TTA CTA TTG TGG ATA 3 ’
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2.2.25 Detection of MHC class I by Fluorescence Activated Cell Sorting
Fluorescence Activated Cell Sorting (FACS) was used to analyse the level of surface and total 
MHC class I in the control cells and cells expressing HPV-16 E5 wild type and mutants. 
HaCaT cells were grown in big flasks (T175 cm^) with complete DMEM until sub-confluent. 
After removal of the medium, the cells were washed once with PBS, then detached from the 
flask with trypsin/EDTA and pelleted at 1000 rpm for 5 minutes at room temperature. The 
cell pellet was re-suspended in complete medium for 1 hour at 37°C to allow surface antigens 
to be re-expressed. The cells were washed and re-suspended in PBS/1% BSA (Sigma) at 
1x10^ cells/ml. Next, the cells were divided in four micro centrifuge tubes (for surface and 
total MHC class I) and incubated at room temperature for 30 minutes. For the detection of 
surface MHC class I, 100 |Lil of cells were aliquoted and incubated with an equal volume of 
either MHC class I monoclonal antibody (mAb) W6/32 (1/100; Serotec) or anti-HLA-C/E 
mAb DT9 (1:50; a kind giftss from Dr. Véronique Braud, Centre National de la Recherche 
Scientifique, Sophia Antipolis, France) at 4°C for 30 minutes. The cells were washed three 
times in PBS-1%BSA and incubated with anti-mouse IgG-FlTC (1/100; Sigma) at 4°C for 30 
minutes in the dark. The cells were washed as above and re-suspended in 500 pi PBS-1% 
BSA and analysed by FACS. If the FACS analysis was not performed immediately, the cells 
were re-suspended in 500 pi of 3.4% paraformaldehyde (fixing solution) in PBS and kept at 
4°C in the dark. For the detection of intracellular MHC class I, the cells were treated as above 
and permeabilised with 0.5% Saponin (Sigma) in PBS-1% BSA for 30 minutes at room 
temperature. Following a wash in PBS 1% BSA solution, the permeabilised cells were 
incubated with primary antibody as described above. All samples were examined in a 
Beckman Coulter EPICS Elite analyser equipped with an ion argon laser with 15 mV of 
excitation at 488 nm. The data were analysed using Expo 2 software.
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2.2.26 Detection of MHC class I by immunofluorescence microscopy
HaCaT cells were aliquoted into 24-well plates containing coverslips, at 1 x 1 cells per well, 
approximately 25-50% confluent, and grown overnight (at least two coverslips cell line). 
After removal of the medium, cells were washed twice with PBS and fixed in fixing solution 
(19ml PBS, 1ml 37% formaldehyde and 0,4g sucrose) for 10 minutes at room temperature. 
After that, the cells were washed twice and incubated in permeabilising solution (19 ml PBS, 
1 ml 10% NP40 and 0.4 g sucrose) at room temperature for 10 minutes and then washed twice 
with PBS+1% PCS, then incubated with mAh W6/32 (1/50) against MHC class I or DT9 
(1/50) against HLA-C and E for 1 hour at room temperature and washed twice as above. The 
cells were then incubated with anti-mouse IgG-FITC (1/500; Sigma) at room temperature for 
1 hour in the dark. Next, the cells were washed twice with PBS and incubated with DAPI 
(1/1000, Sigma), which stains DNA for 10 minutes at room teiuperature in the dark. 
Following two final washes with PBS and one with distilled water, the slides were mounted in 
Citifluor™ (glycerol/PBS solution. Sigma) and analysed with a Leica DM-IRE2 fluorescence 
confocal microscope at 488mn wavelength for FITC, 405 for DAPI and 543 for TRITC. 
Images were acquired using Leica confocal software.
2.2.27 Visualisation of Golgi apparatus by immunofluorescence microscopy
The Golgi apparatus was visualised by immunofluorescence detection using mAb 4A3 raised 
against golgin GM130, an integral GA protein (1/200; Sigma) or Bodipy®-TR Ceramide 
(Molecular Probes Europe BP, The Netherland). HaCaT cells were aliquoted, grown, fixed 
and permeabilised as described above (see section 2.2.26). The cells were incubated with 
mAh 4A3 for 1 hour at room temperature and washed twice with PBS+1% FCS and then 
incubated with anti-mouse IgG- TRITC (1/1000, Sigma) or FITC (1/500) at room temperature
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for 1 hour in the dark. Following three final washes (twice with PBS and one with dHiO), the 
slides were mounted in Citifluor™ and analysed with a Leica DM-IRE2 fluorescence 
confocal microscope. Images were acquired using Leica confocal software. For Bodipy®-TR 
staining (Golgi staining), the cells were washed twice with DMEM without FCS plus 25 mM 
Hepes (PH 7.5). 200 pi of 5 mM Bodipy®-TR in DMEM without serum plus 25 mM Hepes 
was added and incubated at 4°C for 30 minutes and then the cells were washed twice as 
above. Next, 200 pi of DMEM without FCS 25 mM Hepes was added and incubated at 31°C 
for 30 minutes. The cells were washed twice with PBS and fixed with fixing solution as above 
(see 2.2.26).
2.2.28 Co-localisation of Golgi apparatus and MHC class I
For co-localisation of Golgi apparatus and MHC class I in the control HaCaT cells (pcDNA 
and pL2) and cells expressing HPV-16 E5 (pcl6E5 and pL2-16E5), the cells were aliquoted, 
grown, fixed and permeabilised as above (see section 2.2.26). The cells were washed twice 
with PBS+1% FCS and incubated with mAh 4A3 at room temperature for 1 hour. The cells 
were washed as above and incubated with anti-mouse IgG-TRITC (1/1000, Sigma) and with 
mAh W6/32 conjugated with FITC (1/10, Sigma) at room temperature for 1 hour in the dark. 
The cells were then washed twice as above and incubated with DAPI for 10 minutes at room 
temperature in the dark. Following three final washes (twice with PBS and once with dH2 0 ), 
the slides were mounted in Citifluor™ and analysed as above. The merge between FITC and 
TRITC fluorescent signals was achieved with the Leica confocal software.
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2.2.29 SDS-Polyacrylamide Gel Electrophoresis
Protein samples were resolved according to the molecular weight using sodium dodecyl 
sulphate polyacrylamide gel eleetrophoresis (SDS-PAGE). Protein samples were 
electrophoresed on Nu PAGE^^ 4-12% Bis-Tris gel (Invitrogen, UK) under denaturing 
conditions. Prior to loading, equivalent amount of each protein samples (10 pg) was mixed 
with 5 pi of 4x SDS gel loading buffer (Invitrogen, UK) and 2 pi of lOx reducing agent 
(Invitrogen, UK) made up to 20 pi with dHzO. Samples were then boiled at 75°C for 
lOminutes. The prepared protein samples were then loaded into consecutive wells and 10 pi 
See Blue® Plas2 (Invitrogen), which is a protein molecular weight marker, added to the first 
and/or last well on the gel. The gel was run by electrophoresis at a constant voltage of 200V 
for 45 minutes. The running buffer (Nu PAGE^”^  MES buffer, Invitrogen, UK) was used with 
500 pi antioxidant (Invitrogen, UK) added to 200 ml of the running buffer in the inner tank. 
Onee the dye front was approximately 1-3 cm from the bottom of the gel, the gel was 
removed and used for western blot.
2.2.30 Detection of MHC class I by Western Blotting
HaCaT cells were removed from the flasks by trypsinisation, washed with PBS, then lysed by 
syringe in lysis buffer (lOOmM Tris HCl, pH 7.5, 2% SDS, 20% glycerol) and insoluble 
material was removed by centrifugation at 20,000g. 10 pg of lysate were electrophoresed in 4- 
12% NuPAGE gels (Invitrogen), and proteins transferred to nitrocellulose membrane 
(Invitrogen) using a semidry blotting apparatus at 30V/150A for 1 hour. For this purpose the 
gel was removed from the electrophoresis tank and transferred onto a nitrocellulose 
membrane (Invitrogen, UK). Before transferring to the membrane, the Nu PAGE™ gel 
sandwich was pre-soaked with transfer buffer with 500 pi antioxidant added to 200 ml of
83
Chapter 2 Materials and Methods
transfer buffer (with 1 0 % or 2 0 % methanol depending on the number of gels being 
transferred). The gel sandwich contains a pre-cut nitrocellulose membrane sandwiched 
between two filter papers. The gel tank was set up as follows: the first sheet of filter paper, 
soaked in transfer buffer was placed neatly on to the gel avoiding any air bubbles. Then the 
nitro-cellulose membrane was laid on the gel, and then a further sheet of filter paper, all 
soaked in transfer buffer was added to the top. Next, the sandwich was rolled with a glass 
pipette to eliminate any air bubbles and placed into the transfer tank and run at 30V for 
approximately 60 minutes, the time taken for the pre-stained marker proteins to be completely 
transferred. Once the transfer was completed, the membrane was blocked by shaking for a 
minimum of 1 hour in 50 ml of block buffer (5% Marvel [dried milk] in PBS-0.01% Tween) 
at room temperature. The nitro-cellulose filter was washed in washing buffer PBS-Tween 
(PBS-T) for 10 minutes. The filter was then placed in 7 ml blocking buffer containing mAb 
HC-10 (1/50; Kind giftss from Dr. S. Man) or mAb MEM-E2/02 against HLA/E (1/50; 
Serotec) and mAb AB-1 (anti-actin, 1/1000) and incubated at room temperature for 1 hour 
with gentle shaking. The primary antibody solution was removed and the filter rinsed in 
blocking buffer then washed Ix 15 minutes and 2x 5 minutes in 100 ml volumes of fresh 
PBS-T. The filter was then incubated in 20 ml blocking buffer containing anti-mouse Horse 
Radish proxidase (1/5000, Sigma) for 1 hour at room temperature with gentle shaking. The 
filter was washed Ix for 15 minutes and 2x for 5 minutes with PBS-T buffer. Excess surface 
liquid was removed from the filter by briefly blotting with a piece of Whatman 3MM paper. 
The detection consisted of incubating the filter in an equal volume of an Amersham Enhanced 
chemilluminescence (ECL) detection reagents 1 and 2 for 5 minutes at room temperature. The 
excess detection solution was drained off the nitro-cellulose filter and this was then wrapped
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in Saran wrap and exposed to Amersham ECL film for 30 seconds and up to 30 minutes 
(depending on the strength of the signal).
2.2.31 Treatment of cells with interferon
One million parental HaCaT cells, control cells carrying empty vectors and cells expressing 
HPV-16 E5 were seeded in tissue culture dishes. The following day, the old medium was 
removed and cells were washed once with sterile PBS then the fresh medium was added with 
or without 500 U/ml (3-IFN (Sigma). Next the cells were incubated in a dry atmosphere at 
37°C containing 5% (v/v) CO2 for 48 hours. After 48 hoius, the cells were harvested for 
detection of MHC class I by immunofluorescence staining or FACS analysis as described 
before (see sections 2.2.25 and 2.2.26).
2.2.32 Immunoprécipitation and Co-Immunoprecipitation
2.2.32.1 In vitro transcription and translation assay
For translation of proteins labelled with [^^S]methionine (Amersham Pharmacia Biotech) 
HPV-16 E5 wild type and mutants; R79, A54, V36, R30 and Del-1 transcription and 
translation proteins synthesized in vitro, were preformed as follows: 20 pi of Transcription 
and Translation assay (T/T), 1 pi Canine Pancreatic Microsomal Membranes (from Promega), 
2 pi of [^^S]methionine, 0.5-1 pg DNA plasmids and dH2 0  up to 25 pi were added into 1.5 ml 
Screw Top Microtubes (Camlab, Cambridge, England) and incubated at 30°C for 90 minutes 
to translate protein. Prior to loading, 5 pi of each protein samples was mixed with 5pi of 4x 
SDS gel loading buffer (Invitrogen, UK) and 2 pi of lOx reducing agent (Invitrogen, UK) 
made up to 20 pi with dH2 0 . Samples were then boiled at 75“C for 10 minutes. Separated 
protein samples were transferred to the SDS-PAGE gel at a constant voltage of 200V for 45
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minutes and fixed using fixing solution (50% Methanol, 10% Acetic Acid, 40% dHiO) for 1 
hour and then incubated in Amplify solution (Amersham Bioscienees) for 20-30 minutes. The 
gel was dried and then visualized by autoradiography to check the size of protein.
2.2.32.2 In vitro immunoprécipitation and co-immunoprecipitation assays.
Immunoprécipitations and co-immunoprecipitation of HPV-16 E5 and all mutants were 
performed (see section 2.2.32.1) as follows: 25 pi of translated protein was added in the tube 
with 3 pi of HA antibody (1/10; Sigma) against HA-tag on the HPV-16 E5 and all mutants, 10 
pi E5 N-terminus/ E5 C-terminus antisera (1/3; kind gifts from Dr.DiMaio) against E5, or 10 
pi HCIO antibody against HLA-A2 (1/3) and then incubated at 4°C for overnight on the 
rotator. For co-immunoprecipitations, 25 pi of HLA-A2 translated samples with 25 pi of 
HPV-16 E5 or mutants were mixed in the tube and incubated at 4°C for 4-6 hours and then 
appropriate antibody ( 6  pi HA antibody, 20 pi E5 N-terminus/ E5 C-terminus antisera or 20 
pi HCIO antibody) added and incubated at 4 ‘^ C overnight on the rotator. Next 10 pi or 20 pi 
of Sepharose beads protein-G (Amersham Phai'macia) with protease inhibitor cocktail (Roche) 
was added to the mixture and incubated for 1 hour at 4^C. The beads were washed two times 
with washing buffer, once with washing buffer I or high salt (50 mM Tris HCL PH 7.5, 500 
mM NaCl, 0.1% Nonidet-P 40, 0.05% NaDoc and up to 10 ml dHgO) and once with washing 
buffer II or low salt (50 mM Tris HCL PH 7.5, 0.1% Nonidet-P 40, 0,05% NaDoc and up to 
10 ml dHzO). The immunoprécipitation samples were resuspended in the 5 pi of 4x SDS gel 
loading buffer with 2 pi of lOx reduce agent and boiled at 75°C for 15 minutes. The bound 
proteins were resolved by SDS-PAGE and dried and then visualized by autoradiography.
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2.2.33 Agarose gel electrophoresis
Agarose gel electrophoresis was performed using horizontal gel cast apparatus (Biorad). 1- 
1.5% agarose gels were routinely used. The appropriate amount of ultrapure electrophoretic 
grade agarose was dissolved in Ix TBE buffer (lOx TBE: 900mM Tris base, 900 mM boric 
acid, 25 mM EDTA, pH 8.0) by heating the solution in a glass conical flask in a microwave. 
The gel cast apparatus with a comb containing the appropriate number and size of teeth to 
form the sample wells was assembled and the gel was poured. The solidified gel was placed in 
the gel tank and submerged in Ix TBE buffer containing 0.5 pg/ml ethidium bromide. 
Samples containing Ix loading buffer (lOx loading buffer is 65% (w/v) sucrose, lOmM Tris- 
HCl pH7.5, 10 mM EDTA, 0.3% (w/v) Bromophenol Blue) were loaded into individual wells. 
An appropriate sized DNA ladder was loaded into the first and/or last well in the gel and the 
DNA was separated by running at 100-150 constant voltage until the dye front was 1-3 cm 
from the end of the gel. Separated DNA was visualised by illumination on a short wave (312 
nm) UV light box and photographed using UVP Gel Documentation System. Agarose gel 
images were captured on a P.C.
87
Chapter 3 Results
Chapter Three 
Results
88
Chapter 3 Results
3 Results 
Introduction
The analysis of the HPV-16 DNA sequence revealed that E5 ORF is commonly located at the 
3’ end of the early region before the L2 ORF and overlaps the E2 ORF in the early region 
(Bravo et al., 2004). E5 ORF encodes a small hydrophobic membrane protein, 83 amino acids 
long, located mainly at the endosomal membranes, GA and occasionally the plasma 
membranes (Burkhardt et ah, 1989 and Conrad et ah, 1993). By hydropatic analysis, it has 
been determined that HPV-16 E5 protein has three hydrophobic domains connected by less 
hydrophobic regions (Bubb et ah, 1988). In contrast to BPV-1, where E5 is a major 
oncoprotein, little is known about the biological activity of HPV-16 E5. However, the amino 
acid analysis of the HPV-16 E5 protein and BPV-1 E5 has revealed that they are very 
different. The HPV-16 E5 protein is nearly twice as long as BPV-1 E5, but some limited 
sequence similarities have been suggested between the HPV-16 E5 and BPV-1 E5 proteins 
such as a few hydrophobic residues (Bubb et ah, 1888).
Previous studies have shown that cells transformed by BPV E5 show retention of MHC class 
I molecules in the GA and inhibition of transport of the complex to the cell surface (Ashrafi et 
ah, 2002; Marchetti et ah, 2002; O’Brien and Campo, 2003). Also BPV E5 inhibits both 
transcription of the MHC class I heavy chain gene and affects the stability of the heavy chain 
protein (Ashrafi et ah, 2002). Furthermore, BPV E5 down-regulates MHC class I in clinical 
samples of BPV-4 papillomas (Araibi et ah, 2004). The MHC class I molecule plays an 
important role in the eradication of virally infected and transformed cells. The importance of 
MHC class I in virus clearance is highlighted by the acquisition of numerous mechanisms of 
interference with the MHC class I pathway by many viruses (Hewitt, 2003). The MHC class I 
molecules aie subdivided into two families, MHC class la or classical, and MHC class Ib or
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non-classical. The classieal molecules are a family of exceedingly polymorphic cell surface 
glycoproteins found on almost all nucleated somatic cells. These proteins play an important 
role in alerting the immune system to virally infected cells. Independently of the moleculai' 
nature of these mechanisms, employed by viruses to avoid host immunosurveillance the 
outcome is failui'e of the infected cells to effectively present viral peptides to effector CTL, 
resulting in avoidance of detection and destruction. The function of the non-classical MHC I 
molecules may have more specialized antigen presentation activities. In humans, the non- 
classical M H C I molecule binds a wide range of peptides derived from cellular proteins and has 
been suggested to play an important role in the maintenance of maternal tolerance to the fetus 
by interacting with inhibitory receptors on NK cells (Lee et al., 1995).
The aim of this study is to investigate the ability of HPV-16 E5 to down-regulate classical and 
non-classical MHC I, and to investigate the mechanisms by which HPV-16 E5 mediates this 
down-regulation.
3.1 HPV-16 E5 down-regulates MHC class I
3.1.1 HPV-16 E5 constructs
HPV-16 E5 ORF was cloned into two different vectors: pcDNA and pL2. pcDNA is a 
universal expression vector in which the inserted gene is under the control of the CMV early 
promoter, while pL2 is a plasmid in which expression is directed by the epithelial cell-specific 
promoter of EBV ED-L2. In both cases the E5 ORF was tagged at its 5’ and with the 
sequence encoding the HA epitope, a small polypeptide of nine amino acids (YPYDVPDYA).
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3.1.2 Transfection of HPV-16 E5 in human kcratinocytc cells (by Dr.H. Ashrafi)
As E5 is expressed at very low levels in cells and there are no reliable antibodies against the 
protein, it is very difficult to detect its expression (Disbrow et al., 2003). Therefore, we used 
HA-(YPYDVPDYA, peptide from human influenza haemaglutinin protein) tag was 
ineorporated at the N-terminus of HPV-16 E5 wild types and mutants. The human 
keratinocyte (HaCaT) cells were stably transfected with a range of plasmid DNA; pcDNA, 
pL2, pcl6E5 and pL2-16E5 by using Lipofectamine Plus to investigate the role of HPV-16 
E5 on MHC class I. One day before transfection, Ix 10  ^HaCaT cells had been plated in 80 
mm petri dishes with appropriate medium and incubated at 37°C in 5% CO2 overnight 
following the transfection protocol (see section 2.2.15). Following transfection, the cells were 
selected in medium containing 500jug/ml 0418 for 21 days. After this time, G418 resistant 
clones were marked, individually picked from each transfection class and expanded into cell 
lines for analysis (see section 2.2.16).
3.1.3 E5 expression in HaCaT clones
It has been established that E5 is expressed at low levels in cells and there are no reliable 
antibodies against the E5 protein (Disbrow et al, 2003). Therefore, we investigated that the 
E5 ORF was being transcribed in HaCaT cells using quantitative RT-PCR. RNA was isolated 
and the relative level of E5 mRNA expression was determined by comparison to |3-actin 
mRNA using Real-time RT-PCR protocol (see section 2.2.21 and 2.2.24). We analysed three 
pcl6E5 and three pL2-16E5 clones for the presence of E5 transcripts. In each experiment, 
additional reactions, with 10 fold serial dilutions of template DNA, were performed with each 
set of primers and probes on the same 96-well plates to generate standard curves. The 
quantitive RT-PCR was used to determine the relative amount of HPV-16 E5 and (3-actin
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mRNA in triplicate experiments of each E5 transfected cell line and from cells carrying empty 
vectors by using a standard curve (Figure 7A). The results show that all of the transfected 
cells (pcl6E5 and pL2-16E5) express the E5 gene but at 10,000 fold less than p-actin (Figure 
7B). As expected, no E5 RNA was amplified in the control cells (Figm’e 7A).
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7. Expression of HPV-16 E5 RNA in transfected cell lines
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Figure 7: Taq-Man RT-PCR was used to determine the expression of E5 mRNA in the 
transfected HaCaT cells. A) The expression of HPV-16 E5 and actin mRNA was determined 
in HaCaT control cells (pcDNA and pL2) (one clone of each of pcDNA and pL2) or cells 
expressing HPV-16 E5 (pcl6E5 and pL2-16E5) (three clones of each of pcl6E5 and pL2- 
16E5) and each colour represents an RT-PCR experiment. B) Relative amount of HPV-16 E5 
and actin mRNA in HaCaT control cells (pcDNA and pL2) or cells expressing HPV-16 E5 
(pcl6E5 and pL2-16E5). E5 is expressed at 10,000 fold less than (3-actin.
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3.1.4 Down-regulation of MHC class I in cells expressing HPV-16 E5
The effect of HPV-16 E5 on MHC class I was investigated by FACS, immunofluorescence 
microscopy and western blots. FACS was used to investigate the level of MHC class I on the 
cell surface. For intracellular analysis; immunofluorescence microscopy was used to show the 
cellular localization of MHC class I, and western blots to show the expression of the MHC 
class I heavy chain in HaCaT parental cells, cells caring empty vectors or cells expressing 
HPV-16 E5.
3.1.4.1 Detection of MHC class I by FACS
It has been reported that BPV E5 can inhibit transport of MHC class I molecules to the cell 
surface (Ashrafi et al, 2002; Marchetti et al, 2002). We investigated whether HPV-16 E5 
would likewise down-regulate surface MHC class I. Three clones of HaCaT parental cells, 
control pcDNA and pL2 cells or pcl6E5 and pL2-16E5 cells were incubated with mAb 
W6/32 (anti-MHC class I) and analysed for levels of both surface and total MHC class I. We 
determined that the clones harbouring empty vectors were no different from parental HaCaT 
cells, with approximately twice as much total MHC class I than sui'face MHC class I. On the 
contrary, all of the cells expressing HPV-16 E5 (pcl6E5, pL2-16E5) the level of surface 
MHC class I reduced to approximately half that of control cells whereas the level of total 
MHC class I remained constant (Figures 8A and SB).
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8. Down-regulation of MHC class I by HPV-16 E5
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Figure 8: Down-regulation of MHC class I on the cell surface was investigated in the cells 
expressing HPV-16 E5. HaCaT parental cells, cells carrying empty vector (pcDNA, pL2) or 
cells expressing HPV-16 E5 (pcl6E5, pL2-16E5) were stained with mAb W6/32 and 
analysed for expression of surface and total (surface plus intracytoplasmic) MHC class I by 
FACS. A) Representative FACS profiles of single cell lines. Dotted line and open histogram, 
forward fluorescence with secondary antibody only; solid histogram, forward fluorescence 
with primary and secondary antibody. B) The mean fluorescence from at least four 
experiments performed on three clones of each cell line was calculated from FACS analysis. 
A background of 0.4 (the reading of cells stained with only secondary antibody) was 
subtracted in all cell lines.
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3.1.4.2 Detection of MHC class I by immunofluorescence microscopy
To investigate the cellular localization of MHC class I, the cells were aliquoted into 24-well 
plates containing coverslips at IxlO"  ^ cells per well and grown overnight until 20%-50% 
confluent following the immunofluorescence staining protocol (see section 2.2.26). HaCaT 
parental cells, pcDNA, pL2, pcl6E5 or pL2-16E5 cells were stained with mAb W6/32. In 
HaCaT parental cells and pcDNA or pL2 cells, MHC class I was detected both on the cell 
surface and in the cytoplasm, but it was detected only in the cytoplasm in the cells expressing 
HPV-16 E5 (Figure 9). These results confirmed that HPV-16 E5 down-regulates MHC class I 
on the cell surface.
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Figure 9: HaCaT parental cells, cells carrying empty vector (pcDNA and pL2) or cells 
expressing HPV-16 E5 (pcl6E5 and pL2-16E5) were stained with mAb W6/32 (anti MHC 
class 1). The slides were mounted in Citifluor™ and analysed with a Leica TCS SP2 
fluorescence confocal microscope at 488nm wavelength. Images were acquired using Leica 
confocal software to show the localization of MHC class 1. N=nucleus
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9, Detection of MHC class I by immunofluorescence microscopy
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3.1.4.3 Visualisation of the Golgi apparatus by immunofluorescence microscopy
It has been shown that BPV-4 E5 oncoprotein affects the structure of the Golgi Apparatus 
(GA), leading to GA swelling and fragmentation (Marchetti et al, 2002). To see if the 
expression of HPV-16 E5 causes the same affect on the GA, the GA was visualised by 
immunofluorescence using mAb 4A3 raised against golgin GM130, an integral GA protein 
(Barr et al, 1998). HaCaT cells were aliquoted, grown, fixed and permeabilised as described 
in section 2.2.27. The cells were incubated with mAb 4A3 for 1 hour at room temperature and 
washed twice with PBS+1% FCS. Cells were then incubated with anti-mouse IgG-TRITC at 
4°C for 1 hour (in the dark). Following three final washes with PBS, the slides were mounted 
in Citifluor™ and analysed with a Leica TCS SP2 fluorescence confocal microscope at 
543nm wavelength. Images were acquired using Leica confocal software. The results show 
that expression of HPV-16 E5 does not affect the morphology of the GA (see central panels of 
the Figure 10).
3.1.4.4 Localisation of MHC class I in the Golgi apparatus
It has been reported that BPV-1 and 4 E5 causes the retention of MHC class I in the GA and 
prevents its export to the plasma membrane (Ashrafi et al, 2002; Marchetti et al, 2002). To 
see if HPV-16 E5 retains MHC class I in the GA in transformed cells, at least three of each 
control HaCaT clones carrying empty vectors, three pcl6E5 and three pL2-16E5 clones were 
co-stained with mAh W6/32 and mAh 4A3. The cells were aliquoted, grown, fixed and 
permeabilised as described in Materials and Methods section 2.2.28. The merge between 
FITC and TRITC fluorescent signals was achieved with the Leica confocal software. In 
control cells, MHC class I was detected both on the cell surface and in the GA. In contrast, in 
E5 cells MHC class I was detected almost exclusively in the GA (Figure 10, shown only for
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one of each clone of HaCaT control cells and E5 cells), confirming that E5 prevents the MHC 
class I complex from reaching the cell surface, and retains it in the GA, as already observed 
for BPV E5 (Ashrafi et al, 2002; Marchetti et al, 2002).
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10. Immunofluorescence detection of MHC class I and Golgi apparatus
MHCI
pcDNA
pcl6E5
pL2-16E5
Figure 10: HaCaT cells carrying empty vectors or cells expressing HPV-16 E5 were co­
stained with mAb W6/32 (anti MHC class I) and mAb 4A3 (anti golgin, GM130) and 
analysed with a Leica TCS SP2 fluorescence confocal microscope. Images were acquired 
using Leica confocal software to show visualisation of the GA and MHC class I. N=nucleus
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3.1.4.5 Expression of MHC class I heavy chain is not inhibited by HPV-16 E5
The results above suggested that, in contrast to BPV, HPV-16 E5 did not have any effect on 
the overall levels of the MHC class I heavy chain. To confirm this observation, MHC class I 
was investigated by immunoblotting in HaCaT parental cells, pcDNA and pL2 cells or 
pcl6E5 and pL2-16E5 cells using mAb HCIO, specific for human MHC class I heavy chain, 
as described in section 2.2.30. We determined that HPV-16 E5 has no effect on the overall 
levels of the MHC class I heavy chain, which is in similar amounts in control cells and in 
cells expressing E5 (Figure 11). Although the levels of MHC class I heavy chain are slightly 
lower in the pL2 and pL2-16E5 cell lines than in the pcDNA and pcl6E5 cell lines, there is no 
significant difference between them. The results confirm that HPV-16 E5 does not down- 
regulate the expression of total classical MHC I heavy chain.
11. Detection of MHC class I in the HPV-16 E5 cells by immunobloting
HLA I HC
actin
Figure 9: For detection of MHC class I, the membranes were incubated with mAb HCIO 
specific for MHC class I heavy chain and mAb AB-1, specific for P-actin.
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3.1.5 Conclusion
The FACS results show that the levels of surface MHC class I are approximately half of the 
total in HaCaT parental cells and control cells but that in E5 cells, the levels of surface MHC 
class I is reduced to approximately half that of control cells whereas the level of total MHC 
class I remains constant (Figure 8). Furthermore, in control cells, MHC class I was detected 
both on the cell surface and in the GA. In contrast, in E5 cells MHC class I was detected 
almost exclusively in the GA (Figure 10), confirming that E5 prevents the MHC class I 
complex from reaching the cell surface, and retains it in the GA. However, despite the down- 
regulation of surface MHC class I, the overall expression of MHC class I heavy chain as 
measured by intracellular immunofluorescence is not inhibited by E5 (Figure 11).
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3.1.6 Down-regulation of MHC class I by E5 is reversible
3.1.6.1 Introduction
IFNs, which consist of type I (IFN a  and p) and type II (IFN y) are a large family of 
multifunctional secreted proteins that regulate cellular antiviral, anti-tumour and 
immunological responses through IFN-stimulated gene expression. The IFN a  and p are 
produced in virally infected cells but IFN y is not virus inducible and is restricted to mitogen 
or cytokine-activated lymphoid cells such as T lymphocytes and natural killer cells. One of 
the functions of IFNs is to up-regulate the expression of MHC class I, which is able to present 
antigen peptides to CTLs. It has been reported that BPV E5 proteins causes a down-regulation 
of surface MHC class I molecules in transformed cells (Ashrafi et ah, 2002) and IFN 
treatment increases the transcription of the MHC class I heavy chain gene, but cannot 
overcome the block in exocytic transport (Marchetti et ah, 2002 and 2005). To see whether 
down-regulation of MHC class I by HPV-16 E5 is reversible, we treated cells with IFN to 
determine if IFN treatment up-regulated MHC class I expression. Therefore, HaCaT parental 
cells, pcDNA, pL2, pcl6E6 and pL2-16E5 cells were treated with 500U/ml P-IFN for 48 
hours and stained with mAh W6/32 then analysed for expression of total and surface MHC 
class I both by FACS and immunofluorescence.
3.1.6.2 E5 expression in IFN treated HaCaT cells
To see whether IFN treatment affected expression of E5, we measured level of E5 mRNA in 
IFN-treated and untreated cells by quantitative RT-PCR. RNA was isolated and the relative 
level of E5 mRNA expression was determined by comparison to p-actin mRNA (see section 
2.2.21 and 2.2.24). We analysed three pcl6E5 clones. In each experiment, additional reactions 
of 10 fold serial dilutions of template DNA were performed with each set of primers and
106
Chapter 3 Results
probes on the same 96-well plates to generate standard curves. The quantitive RT-PCR was 
used to determine the relative amount of HPV-16 E5 and p-actin mRNA in triplicate 
experiments of each transfected E5 cells and cells carrying empty vector by using a standard 
curve. The Taq-Man RT-PCR results show that IFN treatment has no major effect on E5 
expression at the dose used (Figures 12A and 12B).
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Figure 12: Taq-Man RT-PCR was used to determine the expression of E5 mRNA in the 
transfected HaCaT cells treated or not treated with 500U/ml P-IFN for 48 hours. A) The 
expression of HPV-16 E5 and actin mRNA was determined in HaCaT control cells (one clone 
of pcDNA) or cells expressing HPV-16 E5 (three clones of pcl6E5) treated with p-IFN and 
each colour represents an RT-PCR experiment. B) Relative amount of HPV-16 E5 and actin 
mRNA in HaCaT control cells (pcDNA) or cells expressing HPV-16 E5 (pcl6E5) treated or 
untreated with p-IFN. E5 is expresed at 10,000 fold less than P-actin.
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12. Expression of HPV-16 E5 RNA in transfected cell lines treated with p-IFN 
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3.1.6.3 Treatment of HPV-16 E5 cells with IFN rescues MHC class I traffic to the cell 
surface
P-IFN increases the transcription activity of the MHC class I heavy chain gene promoter 
(Agrawal and Kishore, 2000) leading to higher expression levels of heavy chain. We have 
shown above that HPV-16 E5 retains MHC class I in the GA and impedes its transport to the 
cell surface (Figures 8 and 10). To see if increased synthesis of heavy chain led to an increase 
in transport of MHC class I complex to the cell surface, HaCaT parental cells, pcDNA and 
pL2 cells or pcl6E5 and pL2-16E5 were treated with 500U/ml P-IFN for 48 hours, and 
analysed for MHC class I expression by FACS and localisation by immunofluorescence, as 
described in section 2.2.31. We determined that treatment with P-IFN increased the level of 
total MHC class I both in HaCaT control cells and in E5 cells to approximately the same level 
in all cell lines. Treatment with P-IFN increased total MHC class I approximately two folds in 
all cell lines. At the same time P-IFN treatment increased surface MHC class I approximately 
two folds in HaCaT parental cells, pcDNA and pL2 cells, and approximately four folds in E5 
expressing cells (Figure 13). This resulted in all cell lines, including those expressing E5, 
having similar levels of surface MHC class I. These results indicate that P-IFN treatment can 
overcome the block exerted by E5 on MHC class I transport.
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13. Detection of MHC class I by HPV-16 E5 is reversible by (3-IFN
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Figure 13: The level of MHC class I was investigated in HaCaT parental cells, cells carrying 
empty vectors (pcDNA, pL2) or cells expressing HPV-16 E5 (pcl6E5 and pL2-16E5) with 
500U/ml p-IFN for 48 hour’s. The cells were stained with mAb W6/32 and analysed for 
expression of surface and total MHC class I by FACS. A) Representative FACS profiles of 
single cell lines. Dotted line and open histogram, forward fluorescence with secondary 
antibody only; solid histogram, forward fluorescence with primary and secondary antibody. 
B) The mean fluorescence for each of the HaCaT control cells and E5 cells was calculated 
from three experiments and thi’ee clones from each cell line by FACS analysis. A background 
of 0.4 (the reading of cells stained with only secondary antibody) was subtracted in all cell 
lines. C) Average mean fluorescence for each of the cell lines treated with or without 
500U/ml p-IFN for 48 hours and analysed for expression of total and surface MHC class I by 
FACS analysis with mAb W6/32.
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3.1.6.4 Distribution of MHC class I in HPV-16 E5 cells after IFN-p treatment
To confirm this observation, HaCaT parental cells, cells carrying empty vectors or cells 
expressing HPV-16 E5, treated with P-IFN, were stained with mAb W6/32 and analysed for 
MHC class I localisation by immunofluorescence staining as described in section 2.2.26. We 
determined that MHC class I was mostly detected in the GA in untreated HPV-16 E5 cells, as 
before. In HPV-16 E5 cells treated with p-IFN, MHC class I was detected also on the cell 
surface (Figure 14). This result is in agreement with the FACS analysis, shows that E5 cells 
are responsive to P-IFN and that the E5-induced MHC class I transport inhibition is reversible 
by p-IFN.
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Figure 14: HaCaT parental cells, cells carrying empty vector (pcDNA and pL2) or cells 
expressing HPV-16 E5 (pcl6E5 and pL2-16E5) were treated with 500U/ml P-IFN for 48 
hours and stained with mAb W6/32. The slides were mounted in Citifluor™ and analysed 
with a Leica TCS SP2 fluorescence confocal microscope at 488nm wavelength. Images were 
acquired using Leica confocal software to show the localization of MHC class I. N=nucleus
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14. Detection of MHC class I using p-IFN by immunofluorescence microscopy
HaChT
pL2-16E5
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3.1.6.5 Conclusion
The FACS results show that treatment of the HaCaT control cells and E5 cells with p-IFN 
increased the amount of total MHC class I approximately two-fold in all of the cell lines. 
Moreover, we found an approximately two-fold increase in surface MHC class I in the 
parental HaCaT cells and control cells (no E5 cells), and an approximately four-fold increase 
in the E5-expressing cells (pcl6E5, pL2-16E5). We show that treatments with p-IFN 
increases the syntheses of MHC class I in the cells and rescue the transport of MHC class I to 
the cell surface. IFN has little effect on E5 expression so the abrogation of the retention of 
MHC class I in the GA is not due to inhibition of E5 expression. In fact the expression of E5 
is slightly increased by IFN treatment, but this does not prevent transport of MHC class I to 
the cell surface. These results reveal that p-IFN treatment of the HPV-16 E5 cells did not 
affect the expression of E5. Therefore, the increase of the levels of MHC class I caimot be 
attributed to changes in E5 expression.
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3.2 Which domain of HPV-16 E5 is responsible for down-regulation of MHC I? 
3.2.1 Introduction
The E5 protein is a small hydrophobic protein from 42 amino acids residues in BPV-4 to 83 
amino acids residues in HPV-16. BPV E5 protein can be divided into two domains, N- 
terminus, which is a hydrophobic domain and C-terminus, which is a generally hydrophilic 
domain. The C-terminus of BPV-1 E5 includes two cysteine residues, which are important for 
homodimerization and transforming activity (Burkhardt et al, 1987; Horwitz et al, 1988). It 
has been determined by hydropatic analysis that HPV-16 E5 protein has three hydrophobic 
domains connected by less hydrophobic regions (Bubb et ah, 1988). HPV-16 E5 protein is 83 
amino acids long, located mainly at the endosomal membranes, GA and, to a lesser extent, the 
plasma membranes (Burkhardt et al, 1989; Conrad et al, 1993). The C-terminal portion of 
BPV-1 E5, which appears to be important for biological function, does not have an 
identifiable similar region in HPV-16 E5.
3.2.2 Generation of HPV-16 E5 Del-1
Like BPV E5 (Ashrafi et al, 2002, Marchetti et al, 2002), HPV-16 E5 can inhibit transport of 
MHC class I molecules to the cell surface (Figure 8). It is important to determine the region of 
the E5 protein responsible for down-regulation of MHC class I. To this end, deletion mutants 
of E5 (Figure 16) were used. HPV-16 E5 mutants (R79, A54, V36 and R30), in which double 
stop codons were introduced at these positions, were kind gifts from Professor Alonso. In 
addition, a mutant was constructed by PCR, which lacked the first hydrophobic domain, 
called HPV-16 E5 Del-1.
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15. Sequence of HPV-16 E5 wild type and HPV-16 E5 mutants 
HPV-16 E5 wild type1 atgacaaatc gtgatactgc atccacaaca ttactggcgt gctttttgct ttgcttttgt61 gtgcttttgt gtgtctgcct attaatacgt ccgctgcttt tgtctgtgtc tacatacaca121 tcattaataa tattggtatt actattgtgg ataacagcag cctctgcgtt taggtgtttt181 attgtatata ttatatttgt ttatatacca ttatttttaa tacatacaca tgcacgcttt241 ttaattacat aa
1 MTNRDTASTT LLACFLLCFC VLLCVCLLIR PLLLSVSTYT SLIILVLLLW 
51 ITAASAFRCF IVYIIFVYIP LFLIHTHARF LIT
HPV-16 E5 R791 atgacaaatc gtgatactgc atccacaaca ttactggcgt gctttttgct ttgcttttgt61 gtgcttttgt gtgtctgcct attaatacgt ccgctgcttt tgtctgtgtc tacatacaca121 tcattaataa tattggtatt actattgtgg ataacagcag cctctgcgtt taggtgtttt181 attgtatata ttatatttgt ttatatacca ttatttttaa tacatacaca tgcataa
1 MTNRDTASTT LLACFLLCFC VLLCVCLLIR PLLLSVSTYT SLIILVLLLW 
51 ITAASAFRCF IVYIIFVYIP LFLIHTHA
HPV-16 E5 A54
1 atgacaaatc gtgatactgc atccacaaca ttactggcgt gctttttgct ttgcttttgt61 gtgcttttgt gtgtctgcct attaatacgt ccgctgcttt tgtctgtgtc tacatacaca121 tcattaataa tattggtatt actattgtgg ataacagcat aa
1 MTNRDTASTT LLACFLLCFC VLLCVCLLIR PLLLSVSTYT SLIILVLLLW 
51 ITA
HPV-16 E5 V36
1 atgacaaatc gtgatactgc atccacaaca ttactggcgt gctttttgct ttgcttttgt61 gtgcttttgt gtgtctgcct attaatacgt ccgctgcttt tgtcttaa
1 MTNRDTASTT LLACFLLCFC VLLCVCLLIR PLLLS 
HPV-16 E5 R301 atgacaaatc gtgatactgc atccacaaca ttactggcgt gctttttgct ttgcttttgt 61 gtgcttttgt gtgtctgcct attaatataa
1 MTNRDTASTT LLACFLLCFC VLLCVCLLI 
HPV-16 E5 Dei-1
91 ccgctgcttt tgtctgtgtc tacatacaca tcattaataa tattggtatt actattgtgg151 ataacagcag cctctgcgtt taggtgtttt attgtatata ttatatttgt ttatatacca211 ttatttttaa tacatacaca tgcacgcttt ttaattacat aa
31 PLLLSVSTYT SLIILVLLLW ITAASAFRCF IVYIIFVYIPLFLIHTHARF LIT 
Figure 15: HPV-16 E5 wild type ORF has 249 nucleotides (83 amino acids), R79 lacks the 
last C-terminus 5 amino acids, A54 lacks the third hydrophobic domain, V36 contains the first 
hydrophobic domain plus amino acids 31-36, R30 contains only the first hydrophobie domain 
and Del-1 lacks the first hydrophobic domain.
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16. Schematic diagram of the HPV-16 E5 wild type and HPV-16 E5 mutants.
HP V- 1 6  E5 WT
HP V- 1 6  E5 R79
HP V- 1 6  E5 A54  HA
HP V- 1 6  E5 V36
HP V- 1 6  E 5 R 3 0  h a
HP V- 1 6  E5 De l l  [ HA |—|^
Figure 16: HPV-16 E5 mutants: HPV-16 E5 R30 contains only the first hydrophobic domain, 
V36 contains the first hydrophobic domain plus amino acids 31-36, A54 lacks the third 
hydrophobic domain, R79 lacks the last C-terminus 5 amino acids and Del-1 lacks the first 
hydrophobic domain. HA- (YPYDVPDYA, peptide from human influenza heamaglutinin 
protein) tag was incorporated at the N-terminus of all of E5 mutants. Each box represents a 
hydrophobic domain of the HPV-16 E5 protein, bound by less hydrophobic regions (lines).
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3.2.3 Domain-directed deletion of HPV-16 E5
HPV-16 E5 Del-1 mutant was made by deletion of the first hydrophobic domain (from 1 to 30 
first amino acids) of the HPV-16 E5 ORF. The primers used to make deletion mutant in the 
HPV-16 E5 ORF incorporated two restriction enzyme sites: Nhe~I and EcoR-I, for cloning in 
the multi cloning sites of pci-neo vector, and the forward primer incorporated the HA-tag. 
DNA was constructed as described in section 2.2.7.
3.2.4 Generation of HPV-16 E5 Del-1
The oligonucleotide sequence containing the HPV-16 E5 Del-1 mutation was generated 
following DNA PCR protocol as described in section 2.2.7. The correct product was 
amplified by PCR and purified by using a PCR purification kit (see section 2,2.9). The DNA 
fragment was ligated into the cut vector at an insert:vector ratio of 6:1 using appropriate 
enzyme and buffer. The ligated samples were transformed in E.coli DH5-a competent cells 
and the bacterial culture grown on medium containing the appropriate antibiotic (see section 
2.2.1). A single bacterial clone was used to inoculate 5 ml L-broth medium and grown 
overnight at 37°C (picked at least 10 clones). Plasmid DNA was prepared from the clone 
using the QIAprep Spin plasmid miniprep kit according to the manufacturer’s instruetions 
(see section 2.2.2). The plasmid DNA was sequenced and transfected into HaCaT cells.
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3.2.5 Agarose gel electrophoresis
The correct size of this mutant was analysed by agarose gel electrophoresis. Samples were 
loaded into individual wells with an appropriate sized DNA ladder. Separated DNA was 
visualised by illumination on a short wave (312 nm) UV light box and photographed using 
UVP Gel Documentation System. We determined the size of HPV-16 E5 Del-1 mutant, which 
is 189 base pairs, encoding a protein of 62 amino acids long including the HA tag, of 
approximately 6 KDa (Figure 17).
17. DNA PCR product of HPV-16 E5 Del-1
PCR
Marker: 100 base pair DNA ladder 
Figure 17: HPV-16 E5 Del-1 mutant which is 189 base pairs including HA-tag (162 bp for 
E5Del-l plus 27 bp of HA tag).
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3.2.6 DNA sequencing
The deletion of the first hydrophobic domain was verified using an Applied Bio systems 3100 
automated DNA sequencer. Subsequently the samples were analysed using an ABI3100 
genetic analyser (see section 2.2.12). The sequence of the HPV-16 E5 Del-1 construct was 
aligned and compared to HPV-16 E5 wild type sequence and confirmed by using the 
DNASTAR program.
3.2.7 Transfection of HPV16 E5 mutants in HaCaT clones
The HaCaT cells were stably transfected with a range of plasmid DNA; HPV-16 E5 wild type 
(pcl6E5) and HPV-16 E5 mutants (pcl6E5 R79, pcl6E5 A54, pcl6E5 V36, pcl6E5 R30 and 
pcl6E5 Del-1) by using Lipofectamine Plus to investigate the role of HPV-16 E5 mutants 
(see section 2.2.16).
3.2.8 The expression of HPV-16 E5 mutants in HaCaT clones
We investigated that the HPV-16 E5 wild type (pcl6E5) and HPV-16 E5 mutants (pcl6E5 
R79, pcl6E5 A54, pcl6E5 V36, pcl6E5 R30 and pcl6E5 Del-1) were being transcribed 
using quantitative RT-PCR. RNA was isolated and the relative level of E5 mRNA expression 
was determined by comparison to p-actin mRNA using Real-time RT-PCR protocol (see 
sections 2.2.21 and 2.2.24). We analysed thi'ee clones of each HPV-16 E5 mutants for the 
presence of E5 transcripts. In each experiment, additional reactions, with 10 fold serial 
dilutions of template DNA, were performed with each set of primers and probes on the same 
96-well plates to generate standard curves. The quantitive RT-PCR was used to determine the 
relative amount of HPV-16 E5 mutants and p-actin mRNA in triplicate experiments of each 
transfected cell line and cells carrying empty vectors by using a standard curve (Figure ISA).
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The Taq-Man RT-PCR results show that the transformed cells (pcl6E5 R79, pcl6E5 A54, 
pcl6E5 V36 and pcl6E5 R30) express E5 mRNA but at 10,000 fold less than p-actin sample, 
similar to HPV-16 E5 wild type (Figure 18B). However, expression of HPV-16 E5 Del-1 
could not be detected by real-time RT-PCR.
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Figure 18: Expression of HPV-16 E5 wild type and HPV-16 E5 mutants (R79, A54, V36 
and R30) mRNA in HaCaT cells. A) The expression of HPV-16 E5 wild type, HPV-16 E5 
mutants and actin mRNA was determined in HaCaT parental cells (one clone), cells carrying 
empty vector (one clone of pcDNA) or cells expressing HPV-16 E5 (one clone of pcl6E5) 
and HPV-16 E5 mutants (three clones of each of the pcl6E5 mutants) and each colour 
represents an RT-PCR experiment. B) Relative amount of HPV-16 E5 wild type, HPV-16 E5 
mutants and actin mRNA in HaCaT control cells (one clone), pcDNA (one clone), pcl6E5 
wild type (one clone) and pcl6E5 mutants (three clones each of the mutants: R79, A54, V36 
and R30). HPV-16 E5 wild type and HPV-16 E5 mutants are expressed at comparable levels 
approximately 10,000 fold less than p-actin.
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18. Expression of HPV-16 E5 wild type and mutants RNA in transfected cell lines
HaCaT& ^  
pcDNA
pcl6E5
R79
A54
V36
R30
Actin
A ... % . - *  «S # *  4 #  # #  # #  m# M» # #  * 4  * #  # a  4
II ■ I t I , '  • ■ . ; *4i.; ;; i ; ■ i i
‘ ! I I 4% Ü  ! : : Î
Cycle Cycle
B
600
500
400
300
<  200
100
RT-PCR an a ly sis BE5 □ Actin
_600
-  500
400
300
,200
100
S
<
i
U
126
Chapter 3 Results
3.2.9 Detection of HPV-16 E5 Del-1 RNA from HaCaT cells
We investigated the expression of HPV-16 E5 mutants (R79, A54, V36 and R30) gene by 
Taq-Man RT-PCR as HPV-16 E5 wild type but we could not detect HPV-16 E5 Del-1 
mutant. This mutant has the first hydrophobic domain deleted, which is the best target for the 
probe. Therefore, DNA PCR was used to investigate the presence of HPV-16 E5 Del-1 gene 
in the transfected HaCaT cells. The DNA was extracted from each clone of G418 resistant 
cells as described in section 2.2.18. All reagents were provided in the Genamp® PCR Reagent 
Kit and core Reagents with AmpliTaq® DNA polymerase and appropriated primers as in 
section 2.2.22. Thereafter, 5 pi of each sample was analysed by agarose gel electrophoresis to 
check the correct product had been amplified. The analysis of DNA PCR showed that there 
were detectable products in HaCaT cells with E5 wild type and in HaCaT cells transfected 
with E5Del-l, but not in the negative controls. These results confirm that the HPV-16 E5 Del- 
1 DNA was present in the transfected cells (Figure 19).
127
Chapter 3 Results
19. DNA PCR analysis of HaCaT cells transfected with HPV-16 E5 wild type and HPV-16 
E5 Del-1 mutant
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Marker: 100 base pair DNA ladder
Figure 19: Presence of the gene for HPV-16 E5 wild type (one clone each of pcl6E5 and 
pL2-16E5) or five clones of HPV-16 E5 Del-1 mutant was analysed by DNA PCR.
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3.2.10 Amplification of E5 RNA from HaCaT cells by RT-PCR
To investigate that the HPV-16 E5 Del-1 gene was transcribed in the transfected HaCaT cells, 
to the same extent of the other E5 mutants, we analysed each clone of HaCaT-E5Del-l for the 
presence of mRNA by using RT-PCR. Total cell RNA was prepared as in section 2.2.19 and 
used as the template for reverse transcription and PCR amplification by using Superscript 
one-step RT-PCR with platinum Taq, 100 reaction and appropriate primers (see section 
2.2.23). RNA was isolated and the relative level of E5 mRNA expression was determined by 
comparison to p-actin mRNA. We analysed the presence of B5 transcripts in HaCaT cells 
containing HPV-16 E5 wild type and HPV-16 E5 mutants including Del-1, along with 
positive and negative controls. The results show that the levels of expression of E5 wild type 
and mutants including Del-1 are approximately the same. The RT-PCR results show that all 
of the transformed cells express E5 but in lower amount than p-actin (Figure 20).
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20. RT-PCR analysis o f HaCaT cells with HPV-16 E5 wild type and mutants
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Figure 20: Expression o f HPV-16 E5 wild type, HPV-16 E5 mutants (R79, A54, V36, R30 
and Del-1) and actin mRNA in the transfected HaCaT cells were analysed by RT-PCR at 35 
cycles. Two clones of HPV-16 E5 wild type (pcl6E5), four clones of HPV-16 E5 Del-1, one 
clone o f HPV-16 E5 R79, two clones o f HPV-16 E5 A54, one clone o f HPV-16 E5 V36 and 
two clones o f HPV-16 E5 R30 were used, plus positive and negative controls.
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3.2.11 RT-PCR analysis of HaCaT cells transfected with HPV-16 E5 wild type and HPV- 
16 E5 mutants
HPV-16 E5 wild type, HPV-16 E5 mutants (Del-1, R79, A54, V36 and R30) and actin mRNA 
were analysed by using RT-PCR protocol and run on the gel. The bands of the E5 and actin 
were analysed using Image-Quantification 5.2 P.C. program (Figure 21). The results show 
that cells carrying HPV-16 E5 wild type and all of the HPV-16 E5 mutants including Del-1, 
express E5 at approximately the same level.
21. RT-PCR analysis of HPV-16 E5 wild type and HPV-16 E5 mutants
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Figure 21: RT-PCR analysis shows that the level of expression of HPV-16 E5 wild type and 
HPV-16 E5 mutants (R79, A54, V36, R30 and Del-1) at 35 cycles was comparable. Two 
clones of HPV-16 E5 wild type (pcl6E5), four clones of E5Del-l, one clone of E5R79, two 
clones of E5A54, one clone of E5V36 and two clones of E5R30 were used (the level of E5 
and actin mRNA were analysed using Image-Quantification 5.2 P.C. program).
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3.2.12 Semi-quantitative RT-PCR analysis using different numbers of cycles
The quantitation of RNA was done by RT-PCR at different cycles (15, 20, 25, 30 and 35 
cycles) to determine the quantity of E5 RNA. Total cell RNA was prepared as in section 
2.2.20 and used as the template for reverse transcription and PCR amplification by using 
Superscript one-step RT-PCR with platinum as previously described. 5 pi of each sample was 
run on the gel containing Ix loading buffer and carried out Image-Quantification 5.2 P.C. 
programme. No RNA could be detected at 15 cycles. Actin RNA could be detected at 20 
cycles, whereas E5 RNA could be detected only at 25 cycles (Figure 22), confirming these is 
less E5 RNA than actin RNA. However, RNA from E5 wild type and E5 mutants, including 
E5Del-l, were detected at approximately the same levels (Figure 22).
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22. Semi-quantitative RT-PCR analysis of HPV-16 E5 wild type and HPV-16 E5 mutants 
using different cycles (15, 20, 25, 30 and 35 cycles).
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3,2.13 Down-regulation of MHC class I by HPV-16 E5 mutants
The effect of HPV-16 E5 mutants on MHC class I was investigated by FACS for the level of 
surface and total MHC class I and by immunofluorescence for the cellular localization of 
MHC class I.
3.2.13.1 Down-regulation of MHC class I by the first hydrophobic domain of HPV-16 E5
The aim was to investigate which domain of HPV-16 E5 protein is important for down- 
regulation of MHC class I. To this end we have shown that HPV-16 E5 wild type down- 
regulates surface MHC class I. Tliree clones of HaCaT parental ceils, cells caring empty 
vectors (pcDNA), cells expressing HPV-16 E5 (pel6E5) or cells expressing HPV-16 E5 
mutants (R79, A54, V36, R30 and Del-1) were incubated with mAb W6/32, and analysed by 
FACS for levels of both surface and total MHC class L We determined that the cells 
expressing HPV-16 E5 Del-1 mutant were no different from parental or control HaCaT cells, 
with approximately twice as much total MHC class I than surface MHC class I. In contrast, in 
cells expressing HPV-16 E5 mutants (R79, A54, V36 and R30) the levels of surface MHC 
class 1 was reduced to approximately half of the HaCaT parental or control cells and 
indistinguishable from that of cells expressing E5 wild type. However, the level of total MHC 
class I was constant in the all cell lines (Figure 23). These results suggest that the firs 
hydrophobic domain of HPV-16 E5 is important to reduce surface MHC class I.
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23. Detection of MHC class I by FACS
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Figure 23: Down-regulation of surface MHC class I in the cells expressing HPV-16 E5 wild 
type (pcl6E5) and HPV-16 E5 mutants (R79, A54, V36, R30 and Del-1). HaCaT parental 
cells, pcDNA, pcl6E5 or E5 mutants (three cell lines of each) were stained with mAh W6/32 
and analysed for expression of surface and total MHC class I by FACS. A) Representative 
FACS profiles of one clone of each cell line. Dotted line and open histogram forward 
fluorescence with secondary antibody only; solid histogram forward fluorescence with 
primary and secondary antibody. B) The average fluorescence for the different cell lines was 
calculated from the FACS analysis. A background of 0.4 (the reading of cells stained with 
only secondary antibody) was subtracted in all cell lines.
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3.2.13.2 Detection of MHC class I by immunofluorescence microscopy
To confirm our observation with the FACS analysis we used immunofluorescence staining, as 
described in section 2.2.26, to detect the presence of MHC class I on the cell surface and in 
the cytoplasm of HaCaT carrying HPV-16 E5 wild type and mutants. We determined that 
MHC class I is present on the cell surface and in the cytoplasm in HaCaT E5Del-l cells and 
control cells, but is present only in the cytoplasm of the cells expressing HPV-16 E5 wild type 
(pcl6E5) and HPV-16 E5 mutants; R79, A54, V36 and R30 (Figure 24).
24. Detection of MHC class I by immunofluorescence microscopy 
HaCaT pcDNA Del-1 pc16E5
R30 V36. A54 R79
Figure 24: HaCaT parental cells, cells carrying empty vector (pcDNA), cells expressing 
HPV-16 E5 wild type and HPV-16 E5 mutants (R79, A54, V36, R30 and Del-1) were stained 
with mAb W6/32. The slides were mounted in Citifluor™ and analysed with a Leica TCS 
SP2 fluorescence confocal microscope at 488nm wavelength. Images were acquired using 
Leica confocal software to show the localization of MHC class I. N=nucleus.
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3.2.14 Cloning of HPV-16 E5 wild type and mutants into pEGFP-CI vector
We have established that HPV-16 E5 down-regulates MHC class I on the cell surface and the 
first hydrophobic domain is necessary for down-regulation (Figures 8 and 23). We have 
shown that MHC class I was detected only in the GA in the cells expressing HPV-16 E5, in 
contrast in HaCaT control cells or no E5-cells, MHC class I was detected both on the cell 
surface and the cytoplasm (Figure 10). It has been shown that BPV-4 E5 and MHC class I co- 
localizes in the GA (Marchetti et al, 2002). To investigate the localization of HPV-16 E5 
wild type and mutants we constructed fusion forms of HPV-16 E5 wild type and HPV-16 E5 
mutants with the GFP as described in section 2.2.8. The plasmids pEGFP-Cl HPV-16 E5 
wild type and the pEGFP-Cl HPV-16 E5 mutants were transfected in HaCaT cells by using 
Lipofectamine Plus. Following transfection, the cells were seleeted in medium containing 500 
pg/ml G418. Cells were analysed by confocal microscope to ascertain where the HPV-16 E5 
mutants localized. We determined that GFP alone is expressed throughout the cell in HaCaT 
cells but HPV-16 E5 wild type and all HPV-16 E5 mutants including Del-1 localized to the 
cytoplasm (Figure 25).
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25. Localisation of the HPV-16 E5 wild type and mutants using GFP vector.
V36 R30 Del-1
Figure 25: HaCaT cells expressing pEGFP-Cl, pEGFP-Cl HPV-16 E5 wild type and 
pEGFP-Cl HPV-16 E5 mutants (R79, A54, V36, R30 and Del-1) were aliquoted into 24-well 
plates containing coverslips at 1x10"^  cells per well. The cells were fixed using fixing solution 
at room temperature for 10 minutes, mounted in Citifluor^”^  and analysed with a Leica TCS 
SP2 fluorescence confocal microscope at 488nm wavelength. Images were acquired using 
Leica confocal software. N=nucleus
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3.2.15 Localisation of pEGFP-E5 and visualisation of Golgi apparatus
We established that HPV-16 E5 wild type and HPV-16 E5 mutants including Del-1 localized 
to the cytoplasm but GFP is expressed throughout the cell. To see if HPV-16 E5 mutants 
(R79, A54, V36, R30 and Del-1) localize in the GA like HPV-16 E5 wild type, the GA was 
visualised by immunofluorescence detection using mAb 4A3. FlaCaT cells were aliquoted 
into 24-well plates containing coverslips at 1x1 O'* cells per well and grown overnight till 20%- 
50% confluent. The cells were fixed and incubated in permeabilization solution at room 
temperature for 10 minutes and then stained with mAb 4A3 (for Golgi) and DAPI (for 
nucleus). Cells were analysed by two colours fluorescence to ascertain where the HPV-16 E5 
mutants localized. We determined that HPV-16 E5 wild type and all HPV-16 E5 mutants 
including Del-1 are localized in the GA (Figure 26). The same results were obtained when the 
GA was stained with BODIPY-Ceramide (not shown).
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Figure 26: HaCaT cells expressing pEGFP-Cl HPV-16 E5 wild type and pEGFP-Cl HPV- 
16 E5 mutants (R79, A54, V36, R30 and Del-1) were aliquoted, grown, fixed and 
permeabilised as previously described. The cells were stained with mAb 4A3 (for Golgi 
staining) and DAPI (for nucleus staining) and then analysed with the Leica TCS SP2 
fluorescence confocal microscope. Images were acquired using Leica confocal software to 
show the localization of GFP-E5 and visualisation of the GA. The left panels are GFP-E5 
wild type and GFP-E5 mutants, the middle panels are the GA and the right panels are merge 
between GFP-E5 wild type or GFP-E5 mutants and the GA with nucleus. N=nucleus
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26. Localisation of the pEGFP-HPV-16 E5 wild type and mutants in HaCaT cells
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3.2.16 Conclusion
We determined that the cells expressing HPV-16 E5 Del-1 mutant were no different from 
parental or control HaCaT cells, with approximately twice as much total MHC class I than 
surface MHC class I. In contrast, in cells expressing the other HPV-16 E5 mutants (R79, A54, 
V36 and R30) the levels of surface MHC class I was reduced to approximately half of the 
HaCaT parental or control cells and indistinguishable from that of cells expressing E5 wild 
type. However, the level of total MHC class I was constant in all the cell lines (Figure 23). To 
confirm this, we did immunofluorescence microscopy analysis of the same cell lines. The 
results show that MHC class I was detected on the cell surface and the cytoplasm in HaCaT 
Del-1 cells (Figure 24). These results suggest that down-regulation of MHC class I is due to 
the first hydrophobic domain of HPV-16 E5. To investigate the localization of HPV-16 E5 
wild type and HPV-16 E5 mutants in the transfected HaCaT cells, we determined that HPV- 
16 E5 wild type and HPV-16 E5 mutants including Del-1 localized to the GA, whereas GFP 
is expressed throughout the cell (Figure 25 and 26). These results show that the localization of 
the E5 in the GA is important but not sufficient for the down-regulation of MHC class I as 
E5Del-l fails to down-regulate of surface MHC class I despite its localisation in the GA; and 
that the first hydrophobic domain of HPV-16 E5 is necessary for down-regulation of MHC 
class I.
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3.3 HPV-16 E5 protein physically interacts with MHC class I
3.3.1 Introduction
The E5 protein is a small hydrophobic protein that can interact with cellular proteins, 
including EGF-R, 16K subunit c/ductin and PDGE-R. It has been reported that BPV E5 
protein (Goldstein et al, 1990) and HPV E5 protein (Conrad et al, 1993) bind to 16K subunit 
c/ductin, which is found in two distinct membrane complexes, VO sector of the vacuolar H+ 
ATPase (Mandel et al, 1988) and gap junctions (Finbow and Pitts 1993). The binding of the 
E5 to 16K subunit c/ductin has led to the suggestion that the function of both the gap junction 
and V-ATPase might be impaired. Previous studies (Rodriguez et al, 2000) have identified 
the second domain of HPV-16 E5 as responsible for binding to the 16K subunit c. The V- 
ATPase is a universal transmembrane proton pump of eukaryotes and is responsible for 
acidification of the cytoplasmic organelles (e.g. Golgi, endosomes, lysosomes, and certain 
secretory vesicles) (Finbow et al, 1997). Thus, complex formation between E5 and 16K 
subunit c would inhibit endosomal acidification leading to an increase in receptor recyling to 
the plasma membrane (Straight et al, 1993 and 1995). It has been determined that the 
expression of E5 increases the pH of the GA (Schapiro et al, 2000), which is thought to be 
tlirough its binding to 16K subunit c. Since growth factor receptors are processed in the Golgi 
and are internalized via clathrin-coated vesicles, E5 binding to the 16K protein within these 
components may be an intermediate step to receptor activation and signal transduction.
The ‘ductin’ is a component of a type of gap junction, an intercellular complex that provides 
sites of cell-to-cell movement (Finbow and Pitts 1993). It has been reported that the 
interaction of HPV-16 E5 with ductin is responsible for the observed down-regulation of gap 
junctions (Conrad et al, 1993). HPV-16 E5 reduces gap junction-mediated intercellular 
communication via dephosphorylation of connexin 43 (Oelze et al, 1995). This results in the
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cessation of tissue homeostatic feedback, which has also been described as an eaiiy event in 
cai'cinogenesis progression (King et al, 2000).
It has been demonstrated that mouse fibroblasts transfected with HPV-16 E5, have increased 
cellular growth and this growth is accelerated by addition of epidermal growth factor (Pim et 
al,  1992; Leechanachai et al, 1992; Straight et al, 1995) by binding to the EGF-R when both 
proteins are over-expressed in the transfected cells (Hwang et al, 1995). In human 
keratinocyte cells, the target cells for the papillomavirus, long-term treatment with EGF 
results in an E5-mediated increase in the number of EGF-R at the cell surface (Straight et al, 
1993). Moreover, BPV-1 E5 may act in a similar manner as this transforming protein binds to 
the PDGF-R and BPV-1 E5 expressing cells respond to addition of PDGF (Petti et al, 1991; 
Petti and DiMaio, 1992).
It has been shown (Ashrafi et al, 2002; Marchetti et al, 2002) that cells transformed by BPV 
E5 can inhibit transport of MHC class I molecules to the cell surface. Down-regulation of 
MHC class I in the cell expressing BPV-4 E5 is caused by physical interaction between MHC 
class I heavy chain protein and the C-terminus of the BPV-4 E5 protein (Marchetti et al, 
2006). We have found that HPV-16 E5 down-regulates MHC class I on the cell surface and 
the first hydrophobic domain of HPV-16 E5 is responsible for this down-regulation. It is 
important to determine how HPV-16 E5 protein down-regulates MHC class I on the cell 
surface. To this end, we have investigated the physical interaction of HPV-16 E5 and MHC 
heavy chain by Co-immunnoprecipitation.
3.3.2 In vitro immunoprécipitation and Co-immunoprecipitation assays
Immunoprécipitation (IP) and co-immunoprecipitation (Co-IP) are key techniques for 
studying protein-protein interactions. These methods utilize immobilized Sepharose beads
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protein-G or protein A to isolate antibody-bound target antigens. IP is a powerful 
immunochemical technique that has been used to study antigen characteristics such as 
interactions with proteins. The IP procedure involves interacting antigens with antibody to 
allow formation of immune complexes, and precipitating those complexes with beads. Co-IP 
is a key teclmique used to study protein-protein interactions, such as interactions of subunits 
within a protein complex. Typically, an antibody specific for one protein is incubated with a 
protein mixtuie to form an immune complex with the target protein (antigen). The target 
protein may be interacting with one or other more proteins to form a protein complex. The 
entire protein complex is then precipitated with beads. We have done in vitro transcription 
and translation of HPV-16 E5 wild type, HPV-16 E5 mutants (R79, A54, V36, R30 and Del- 
1) and HLA-A2 were performed as described in section 2.2.32.1.
3.3.3 HPV-16 E5 wild type physically interacts with HLA heavy chain by Co-IP
Given that BPV E5 can inhibit transport of MHC class I molecules to the cell surface (Ashrafi 
et al, 2002; Marchetti et al, 2002 and 2006), we investigated that HPV-16 E5 inhibits the 
transport of MHC class I to the cell surface, reducing the level of surface MHC class I to 
approximately half of that in the control cells. It is necessary to determine how HPV-16 E5 
protein down-regulates surface MHC class I on the cell surface. We have shown that both 
MHC class I and HPV-16 E5 co-localize in the GA by using GFP vector, as does BPV E5 
(Marchetti et al, 2002). The complete co-localization of HPV-16 E5 and the residual MHC 
class I in the GA would suggest an interaction between HPV-16 E5 and the MHC complex. 
To this end, we performed Co-IP experiments to investigate if any such interaction existed. 
HPV-16 E5 and HLA-A2 were separately transcribed/translated, in vitro, in the presence of 
^^S-labelled methionine and were then kept separately or mixed together as described in
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section 2.2.32.1. The protein samples were precipitated with four different antibodies; mAb 
HCIO against human MHC heavy chain, mAb HA against HA-tag of HPV-16 E5 and rabbit 
polyclonal antisera against synthetic peptides corresponding to the amino-terminal (E5N- 
terminus antiserum) or carboxy-terminal (E5C-terminus antiserum) sequences of the HPV-16 
E5 protein. The samples were then loaded into eonsecutive wells in the SDS-PAGE gels. The 
results showed that there was no significant precipitation in the absence of antibody (Figure 
27A, lanes 1, 4; Figure 27B, lanes 2, 4, 6; Figure 27C and 27D, lanes 3, 5, 7). The HCIO 
antibody precipitated HLA heavy chain but not E5 (Figure 27A, lane 3), and co-precipitated 
HLA heavy chain and E5 (Figures 27A, lane 2). The HA antibody precipitated E5 and co­
precipitated E5 and HLA heavy chain (Figure 27B, lanes 5 and 7). The HLA heavy chain 
band was also visible in the lanes without the antibody (Figure 27B, lanes 2 and 6) or without 
E5 (Figure 27B, lane 3); this was often observed with the HA antibody (see Figure 30A and 
Figure 31 A), but we consider this an artifact as the heavy chain band was stronger in the lanes 
with the co-precipitated.
The Co-IP experiment between HPV-16 E5 and HLA heavy chain was repeated using antisera 
against the N-terminus and the C-terminus of E5. Also in this case, E5 and heavy chain co- 
precipitated (Figures 27C and 27D, lanes 6), while there were no bands in the lanes without 
antibody (Figures 27C and 27D, lanes 7). However, HLA heavy chain was detected also in 
the lanes without E5 and without antibody (Figures 27C and 27D, lanes 2 and 3). The reason 
for this artifact is not known.
Taking all these results together (see also Figure 34, lane 4), we conclude that HPV-16 E5 is 
likely to interact physically with MHC class I heavy chain
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Figure 27: For Co-IP, HPV-16 wild type and HLA-A2 were translated and labelled with 
[^^SJmethionine and precipitated with four different antibodies: mAb HCIO against HLA 
heavy chain, mAb HA against E5HA tag, E5 N-terminus antiserum and E5 C-terminus 
antiserum against E5 N-terminus or E5 C-tenninus.
A panel: immunoprecipitated with HCIO antibody against HLA-A2 heavy chain. Lanes 1 
and 2 are Co-IP with HLA-A2+HPV-16 E5 with or without HCIO antibody. Lanes 3 and 4 
are IP-A2 with or without HCIO antibody. Lane 5 is E5 input (5pi) and lane 6 is HLA-A2 
input (5 pi).
B panel: immunoprecipitated with HA antibody against E5HA-tag. Lane 1 is HLA-A2 input 
(5pl). Lanes 2 and 3 are IP-A2 with or without HA antibody. Lanes 4 and 5 are IP-E5 with or 
without HA antibody. Lanes 6 and 7 are Co-IP with HLA-A2+HPV-16 E5 with or without 
HA antibody and lane 8 is E5 input (5pi).
C panel: immunoprecipitated with E5 C-terminus antiserum against E5. Lane 1 is HLA-A2 
input (5pi). Lanes 2 and 3 are IP-A2 with or without E5 C-terminus antiserum. Lanes 4 and 5 
are IP-E5 with or without E5 C-terminus antiserum. Lanes 6 and 7 are Co-IP with HLA- 
A2+HPV-16 E5 with or without E5 C-terminus antiserum and lane 8 is E5 input (5pi).
D panel: immunoprecipitated with E5 N-terminus antiserum against E5. Lane 1 is HLA-A2 
input (5pl). Lanes 2 and 3 are IP-A2 with or without E5 N-terminus antiserum. Lanes 4 and 5 
are IP-E5 with or without E5 N-terminus antiserum. Lanes 6 and 7 are Co-IP with HLA- 
A2+HPV-16 E5 with or without E5 N-terminus antiserum and lane 8 is E5 input (5pi).
The E5 and MHC class I heavy chain bands are indicated by red dots and the other bands 
originate from the translated E5 protein (see input lanes) and may represent multimers of E5.
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27. Interaction of HPV-16 E5 wild type and HLA heavy chain
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3.3.4 IP and Co-IP of HPV-16 E5 mutants and HLA-A2
We have determined that the first hydrophobic domain of HPV-16 E5 is necessary for down- 
regulation of surface MHC class I. In contrast, in BPV E5, the C-terminus is important for 
down-regulation of MHC class I (Marchetti et al, 2006). We have found that both MHC class 
I and HPV-16 GFP-E5 mutants co-localize in the GA, similar to HPV-16 E5 wild type. We 
have also found that HPV-16 E5 wild type physically interacts with HLA heavy chain. To 
determine the region of the HPV-16 E5 protein responsible for binding to HLA heavy chain, 
we used the previously described deletion mutants. E5R79, E5A54, E5V36 and E5R30 have 
the same N-terminus and lack increasing portions of the C-terminus; E5Del-l has a complete 
C-terminus but lacks the first hydrophobic domain. To investigate if any such interaction 
exists, we performed Co-IP experiments. HPV-16 E5 mutants and HLA-A2 were separately 
transcribed/translated, in vitro, in the presence of ^^S-labelled methionine and were then kept 
separately or mixed together as described before. The protein samples were precipitated with 
three different antibodies: mAb HCIO, mAb HA and E5 N-terminus antiserum. The samples 
were then loaded into consecutive wells in the SDS-PAGE gels. The results show that there 
was no significant precipitation in the absence of antibody (Figure 28, lanes 3, 5, 7; Figuie 29, 
lanes 2, 4; Figure 30A, lanes 3, 5, 7; Figure 3OB, lanes 3, 5; Figure 31 A, lanes 2, 4; Figure 
3 IB, lanes 3, 5, Figure 31C, lanes 3, 5 and Figure 32, lanes 3, 5).
The HCIO antibody precipitated HLA heavy chain but not E5 mutants (Figure 28, lane 6, 
Figure 31 A, lane 5 and Figure 32, lane 4), and the HA antibody and E5 N-terminus antiserum 
precipitated E5 mutants (Figure 30A, lane 4; Figui'e 30B, lane 4 and Figures 3IB and 31C, 
lanes 4). We found that E5R79, E5A54 and E5R30 were all co-precipitated with HLA-A2 by 
HCIO antibody against HLA heavy chain (Figure 28, lane 2; Figure 29, lane 3 and Figure 
31 A, lane 3). Moreover, HLA-A2 co-precipitated with E5R30 using either HA antibody or
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E5N-terminus antiserum against E5 (Figures 3IB and 29C, lanes 2), and E5V36 co- 
precipitated with either HA antibody or E5N-terminus antiserum against E5 (Figures 30A, 
and 30B, lanes 2). When the E5Del-l and HLA-A2 proteins were mixed together, the E5Del- 
1 protein did not precipitate using HCIO antibody (Figure 32, lane 2).
There were additional bands, particularly in lane 2 of Figure 28 and lane 3 of Figure 29. These 
bands appeared to derive from the transcription reactions (see corresponding “input” lanes) 
and were considered background.
As E5Del-l mutant does not interact with HLA-A2 heavy chain and E5V36 and E5R30 
mutants interact, we conclude that the physical interaction between E5 and HLA-A2 heavy 
chain takes place between the first hydrophobic domain of HPV-16 E5 and HLA heavy chain.
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28. IP and Co-IP of HPV-16 E5 R79 and HLA heavy chain
Co-IP 
R79+AInput j  _ -  . 7  . Input2 IP R79 IP A2
A2
R79 f
Figure 28: For Co-IP, HPV-16 E5 R79 mutant and HLA-A2 were translated and labelled 
with [^^S]methionine and precipitated with HCIO antibody against HLA heavy chain. Lane 1 
is E5R79 input (5pl). Lanes 2 and 3 are Co-IP with HLA-A2+E5R79 with or without HCIO 
antibody. Lanes 4 and 5 are IP-E5R79 with or without HCIO antibody. Lanes 6 and 7 are IP- 
A2 with or without HCIO antibody and lane 8 is HLA-A2 input (5pi).
The E5R79 and MHC class I heavy chain bands are indicated by red dots and the other bands 
originate from the translated E5R79 protein (see input lanes) and may represent multimers of 
E5R79.
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29. IP and Co-IP of HPV-16 E5 A54 and HLA heavy chain
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Figure 29: For Co-IP, HPV-16 E5 A54 mutant and HLA-A2 were translated and labelled 
with [^^S]methionine and precipitated with HCIO antibody against HLA heavy chain. Lane 1 
is E5A54 input (5pl). Lanes 2 and 3 are Co-IP with HLA-A2+E5A54 with or without HCIO 
antibody. Lanes 4 and 5 are 1P-E5A54 with or without HCIO antibody and lane 6 is HLA-A2 
input (5pl).
The E5A54 and MHC class 1 heavy chain bands are indicated by red dots and the other bands 
originate from the translated E5A54 protein (see input lanes) and may represent multimers of 
E5A54.
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30. IP and Co-IP of HPV-16 E5 V36 and HLA heavy chain
A B
E5-V36 mutant and HLA-A2 with mAh HA E5V36 mutant and HLA-A2 with E5 N-termmus
TT-jr Co-IP Co-IP
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Figure 30: For Co-IP, HPV-16 E5 V36 mutant and HLA-A2 were translated and labelled 
with [^^SJmethionine and precipitated with two different antibodies: HCIO antibody against 
HLA heavy chain and E5N-terminus anti serum against E5 protein.
A panel: immunoprecipitated with HA antibody against E5HA-tag. Lane 1 is E5V36 input 
(5 pi). Lanes 2 and 3 are Co-IP with HLA-A2+E5V36 with or without HA antibody. Lanes 4 
and 5 are 1P-E5V36 with or without HA antibody and lane 6 is HLA-A2 input (5pi).
B panel: immunoprecipitated with E5 N-terminus antiserum against E5. Lane 1 E5V36 is 
input (5pl). Lanes 2 and 3 are Co-IP with HLA-A2+E5V36 with or without E5 N-terminus 
antiserum. Lanes 4 and 5 are 1P-E5V36 with or without E5 N-terminus anti serum and lane 6 
is HLA-A2 input (5pi).
The E5V36 and MHC class 1 heavy chain bands are indicated by red dots and the other bands 
originate from the translated E5V36 protein (see input lanes) and may represent multimers of 
E5V36.
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Figure 31: For Co-IP, HPV-16 E5 R30 mutant and HLA-A2 were translated and labelled 
with [^ ^S] methionine and precipitated with three different antibodies: HCIO antibody against 
HLA heavy chain, and HA antibody and E5N-terminus antiserum against E5.
A panel: immunoprecipitated with HCIO antibody against HLA heavy chain. Lane 1 is 
HLA-A2 input (5pi). Lanes 2 and 3 are Co-IP with HLA-A2+E5R30 with or without HCIO 
antibody. Lanes 4 and 5 are 1P-E5R30 with or without HCIO antibody and lane 6 is E5R30 
input (5pi).
B panel: immunoprecipitated with HA antibody against E5HA-tag. Lane 1 is E5R30 input 
(5pi). Lanes 2 and 3 are Co-IP with HLA-A2+E5R30 with or without HA antibody. Lanes 4 
and 5 are 1P-E5R30 with or without HA antibody and lane 6 is HLA-A2 input (5pi).
C panel: immunoprecipitated with E5 N-terminus antiserum against E5. Lane 1 is E5V36 
input (5pl). Lanes 2 and 3 are Co-IP with HLA-A2+E5R30 with or without E5 N-terminus 
antiserum. Lanes 4 and 5 are IP-E5R30 with or without E5 N-terminus antiserum and lane 6 
is HLA-A2 input (5 pi).
The E5R30 and MHC class I heavy chain bands are indicated by red dots and the other bands 
originate from the translated E5R30 protein (see input lanes) and may represent multimers of 
E5R30.
156
Chapter 3 Results
31. IP and Co-IP of HPV-16 E5 R30 and HLA heavy chain
E5 R30 mutant and HLA-A2 with mAh HCIO
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32. IP and Co-IP of HPV-16 E5 Del-1 and HLA heavy chain
Co-IP 
)el-l+v'Input ~  7 ~  _ InputD I+A2 IPA2
M r A2
Del-1
Figure 32: For Co-IP, HPV-16 E5 Del-1 mutant and HLA-A2 were translated and labelled 
with [^^S]methionine and precipitated with HC10 antibody against HLA heavy chain. Lane 1 
is E5Del-l input (5|il). Lanes 2 and 3 are Co-IP with HLA-A2+E5Del-l with or without 
HCIO antibody. Lanes 4 and 5 are IP-A2 with or without HCIO antibody and lane 6 is HLA- 
A2 input (5 pi).
The MHC class I heavy chain bands are indicated by red dots.
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3.3.5 IP and Co-IP of HPV-16 E5 wild type, HPV-16 E5 DeI-1 mutant and HLA-A2
We found that HPV-16 E5 wild type and HPV-16 E5 mutants (E5R79, E5A54, E5V36 and 
E5R30), which have the same N-terminus, physically interact with HLA heavy chain, but the 
mutant HPV-16 E5 Del-1 does not. There were non-specific bands in addition to HLA-A2 
and HPV-16 E5. To decrease the number of non-specific bands, we performed Co-IP 
experiment using unlabelled HLA-A2. HPV-16 E5 wild type and HPV-16 E5 Del-1 were 
separately transcribed/translated, in vitro, in the presence of ^^S-labelled methionine, but 
HLA-A2 was transcribed/translated without ^^S-labelled methionine and was then kept 
separately or mixed together as described above. The protein samples were precipitated with 
mAb HCIO and loaded into consecutive wells in the SDS-PAGE gels.
Figure 3 3 A, lane 4 shows that there is one band corresponding to HPV-16 E5 wild type but no 
bands corresponding to HLA-A2 because this is not labelled. Figure 33B, lane 4 shows that 
there is no band corresponding to E5Del-l. These results confirm that HPV-16 E5 wild type 
physically interacts with HLA heavy chain but HPV-16 E5 Del-1 mutant does not.
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33. IP and Co-IP of HPV-16 E5/ HPV-16 E5 Del-1 and HLA- A2
A B
HPV-16 E5 wt and HLA-A2 with mAb HCIO E5Del-l mutant and HLA-A2 with mAb HCIO
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Figure 33: For Co-IP, HPV-16 E5 wild type and HPV-16 E5 Del-1 mutant were translated 
and labelled with [^^S]methionine but HLA-A2 was not labelled and precipitated with HCIO 
antibody against HLA heavy chain.
A panel; Co-IP, HPV-16 E5 wild type and HLA-A2 precipitated with HCIO antibody. Lane 1 
is HLA-A2 input (5pi). Lanes 2 and 3 are IP-E5 with or without HCIO antibody. Lanes 4 and 
5 are Co-IP with HLA-A2+E5 with or without HCIO antibody. Lanes 6 and 7 are IP-A2 with 
or without HCIO antibody and lane 8 is E5 input (5pi).
B panel: Co-IP, E5Del-I mutant and HLA-A2 precipitated with HCIO antibody. Lane 1 is 
HLA-A2 input (5pi). Lanes 2 and 3 are IP-A2 with or without HCIO antibody. Lanes 4 and 5 
are Co-IP with HLA-A2+E5Del-l with or without HCIO antibody. Lanes 6 and 7 are IP- 
E5DeI-I with or without HCIO antibody and lane 8 is E5Del-I input (5pi).
The E5 band is indicated by red dot.
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3.3.6 Competition between HPV-16 E5 wild type and HPV-16 E5 Del-1 mutant for HLA- 
A2 binding
To confirm the above results, a competition experiment was designed between E5 wild type 
and E5Del-l. If E5Del-l does not bind to MHC heavy chain, E5Del-l will not inhibit the 
binding of E5 wild type to MHC heavy chain. If E5Del-l binds to MHC heavy ehain, it will 
prevent the E5 binding. To this end, Co-IP of HPV-16 E5 wild type, HPV-16 E5 Del-1 and 
HLA-A2 were performed as described in section 2.2.32.2. HPV-16 E5 Del-1 was mixed with 
HLA-A2 and then HPV-16 E5 wild type and HCIO antibody were added as previously 
described. As expected, E5Del-l did not co-precipitate with HLA-A2 (Figure 34, lane 2), 
whereas E5 wild type did (Figure 34, lane 4). E5 wild type co-precipitated with HLA-A2 even 
in the presence of E5Del-l (Figure 34, lane 6), showing that E5Del-l did not compete with E5 
wild type for binding to FILA-A2. These results also confirm that HPV-16 E5 wild type 
physically interacts with HLA heavy chain but HPV-16 E5 Del-1 mutant does not.
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34. IP and Co-IP of HPV-16 E5 DeI-1 and HLA-A2/HPV-16 E5 wild type
Co-IP Co-IP Co-IP
Del-1 Del-I+A2 E5+A2 Del-1+A2+E5 IP A2Input -r — + + + Input Input
# A2
Del-1 E5
10 11
Figure 34: For Co-IP, HPV-16 E5 wild type, HPV-16 E5 Del-1 mutant and HLA-A2 were 
translated and labelled with [^^S]methionine, competed as described above and precipitated 
with HCIO antibody against HLA heavy chain.
Lane I is E5Del-I input (5pi). Lanes 2 and 3 are Co-IP with A2-i-E5DeI-l with or without 
HCIO antibody. Lanes 4 and 5 are Co-IP with A2-I-E5 wild type with or without HCIO 
antibody. Lanes 6 and 7 are Co-IP with A2-HE5Del-I-bE5 wild type with or without HCIO 
antibody. Lanes 8 and 9 are IP-A2 with or without HCIO antibody. Lane 10 is E5 input (5pl) 
and lane 11 is HLA-A2 input (5pi).
The E5 and MHC class I heavy chain bands are indicated by red dots.
162
Chapter 3 Results
3.3.7 Competition between HPV-16 E5 wild type and HPV-16 E5 mutants (R30 and 
V36) for binding to HLA-A2
To confirm the above results, a similar competition experiment was performed with E5V36 
and E5R30 mutants (also E5 wild type; Dr.Ashrafi, personal communication). As expected, 
E5V36 and E5R30 co-precipitated with HLA-A2 (Figures 35 and 36, lanes 5). Furthermore, 
the presence of E5V36 and E5R30 mutants, either labelled or not labelled, prevented the co­
precipitation of E5 wild type with HLA-A2 (Figures 35 and 36, lanes 5 and 7). These results 
show that both E5V36 and E5R30 mutants compete with E5 wild type and that therefore the 
binding to HLA-A2 takes place in the first hydrophobic domain of E5.
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35. IP and Co-IP of HPV-16 E5 V36 and HLA-A2/HPV-16 E5 wild type
Co-IP Co-IP
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Figure 35: For Co-IP HPV-16 E5 wild type, HPV-16 E5 V36 mutant and HLA-A2 were 
translated and labelled or not labelled with [^^SJmethionine, competed as described above and 
precipitated with HCIO antibody against HLA heavy chain.
Lane 1 is HLA-A2 input (5pi). Lanes 2 and 3 are 1P-A2 with or without HCIO antibody.
Lanes 4 and 5 are Co-IP with HLA-A2+E5V36+E5 wild type with or without HCIO antibody. 
Lanes 6 and 7 are Co-IP with A2+E5V36+ E5 wild type with or without HCIO antibody.
E5V36 is labelled in lane 5 and not labelled in lane 7. Lane 8 is E5 wild type input (5pl) and
lane 9 is E5V36 input (5pl).
The E5V36 and MHC class 1 heavy chain bands are indicated by red dots.
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36. IP and Co-IP of HPV-16 E5 R30 and HLA-A2/HPV-16 E5 wild type
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Figure 36: For Co-IP HPV-16 E5 wild type, HPV-16 E5 R30 mutant and HLA-A2 were 
translated and labelled or not labelled with [^^S]methionine, competed as described above and 
precipitated with HC 10 antibody against HLA heavy chain.
Lane 1 is HLA-A2 input (5pi). Lanes 2 and 3 are 1P-A2 with or without HCIO antibody. 
Lanes 4 and 5 are Co-IP with HLA-A2+E5R30+E5 wild type with or without HCIO antibody. 
Lanes 6 and 7 are Co-IP with HLA-A2+E5R30+E5 wild type with or without HCIO antibody. 
E5R30 is labelled in lane 5 and not labelled in lane 7. Lane 8 is E5 wild type input (5pl) and 
lane 9 is E5R30 input (5pl).
The E5R30 and MHC class 1 heavy chain bands are indicated by red dots.
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3.3.8 Conclusion
We found that HPV-16 E5 wild type physically interacts with HLA heavy chain using four 
different antibodies: HA antibody, HCIO antibody, E5N-terminus antiserum and E5C- 
terminus antiserum (Figure 27). We determined that HPV-16 E5 mutants (R79, A54, V36 and 
R30) which have the same N-terminus, physically interact with HLA heavy chain, similar to 
HPV-16 E5 wild type (Figures 28, 29, 30 and 31), but the HPV-16 E5 Del-1 mutant, which 
lacks the first hydrophobic domain, does not (Figure 30). Also the results of competition 
experiments between E5 wild type and three mutants (E5Del-l, E5V36 and E5R30) confirm 
that the E5V36 and E5R30 physically interact with HLA heavy chain (Figures 35 and 36) but 
E5Del-l does not (Figure 34). We conclude that the first hydrophobic domain of the HPV-16 
E5 protein is critical for binding to HLA heavy chain. As determined before, HPV-16 E5 
down-regulates MHC class 1 on the cell surface and the first hydrophobic domain is important 
to this down-regulation. It appears that the interaction of E5 with HLA heavy chain is 
necessary for down-regulation of MHC class I.
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3.4 HPV-16 E5 does not down-regulate non-classical MHC I 
3.4.1 Introduction
Like the classical MHC class I loci, the non-classical MHC class I genes that include HLA-E, 
HLA-F, and HLA-G molecules are highly transcribed in many tissues, but they display only 
limited genetic variation. These molecules show homology to the classical MHC 1 molecules 
but generally have limited polymorphism, low cell suiTace expression, and more restricted 
tissue distribution. While classical MHC I molecules (HLA-A and B) are the main presenters 
of antigenic peptides to CTL, HLA-C and non classical HLA-E inhibit NK cell-mediated lysis 
by interacting with inhibitory NK receptors; NK killing is part of the innate immune response. 
Inliibitory receptors prevent NK killing if MHC class I molecules are present but lysis of the 
target cell occurs if MHC class I is absent. Thus, classical MHC I negative virus-infected cells 
would be killed by NK (Yokoyama et al, 1998; Lee et al, 1998; Braud et al, 1999), unless 
non-classical MHC I molecules are present. It has been shown that several viruses ai*e capable 
of inhibiting classical MHC I but do not inhibit non-classical MHC I thus escaping both CTLs 
and NK cells. It has been demonstrated that the HIV Nef and HCMV US10/UL40 proteins 
down-regulate HLA-A/B but do not down-regulate HLA-C/E, which are mostly involved in 
positive selection of inhibitory receptors on NK cells (Cohen et al, 1999; Tomasec et al, 
2000; Furman et al, 2002). As a part of understanding how HPV-16 E5 could selectively 
down-regulate MHC class I molecules, we determined the levels of HLA-C and E in the 
HPV-16 E5 expressing cells. The effect of E5 on HLA-C/E was investigated by FACS, by 
immunofluorescence microscopy and by western blots.
3.4.2 Detection of HLA-C and non-classical HLA-E by FACS
We investigated whether HPV-16 E5 selectively down-regulates surface MHC class I. Using
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FAC analysis, we determine the levels of HLA-C/E in HaCaT parental cell, cells earring 
empty vector (pcDNA and pL2) or cell expressing HPV-16 E5 (pcl6E5 and pL2-16E5). Cells 
were stained with mAh DT9 that recognizes both HLA-C and HLA-E, and were analyzed by 
FACS for surface and total HLA-C/E following the previously described protocol (see section 
2.2.25). This results show that the shift in forward fluorescence was small (Figures 37A and 
37B), in agreement with the observation that human fibroblasts have little HLA-E (Tomasec 
et al, 2000), but it was consistently higher than background (secondary antibody only; Figure 
37A). Importantly, there were no significant differences between the control and E5- 
expressing cells (Figui’e 37B).
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37. Detection of HLA-C/E by FACS
HaCaT Surfece HLA-E/C HaCaT Total HLA-E/C
pcDNA Total HLA-E/CpcDNA Surfece HLA-E/C
pL2 Total HLA-E/CpL2 Surface HLA-E/C
pcl6E5 Total HLA-E/Cpcl6E5 Surfece HLA-E/C
pL2-16E5 Surfece HLA-E/C pci6E5 Total HLA-E/C
Forward fluorescence
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Figure 37; HPV-16 E5 does not down-regulate non-classical MHC I on the cell surface. 
HaCaT parental cells, pcDNA and pL2 cells or pcl6E5 and pL2-16E5 cells (three cell lines of 
each) were stained with mAh DT9, specific for HLA-C/E and analysed for expression of 
surface and total HLA-C/E by FACS. A) Representative FACS profiles of single cell lines. 
Dotted line and open histogram, forward fluorescence with secondary antibody only; solid 
histogram, forward fluorescence with primary and secondary antibody. B) The mean 
fluorescence from at least three experiments performed on three cell lines was calculated from 
FACS analysis. A background of 0.4 (the reading of cells stained with only secondary 
antibody) was subtracted in all cell lines.
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3.4.3 Localisation of HLA-C/E by immunofluorescence microscopy
The cellular localisation of HLA-C/E was investigated by immunofluorescence. The cells 
were aliquoted into 24-well plates containing coverslips at 1 x 1 cells per well, grown and 
stained with mAb DT9 to show the localization of non-classical MHC I as previously 
described (see section 2.2.26). For the detection of HLA-C/E, the control HaCaT cells 
carrying empty vectors and cells expressing HPV-16 E5 were incubated with mAb DT9 and 
analysed under the confocal microscope. We determined that there were no differences 
between the staining patterns of HLA-C/E in control cells and in E5 cells (Figure 38), and 
therefore we conclude that expression of E5 does not lead to any appreciable decrease in 
surface HLA-C/E, in agreement with the FACS data.
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38. Detection of HLA-C/E by immunofluorescence microscopy
HaCaT pcDNA
pcl6E5 pL2-16E5
Figure 38: HaCaT parental cells, cells carrying empty vector (pcDNA and pL2) or cells 
expressing HPV-16 E5 (pcl6E5 and pL2-16E5) were stained with mAh DT9, specific for 
HLA-E/C. The slides were mounted in Citifluor^^ and analysed with a Leica TCS SP2 
fluorescence confocal microscope at 488nm wavelength. Images were acquired using Leica 
confocal software. N=nucleus
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3.4.4 Detection of non-classical MHC I by Western Blots
The results above showed that, similarly to HIV Nef and HCMV US3/UL40, HPV-16 E5 did 
not have any effect on the levels of the HLA-C and non-classical HLA-E. Here we 
investigated the level of HLA-E heavy chain using mAb MEM-E/02, specific for HLA-E. We 
determined that there were no significant differences between control cells and E5 cells 
(Figure 39). These results confirm that HPV-16 E5 does not affect the expression of HLA- 
E/C. We cannot however discriminate between HLA-C and HLA-E on the cell surface 
because mAb DT9 recognises both molecules, and mAb MEM-E/02, specific for HLA-E, 
does not function in FACS or immunofluorescence.
39. Detection of non classical MHC class I by Western Blots
HLA-E
actin
Figure 39: For western blots detection of non classical HLA-E heavy chain, protein lysates 
from one line each of HaCaT parental cells, cells carrying empty vector (pcDNA and pL2) or 
cells expressing E5 (pcl6E5, pL2-I6E5) was probed with mAb MEM-E/02, specific for 
HLA-E, or mAb AB-1 (anti-actin) to determine the levels of the HLA-E.
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3.4.5 Conclusion
To determine whether HPV-16 E5 could selectively downregulate MHC class I molecules, we 
determined the levels of HLA-C/E in parental, control and E5-expressing HaCaT cell lines. 
The results show that there were no differences between the staining patterns of HLA-C/E in 
the control cells and in the E5-expressing cells; therefore, we conclude that expression of E5 
does not lead to any appreciable decrease in surface HLA-C/E using FACS and 
iimnunofluorescence microscopy (Figures 37 and 38). Similarly, we did not detect any 
significant differences between HLA-E levels in the control cells and the E5-expressing cells 
by immunoblotting with mAb MEM-E/02, specific for HLA-E (Figure 39). The ease of HLA- 
C/E detection by immunofluorescence and immunoblotting compared with FACS is likely 
attributable to the different affinities of the two antibodies for HLA (mAb DT9 and mAb 
MEM-E/02) and to the greater sensitivity of mAb DT9 in immunofluorescence. These results 
confirm that HPV-16 E5 does not down-regulate the surface expression of the HLA-C or non- 
classical HLA-E.
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4 Discussion
4.1 Introduction
Viruses that infect humans have evolved mechanisms of avoiding the immune response. A 
component of cellular immunity, CTL control viral infection by recognizing virus-encoded 
peptides presented on the surface of the infected cells by MHC class I molecules. MHC class 1 
plays an important role in alerting the immune system to virally infected cells and presents 
peptide fragments derived from intracellular proteins. To avoid detection by CTL, viruses 
encode protein that inhibits the expression of the MHC complex on the surface of infected 
cells (Hewitt, 2003). Down-regulation of surface MHC class I potentially exposes the virus- 
infected cell to attack by NK cells, which possess the ability to recognise and lyse virally 
infected cells, and the expression of "se lf MHC molecules inhibits NK lysis of target cells 
(Ploegh, 1998).
In human, many types of papillomaviruses cause benign infection but specific types of HPV, 
particularly types 16 and 18, are associated to malignancy, which in turn appears to depend on 
several factors, including the genetic background of the host (Breitburd et al, 1996; Krul et 
al, 1999), environmental cofactors (Castellsague et al, 2002), and the ability of the virus to 
avoid immune clearance (Frazer et a l, 1999). The immune system plays a crucial role in 
determining the clinical outcome of HPV disease, as demonstrated by the increased 
persistence and enhanced neoplastic progression of HPV infections in hosts with cell- 
mediated immune deficiencies (Heard et al, 2000; Harwood et al, 2000). However, even in 
immunocompetent individuals, HPVs persist for a significant period of time before activation 
of the host immune system. This lack of recognition suggests that the host immune system 
escapes, or disables to recognize HPV infection. HPVs can impair the immune response 
indirectly via the nature of the virus life cycle (Frazer, 1996), and by direct interference with
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the host antiviral immune mechanisms, including the IFN response and MHC class I antigen 
presentation to CTLs (O'Brien and Campo, 2003).
It has been shovra (Ashrafi et al, 2002; Marchetti et al, 2002) that down-regulation of MHC 
class I by BPV E5 takes place at several steps of the MHC pathway, including transcription of 
the MHC class I heavy chain mRNA, expression of MHC class I heavy chain, and transport of 
the MHC class I complex to the cell surface. However, the amino acid analysis of the HPV E5 
proteins and BPV-1 E5 has revealed that they are very different. But some limited sequence 
similarities have been suggested between the HPV and BPV-1 E5 proteins such as a few 
hydrophobic residues (Bubb et al, 1988). The C-terminal portion of BPV-1 E5, which 
appears to be important for biological function, does not have an identifiable similar region in 
the HPV E5s. In contrast to BPV-1 E5, where E5 is the main oncoprotein, little is known 
about the biological activity of HPV-16 E5.
4.2 Down-regulation of MHC class I by HPV-16 E5
The MHC class I molecules are essential for presentation of foreign peptides to the host CTL 
and play a critical role in immune surveillance of many pathogens (Tortorella et al, 2000; 
Hewitt, 2003). The MHC class I complex consists of a heavy chain containing the peptide 
binding site and piM, which assemble in the lumen of the ER, where peptides are loaded onto 
the MHC class I heavy chain in a pH-dependent process. The complex proteins are 
transported to the G A, where dissociation of MHC class I from TAP takes place, and then 
transported to the cell surface for presentation to CTL (York and Rock, 1996). As MHC class 
I travel thr ough the GA, and the E5 protein of papillomavirus interferes with the functions of 
the GA and endosomes (Schapiro et al, 2000; Bravo et al, 2004), it was expected that the 
transport of the MHC class I complex would be disrupted in E5 expressing cells. We have
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shown that HPV-16 E5 wild type down-regulates MHC class I on the cell surface, reducing 
the level of surface MHC class I to approximately half of that in the control cells (Figure 8). 
Additionally, we found that MHC class 1 was retained in the GA (Figure 9). In this respect, 
HPV-16 E5 is similar to BPV E5. However, HPV-16 E5 does not affect the morphology of 
the GA (Figure 10, central panels) while BPV-4 E5 affects the structure of the GA, leading to 
Golgi swelling and fragmentation (Marchetti et al, 2002). Despite the similarities, there are 
also differences between the extent to which BPV-4 E5 and HPV-16 E5 interfere with the 
MHC class I pathway. BPV-4 E5 down-regulates transcription of the MHC class I heavy 
chain gene, promotes degradation of the translated polypeptide and blocks the transport of the 
MHC class 1 complex to the cell suiface (Aslirafi et al, 2002; Marchetti et al, 2002 and 
2006). In contrast, HPV-16 E5 does not inhibit expression of the heavy chain (Figure 11), but 
retains the complex in the GA and reduces its transport to the cell surface without completely 
abolishing it. Prevention of transport of MHC class 1 to the cell surface is a property shared by 
papillomaviruses E5. It has been reported that also HPV2a E5 can inhibit the transport of 
MHC class 1 to the cell surface (Cartin and Alonso, 2003). Therefore, down-regulation of 
surface MHC class I appears to be a property of many, if not all, papillomavirus E5 proteins. 
Moreover, whereas the transport of MHC class I to the cell surface was irreversibly inhibited 
in cell expressing BPV-4 E5, treatment with (3-lFN increased the transport of MHC class I to 
the cell surface in cell expressing HPV-16 E5. The reason for this difference is not known but 
it can be speculated that the increased production of MHC class I heavy chain by IFN is 
sufficient to overcome the inhibitory effect mediated by the low levels of HPV-16 E5. In 
contrast, as BPV E5 also inhibits transcription and promotes degradation of the MHC class I 
heavy chain (Ashrafi et al, 2002; Marchetti et al, 2006), IFN treatment is insufficient to 
restore MHC class 1 expression to normal levels. These observations are consistent with the
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hypothesis that there is a correlation between oncogenicity and immune evasion (O'Brien and 
Campo 2003). As discussed earlier, BPV E5 is a more effective transforming protein than 
HPV-16 E5 (Venuti and Campo, 2002) and therefore would be predicted to have a greater 
effect on MHC class I down-regulation (and other immune evasion mechanisms) than HPV- 
16 E5. In HPV-16, E6 and E7, which are two major transforming proteins would complement 
the inhibitory effect of the lesser transforming protein E5 on the MHC class I pathway. HPV- 
16 E7 can repress the MHC class I heavy chain gene promoter (Georgopoulos et al,. 2000) 
thus likely replacing the inhibitory action of BPV on the same promoter, and HPV-11 E7 can 
bind directly to TAP, thus further contributing to the down-regulation of MHC class I 
(Vambutas et al, 2001). Furthermore, both HPV E6 and E7 can inhibit the type I IFN 
pathway, thus preventing the IFN-mediated release of E5-induced blockage in MHC class I 
trafficking (Ronco et al, 1998; Barnard et al, 2000).
4.3 Down-regulation of MHC class I by the first hydrophobic domain of HPV-16 E5
We found that HPV-16 E5, which has three hydrophobic domains, down-regulates MHC class 
I on the cell surface. It was important to determine the domain of the HPV-16 E5 protein 
responsible for down-regulation of surface MHC class I. We used deletion mutants of HPV- 
16 E5 lacking each of the hydrophobic domains (Figure 16). We found that the level of 
surface MHC class I was not different between the cells expressing HPV-16 E5 Del-1 and 
HaCaT parental or no E5 cells. In contrast, the level of surface MHC class I was reduced in 
the cells expressing HPV-16 E5 mutants (R79, A54, V36 and R30), similar to HPV-16 E5 
wild type (Figures 23A, 23B and 24). So, these results confirmed that the first hydrophobic 
domain of HPV-16 E5 is important for down-regulation of surface MHC class I. We could not 
detect HPV-16 E5 protein in HaCaT cells, because E5 is hydrophobic and small and difficult
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to detect in cells, and therefore we used indirect methods of detection such as RNA 
expression. We have done Taq-Man RT-PCR to show the level of E5 RNA expression in the 
cell transfected with HPV-16 E5 wild type and all mutants. Whereas, we could detect E5 
RNA in the cell transfected with HPV-16 E5 wild type and mutants (E5R79, E5A54, E5V35, 
E5R30), but we could not detect E5Del-l RNA, because the E5Del-l mutant lacks the first 
hydrophobic domain, which is the best target for the probe (Figure 18). Therefore, we have 
done semi-quantitive RT-PCR to show the expression of E5 RNA in the cell transfected HPV- 
16 E5 wild type and mutants including E5Del-l. The results showed that the expressions of 
E5 RNA were approximately the same level in the cells transfected with HPV-16 E5 wild 
type and mutants including E5Del-l (Figures 20, 21 and 22). Also, HPV-16 E5 wild type and 
all mutants were expressed as GFP-fusion proteins visualise their cellular localization. We 
found that GFP-HPV-16 E5 wild type and GFP-HPV-16 E5 mutants including GFP-E5Del-l 
localized in the GA, as does BPV-4 E5 (Marchetti et al, 2002), whereas GFP alone is 
expressed throughout the cell (Figures 25 and 26). These results suggest that the localization 
of the HPV-16 E5 protein in the GA is important but not sufficient for down-regulation of 
sui'face MHC class I, because the only mutant that failed to down-regulate surface MHC class 
I was still localized in the GA. Another difference between HPV-16 E5 and BPV-4 E5 is that 
the C-terminus of BPV-4 E5 is important for the down-regulation of MHC class I (Marchetti 
at al, 2006), whereas, it is the first hydrophobic domain of HPV-16 E5 which is important to 
reduce surface MHC class I as shown by the failure of E5Del-l mutant to retain MHC class I 
in the membrane compartment.
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4.4 How does HPV-16 E5 down-regulate MHC class I?
We found that HPV-16 E5 down-regulates MHC class I on the cell surface and the first 
hydrophobic domain of HPV-16 E5 is important for this down-regulation. We also found that 
HPV-16 E5 and the residual MHC class I co-localized in the GA, which is similarly to BPV-4 
E5 (Marchetti et al, 2002). This complete co-localization would suggest an interaction 
between the HPV-16 E5 protein and MHC heavy chain. Indeed, this is the case and the HPV- 
16 E5 protein and HLA-A2 protein co-precipitate, in vitro, using four difference antibodies 
(Figures 27 A-D). In addition, the HPV-16 E5 protein also interacts "Hn vitro'" with HLA-Al 
and HLA-B8 (Dr.Aslirafi and Dr.Marchetti, personal communications). These results reveal 
that HPV-16 E5 wild type physically interacts with MHC class I heavy chain in non- 
dependently of HLA heavy chain. Also, we determined that HPV-16 E5 mutants (R79, A54, 
V36 and R30), which have the same first hydrophobic domain, physically interact with MHC 
heavy chain, similarly to HPV-16 E5 wild type (Figures 28,29,30  and 31) but the HPV-16 
E5 Del-1 mutant, which truncates the first hydrophobic domain of HPV-16 E5 wild type, does 
not interact with MHC heavy chain (Figure 32). This interaction is not an artifact, as E5 is 
precipitated by HCIO antibody against MHC heavy chain even when HLA-A2 is not labelled 
(Figure 3 3A), and HPV-16 E5 Del-1 mutant does not interact with MHC heavy chain (Figure 
33B). We confirmed by competition experiments that the first hydrophobic domain of the 
HPV-16 E5 protein is necessary for binding to MHC heavy chain (Figures 34, 35 and 36). 
Also, we determined that this interaction is not an artifact, as E5V36 and E5R30 mutants can 
compete with E5 wild type for binding to MHC class I heavy chain (Figure 35 and 36, lane 7). 
It has been demonstrated that HPV-16 E5 wild type and MHC heavy chain interact also in 
HaCaT-16 E5 cells but HPV-16 E5 Del-1 mutant does not interact in the HaCaT-E5Del-l 
cells (Ashrafi et al. Submitted). Therefore, these results suggest that down-regulation of
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MHC class I in the cell expressing HPV-16 E5 takes place by physically interaction between 
MHC heavy chain and the first hydrophobic domain of the HPV-16 E5 protein, and this 
interaction may impair the function of the MHC class I. In contrast, down-regulation of MHC 
class I in the cell expressing BPV-4 E5 is caused by physically interaction between MHC 
class I protein and the C-terminus of the BPV-4 E5 protein (Marchetti et al, 2006).
4.5 HPV-16 E5 does not down-regulate non-classical MHC I
While classical MHC I molecules (HLA-A and B) are the main presenters of antigenic 
peptides to CTL, HLA-C and non-classical HLA-E inliibit NK cell-mediated lysis by 
interacting with inhibitory NK receptors. Inhibitory receptors prevent NK killing if MHC 
class I molecules are present but lysis of the target cell occurs if MHC class I is absent. Thus, 
classical MHC I negative virus-infected cells would be killed by NK cells (Ploegh, 1998; 
Natarajan et al, 2002), unless non-classical MHC I molecules are present. Human NK cells 
express multiple receptors that interact with MHC class I molecules to inhibit or activate their 
effector function. Two types of receptors are specific for self MHC class I molecules to 
inhibit NK cells, including KIRs that predominantly recognize classical MHC I, and the 
lectin-like heterodimer CD94/NKG2 receptors that recognize HLA-E which is non-classical 
MHC I molecule (Yokoyama et al, 1998; Lee et al, 1998; Braud et al, 1999). Recognition 
of the class I molecules by their inhibitory receptors inliibits NK-mediated cell lysis, which 
would occur in the absence of classical HLA-C and non-classical HLA-E. To investigate 
whether HPV-16 E5 could down-regulate non-classical MHC I molecules, we determined the 
effect of HPV-16 E5 on HLA-C and non-classical HLA-E. Our experiments establish that the 
expression of HLA-C and non-classical HLA-E in HaCaT control cells or cells expressing 
HPV-16 E5 are at the same level in the cell surface and total (Figures 37 and 38). These
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results confirm that HPV-16 E5 does not down-regulate the expression of non-classical MHC 
I. Likewise, it has been determined that BPV E5 protein down-regulates bovine classical 
MHC I but does not affect non-classical MHC I (Marchetti and Araibi, personal 
communication). We conclude that HPV-16 E5 selectively inliibits surface expression of 
HLA-A and B but does affect neither the synthesis of HLA-C and non-classical HLA-E nor 
the transport of them to the cell surface. NK cells of patients with HPV-induced anogenital 
lesions are incapable of specific killing HPV-16-infected cells (Malejczyk et al, 1989), 
although the mechanism by which this occurs is as yet unknown. Moreover, concordant with 
loss of MHC class I molecules that present viral peptides to the CTL, there is a very low 
frequency of HPV-specific HLA-A-restricted CTLs in patients infected with HPV-16, an 
order of magnitude lower than those found in other viral infections, including influenza A and 
EBV (Youde et al, 2000). It is not yet known whether these obseivations are the consequence 
of E5 expression; however, experiments to establish the functional outcome of E5 expression 
on CTL and NK cell recognition of HPV-transfected cells are in progress. Regardless, our 
results support the hypothesis that E5 plays a major role in immune evasion by HPV. It is 
interesting to note that HPV-16 E5 has also been reported to protect HaCaT cells from tumour 
necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas ligand- mediated apoptosis 
and this effect correlates with the level of E5 expression (Kabsch and Alonso, 2002). FasL 
binds to the Fas receptor (CD96) leading to activation and clustering of the death receptors 
(Walczak et al, 2000). TRAIL interacts with several cellular soluble receptors, the TRAIL 
receptors 1 and 2, (Emery et al, 1998) that contain intracellular death domains (DDs) to 
transmit the apoptotic signal (Kisclikel et al, 2000; Sprick et al, 2000). Fas and TRAIL 
receptors are expressed on a broad panel of normal epithelial cells (Wiley et al, 1995). 
Down-regulation of Fas expression is a common abnormality in gynecological cancers (Das et
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al, 2000), whereas the expression of TRAIL receptors is not reduced in cervical cancer (Ryu 
et al, 2000) compared to normal tissue. Therefore, E5 can disrupt several critical components 
of the cell-mediated immune response to viruses, which may contribute to the establishment 
and persistence of HPV infection. The down-regulation of MHC class I has been observed in 
CIN (Bontkes et al, 1998) and in cervical carcinomas (Keating et al, 1995). However, the 
down-regulation of MHC class I in cervical carcinomas, which often do not express E5, is 
common to other cancer types and therefore unlikely to be due to E5. No correlation was 
made between MHC class I down-regulation and E5 expression in CIN, and this point 
warrants further investigation.
4.6 HPV-16 E5 binds to 16K subunit c and HLA-A2 heavy chain
The E5 protein is able to interact with several different cellular proteins including epithelial 
growth factor and 16K subunit c/ductin. It has been reported that BPV E5 (Goldstein et al, 
1990) and HPV E5 (Conrad et al, 1993) bind to 16K subunit c, which is a component of the 
VO sector of the H^ V-ATPase. The binding of the E5 polypeptide to 16K subunit c has led to 
the suggestion that the function of the V-ATPase might be impaired. The V-ATPase is a 
universal transmembrane proton pump of eukaryocytes and is responsible for acidification of 
endomembrane components (e.g. Golgi, endosomes, lysosomes, and certain secretory 
vesicles) (Finbow et al, 1997). As shown previously (Rodriguez et al, 2000) the second 
hydrophobic domain of the HPV-16 E5 protein is critical for interaction with the 16K subunit 
c of the V-ATPase. The interaction of E5 and 16K subunit c takes place to increase the pH of 
the GA (Schapiro et al, 2000), which was attributed to a malfunction of the vacuolar H+ 
ATPase (Briggs et al, 2001). The acidification of the Golgi may impair the MHC complex, 
which presents viral peptides to the host CTL through ER and the GA. The retention of MHC
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class I in the G A by BPV-4 E5 is due at least in part to the impeded acidification of the 
endomembrane components, as retention in the GA and down-regulation of surface MHC 
class I are also caused by monensin, an inhibitor of V-ATPase and the acidification of the GA 
(Marchetti et al, 2002). The same mechanism may support the retention of MHC class I in 
the GA by HPV-16 E5. However, given the selective down-regulation of HLA-A and B by 
HPV-16 E5, the lack of the GA acidification cannot be the whole explanation and other 
mechanisms must come into play. These results lead us to conclude that HPV-16 E5 down- 
regulates surface MHC class I by interaction with 16K subunit c that inhibits acidification of 
the GA, and by binding to MHC class I heavy chain.
4.7 Similarities between HPV-16 E5 and other viral protein
CTL recognize virus-infected cells through the specific interaction of their T-cell receptor 
with an MHC class I molecule presenting a viral peptide. Peptides, generated by the 
proteasome in the cytoplasm, are translocated by TAP into the ER where they assemble in 
ternary complexes and are transported to the cell surface for presentation to CTL (York and 
Rock, 1996). Interference with the assembly and/or trafficking of the MHC class I complex 
can contribute to the persistence of a vims. It has been reported that several viral proteins 
induce chronic infections by targeting or modulating the host's immune system. E3/19K 
adenovirus protein binds to MHC class I in the ER and prevents its transport to the cell 
surface. Murine CMV glycoprotein, gp34, also interacts with the heavy chain (32M complex in 
the ER and has been recently shown to target MHC class I for degradation in the lysosomes. 
Infected cell protein (ICP) 47, a protein encoded by herpes simplex virus, inhibits the TAP 
transporter (Tortorella et al, 2000). More recently, it was demonstrated that the K3 and K5 
proteins encoded by Kaposi's sarcoma-associated herpesvirus down-regulate MHC class I
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fi'om the cell surface (Ishido et al, 2000). It has been demonstrated that the HIV Nef and 
HCMV US10AJL40 proteins down-regulate HLA-A and B by interaction but do not down- 
regulate HLA-C and non-classical HLA-E, which are mostly involved in positive selection of 
inhibitory receptors on NK cells (Cohen et al, 1999; Tomasec et al, 2000; Furman et al, 
2002). We found that the HPV-16 E5 protein binds to MHC heavy chain in the GA and 
prevents the transport of MHC class I to the cell surface but does not inhibit HLA-C and non- 
classical HLA-E thus potentially escaping both CTLs and NK cells. Thus HPV-16 E5 joins 
numerous other viral proteins in the avoidance of the host immune response.
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Future works
We found that HPV-16 E5 inhibits the transport of MHC class I to the cell surface, reducing 
the level of surface MHC class I to approximately half of that in the control cells. MHC class 
I is essential for presentation of foreign peptides to the host CTL and play a critical role in 
immune surveillance of many pathogens (Tortorella et al, 2000). We also found that down- 
regulation of MHC class I is due to the first hydrophobic domain of HPV-16 E5 by physical 
interaction with HLA heavy chain. We determined that HPV-16 E5 down-regulates 
selectively HLA-A and B but does not inliibit HLA-C and non-classical HLA-E thus escaping 
both CTLs and NK cells. Future work should concentrate on the effects of HPV-16 E5 on the 
MHC class I.
Firstly, it should be investigated which amino acid(s) within the first hydrophobic domain of 
the HPV-16 E5 protein is/are essential for the down-regulation of surface MHC class I. It has 
been shown that the HIV Nef and HCMV US10/UL40 proteins down-regulate selectively 
HLA-A/B by physical interaction but do not down-regulate HLA-C and non-classical HLA-E 
(Cohen et al, 1999; Tomasec et al, 2000; Furman et al., 2002). It has been also shown that 
the di-leucine amino acid motif of the HIV Nef protein is important in the Nef-function and in 
the interaction of Nef with adaptor protein (AP) complexes (Coleman et al, 2006). The first 
hydrophobic domain of HPV-16 E5 has four di-leucine motifs (Table 6). A deletion or point 
mutation analysis will identify which amino acid(s) is/are responsible.
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Table 6. Amino acid sequences of BPV-1 E5, BPV-4 E5, HPV-16 E5 and HPV-18 E5 
proteins
BPV-1 E5 1MPNLWFLLFL GLVAAMQLLL LLFLLLFFLV YWDHFECSCT GLPF
44
BPV-4 E5 1MSLWLIYVLL LFWCAFNFLA LLFAIIVYLL LISTITRLDG WD 42
HPV-16 E5 1MTNRDTASTT LLACFLLCFC VLLCVCLLIR PLLLSVSTYT 
SLIILVLLLWITAASAFRCF IVYIIFVYIP LFLIHTHARF LIT 83
HPV-18 E5 1MLSLIFLFCF CVCMYVCCHV PLLPSVCMCA YAWVLVFVYI 
VVITSPATAF TVYVFCFLLP MLLLHIHIL SLQ 83
Table 6: Amino acid sequences of BPV-1 E5, BPV-4 E5, HPV-16 E5 and HPV-18 E5 
proteins Bold: domains know to be critical for interaction with MHC class I heavy chain and 
underline sites are potential leucine motifs.
Secondly, as HPV-16 E5 physically interacts with HLA heavy chain, it is important to 
investigate which site of HLA heavy chain is involved in this interaction. A deletion or point 
mutation analysis will identify which amino acid(s) is/are responsible.
Thirdly, it has been shown that expression of HPV-16 E5 increased the pH of the Golgi, 
which is thought to be a result of its binding to 16K subunit c (Schapiro et al, 2000; Bravo et 
al, 2004). The acidification of the Golgi impairs the transport of the MHC complex. Our 
results showed that HPV-16 E5 physically interacts with HLA heavy chain and this 
interaction is associated with the down-regulation of the MHC complex. This suggests that 
HPV-16 E5 down-regulates surface MHC class I both by interaction with 16K subunit c of 
the V-ATPase and by binding to HLA heavy chain. It is important to investigate that HPV-16 
E5 physically interacts with both 16K subunit c and HLA heavy chain at the same time. 
Fourthly, lack of surface MHC I in infected epithelial cells expressing E5 would allow 
evasion of cytotoxic T lymphocyte killing and thus establishment of viral infection, and the 
presence of non-classical MHC I would allow escape from NK killing. CTL and NK killing 
assays of E5-expressing cells would clarify this point.
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